Therapeutic Drug-Monitoring of Methotrexate-Polyglutamates in Rheumatoid Arthritis by Boer, E. (Ethan) den
Therapeutic Drug-Monitoring of 
Methotrexate-Polyglutamates 
in Rheumatoid Arthritis
The work presented in this thesis was performed at the department of Clinical Chemistry 
of the Erasmus University Medical Center, Rotterdam, The Netherlands. The work was 
financially supported by the Dutch Arthritis Foundation (Reumafonds, grant no. 9-1-402).
Financial support for the publication of this thesis was kindly provided by the Dutch Arthritis 
Foundation (Reumafonds) and the Erasmus University Rotterdam.
ISBN/EAN: 978-90-7138-200-0
Printed by: Gildeprint Drukkerijen - www.gildeprint.nl
All rights reserved. No part of this thesis may be reproduced or transmitted in any form or 
by any means without prior permission of the author, E. den Boer, or when appropiate, of 
the scientific journal in which parts of this thesis have been published.
© 2014 E. den Boer
Therapeutic Drug-Monitoring of 
Methotrexate-Polyglutamates 
in Rheumatoid Arthritis
Therapeutische bloedspiegel bepaling 
van methotrexaat-polyglutamaten 
bij reumatoïde artritis
Proefschrift
Ter verkrijging van de graad doctor aan de 
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties. 
De openbare verdediging zal plaatsvinden op 
18 juni 2014 om 13:30
door
Ethan den Boer
Geboren te Rotterdam
Promotie commissie
Promotor:   Prof.dr. J. Lindemans
Overige leden:   Prof.dr. I.P. Kema 
   Prof.dr. P.L.C.M. van Riel
   Prof.dr. A.G. Vulto
Copromotoren:   dr. R. de Jonge
   dr. T.M. Luider
 
The anthropologists got it wrong when they named our species Homo sapiens (‘wise man’). 
In any case it’s an arrogant and bigheaded thing to say, wisdom being one of our least 
evident features. In reality, we are Pan narrans, the storytelling chimpanzee.
― Terry Pratchett, Ian Stewart and Jack Cohen - The Science of Discworld II: The Globe
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Introduction
Reumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic autoimmune disease, characterized by the swelling 
of joints, uncontrolled proliferation of synovial tissue and multisystem co-morbidities. RA 
mainly affects the joints of the hands, feet, knees, wrist and elbows, with joint damage 
occurring early in the disease course. RA affects an estimated 1% of the general population 
and women have a higher risk of developing RA than men. Despite the fact that treatment 
strategy has changed considerably over the years, reflected by a much improved disease 
outcome, there is still no cure for RA. 
 Early initiation of therapy is effective in prevention of joint damage and results in 
milder medication regimes while maintaining disease remission. [1-4] Early in the disease, 
the inflammation is less self-perpetuating and easier to suppress, therefore it is important 
to start treatment as early as possible in order to optimize outcome, minimize medical costs, 
improve quality of life, and improve medical decision making. 
MTX as cornerstone in RA treatment
Most newly diagnosed chronic inflammatory arthritis patients are prescribed methotrexate 
(MTX) monotherapy with glucocorticoid bridging therapy during the first months as 
recommended by the guidelines of the European League Against Rheumatism (EULAR). [4-6]
Although the exact workings of MTX in RA are still unknown, MTX is the ‘gold standard’ 
in the treatment of various forms of chronic arthritis because it is an effective, safe and 
inexpensive drug. [6, 7] 
 MTX is administered in a fixed (non-personalized) dose, which can be increased 
when response is insufficient. Optimal treatment dosage is very different from patient to 
patient and a significant number of patients do not achieve sufficient remission (20-40%) 
or develop adverse events (30%), leading some patients to stop treatment. [8] The EULAR 
guidelines for treatment recommend to strive for remission in the first three months of 
treatment. [4-6] In order to achieve this, patients are monitored quite closely and every 
1-3 months disease activity is measured. If the target remission in disease activity is not 
achieved, treatment is intensified by increasing the dose or adding co-medication such as 
biologicals. This leads to an unpredictable search for the right treatment and dose of MTX 
until it is determined by trial and error. 
Therapeutic drug monitoring and individualized treatment
Individualized MTX therapy could result in better and faster disease control (lower disease 
activity and less erosive damage) without the need to titrate MTX over the course of 
treatment. This could potentially result in a higher quality of life with less adverse events 
leading to improved drug compliance. 
 A method for the prediction or early detection of non-response is not yet available, 
although some models have been proposed. [9-11] Reliable instruments to predict MTX 
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response/adverse-events and to adjust MTX dosing (individualized therapy) in daily routine 
patient care are lacking. 
 Therapeutic drug monitoring (TDM) of intracellular MTX concentrations may help 
to predict response to treatment and adverse events. Generally plasma levels of a drug are 
used for TDM and MTX levels can be easily measured in plasma, which is used for TDM in 
high-dose treatment of acute lymphoblastic leukemia (ALL). However, during low-dose MTX 
treatment such as in RA there is no accumulation in plasma because of the short half-life of 
<12 hours. MTX is rapidly cleared from the plasma and is unrelated to response. Therefore, 
MTX plasma levels are not a reliable tool for TDM in RA. [12-15]
 In recent years, multiple pharmacogenetic studies found associations between 
several polymorphisms in the purine and folate metabolism and MTX response. [10, 16-
19] These studies have shown that polymorphisms in folate pathway genes contribute 
significantly in predicting response to MTX. In addition, we have recently shown that the 
erythrocyte folate levels also predict response to MTX. [20] Next to these factors, the MTX 
concentration in erythrocytes has been associated with response in multiple studies. [12, 14, 
16, 17, 21, 22] The intracellular MTX levels even override the contribution of certain genetic 
polymorphisms to predict MTX efficacy, [10, 16] making intracellular MTX an interesting 
target for TDM. [12, 16, 17, 21, 23-28] A cut-off value for response has been proposed by 
one research group, they found that patients with less then 60 nmol of MTX-PG3 per liter of 
erythrocytes were 4.4-fold more likely to have a poor response to MTX. [16]
 Although evidence exists for the presence of a correlation between erythrocyte 
MTX levels and response, some studies have not found a correlation between erythrocyte 
MTX and response. [29, 30] However, most studies that investigated the relation between 
erythrocyte MTX levels and response were cross-sectional in nature and included patients 
that had been treated with MTX for extended period of time. This could lead to a selection 
bias for well tolerating, but low/moderately-reacting patients thereby influence the results. 
Pharmacodynamics/metabolism of MTX
MTX is generally administered weekly by orally administered tablets, but can be given 
subcutaneous (or intramuscular) when response is insufficient, when patients do not 
tolerate oral tablets or when compliance is low. Orally administered MTX is rapidly absorbed 
in the small intestine and in RA maximum plasma concentrations are reached by 1.5 hours 
under fasting conditions. [31-33] Parenteral administration leads to more rapid absorption 
and higher plasma levels compared to oral intake. In plasma, the major metabolite of MTX 
is 7-OH MTX, which is thought to be formed in the liver and excreted in the bile. The other 
metabolite that is found in plasma is 4-amino-4-deoxy-N-methylpteroic acid (DAMPA), 
which is most likely formed by gut-bacteria. 
 Methotrexate is structurally similar to folic acid (Figure 1) and is therefore thought 
to share most of the uptake and metabolism routes. [25, 34]  MTX is transported into the cell 
primarily by the reduced folate carrier (RFC). While circulating MTX contains one glutamate 
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moiety (MTX-PG1), intracellular MTX consists of multiple metabolites with a varying amount 
of glutamate groups (Figure 1). Once in the cell, extra glutamate moieties are added in a 
ATP dependent process  by folylpolyglutamate synthase (FPGS) to MTX polyglutamates 
(MTX-PGs) by γ-linked sequential addition of glutamic acid residues. [35] In a competing 
reaction, the MTX-PGs are deconjugated by γ-glutamyl hydrolase (GGH), returning MTX 
to its monoglutamate form, which is pumped out of the cell by the ATP-binding cassette 
(ABC) family of transporters. The balance between import, export, polyglutamation and 
deconjugation leads to a variety of MTX-PG chain-lengths of up to 7 glutamates (MTX-PG2-7, 
Figure 2). The concentration and distribution of these MTX-PGs is dependent on multiple 
factors such as MTX dosage, route of administration and age. [13, 23, 27, 36, 37] Multiple 
SNPs in the folate pathway have also been shown to be associated with MTX-PG status. [12, 
38, 39] 
Figure  1. Molecular structures of folate and methotrexate. The glutamate group of methotrexate is indicated 
between brackets, up to 6 additional (n=7) glutamate groups are added during polyglutamation in the cell. 
Polyglutamation is important for MTX treatment as it is responsible for increasing the size 
of the molecule, making it much more anionic. As a result MTX-PGs cannot diffuse out of 
the cell. [40] Also, the efflux of MTX is severely hindered after polyglutamation. In fact, with 
increasing polylgutamation and a longer MTX-PG chain, the efflux rapidly decreases. While 
MTX-PG1 is actively pumped out of the cell by the ABCC1 to ABCC4 efflux transporters, 
MTX-PG2 and MTX-PG3 are only transported by the ABCC5 and ABCG2 efflux transporters 
and there is no evidence of MTX-PG4-7 being transported out of the cell (Figure 2). The 
results hereof is a build-up of MTX-PGs in the cell over time. [40] 
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Figure 2. MTX-PG metabolism in the cell. After entering the cell via the reduced folate carrier (RFC), MTX is 
polyglutamates by FPGS, increasing activity and leading to retention of intracellular MTX as MTX-PGs are not a 
suitably substrate for the efflux proteins. In a competing reaction, MTX-PGs are de-glutamated by GGH, leading to 
a dynamic equilibrium that is dependent on the import, export and (de-)polyglutamation of MTX.
MTX: Methotrexate; Glu: glutamate group; RFC: reduced folate carrier; ABCC1-5/ ABCG2: ATP-binding cassette 
(ABC) transporters; FPGS: Folylpolyglutamate synthase; GGH: gamma-glutamyl hydrolase.
The importance of MTX-PGs
 The polyglutamated forms of MTX also have significantly higher affinity for its targets 
enzymes compared to native MTX and efficacy of MTX is thought to increase with the 
polyglutamation levels.  [10, 12, 23, 28, 41, 42] In low-dose MTX treatment, the setting for RA 
treatment, the pentaglutamate (MTX-PG5) is the highest order of glutamylation detected, 
while the triglutamate form (MTX-PG3) of MTX predominates. [13, 22, 27, 36, 43, 44]
 In line with the highly variable clinical response to MTX, the time to reach 
steady-state erythrocyte MTX levels is highly variable between patients as are the steady 
state erythrocyte MTX levels. [13, 14, 37] This link between inter-patient MTX response 
variability and the large inter-individual variation in the rate and extent of erythrocyte MTX 
accumulation suggests that erythrocyte MTX measurement may be a valuable tool for the 
clinician to individualize MTX treatment in an early phase in order to achieve faster disease 
remission and less erosive damage. 
 In low dose MTX, the median time to reach steady-state erythrocyte MTX levels is 
highly variable between patients and increases with the number of PGs attached to MTX. 
[13, 37] For example, MTX-PG3 has a median time to reach steady-state of 41.2 weeks 
(range 19.8-66.7 weeks) compared to 139.8 weeks (range 15.5-264.0 weeks) for MTX-PG5. 
Adapted from Dalrymple et al. Arthritis Rheum. 2008 Nov;58(11):3299-308
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[13] Steady-state levels also are highly variable between patients: total erythrocyte MTX-PG 
concentration varied between 90.9 and 351.5 nmol/8*1012 erythrocytes. [13, 14, 23, 27, 43] 
The mechanisms and determinants of the highly variable intracellular MTX-PG levels are still 
not completely known, as most studies focus on the prediction of response/adverse events. 
Previous research has shown that increased age, higher dose, route of administration and 
decreased renal function are associated with higher erythrocyte MTX-PG levels.27, [36, 
37] A relation betwee multiple single nucleotide polymorphisms (SNP) in MTX pathway 
genes with MTX-PG levels has also been suggested. [24, 28] However, these studies used 
cross-sectional cohorts with a wide range of treatment duration between patients making 
it difficult to interpret the results or extrapolate them to a currently treated patient. Also, 
none of the studies included an independent cohort to validate their findings.
Measurement of MTX-PGs
The physiological action of Methotrexate (MTX) is most likely exerted by the white blood 
cells. However, when determining MTX-PGs in the cells, erythrocytes are mainly chosen. 
Erythrocytes are a more accessible, cost-effective and patient-friendly resource because of 
the high amounts of erythrocytes in the blood and the ease of isolation, facilitating clinical 
implementation. As erythrocytes lack the cellular machinery for the polyglutamation of MTX, 
the erythrocyte MTX-PG levels are considered to be a representation of the incorporation 
of MTX-PGs in the progenitor cell and are thought to function as a surrogate marker for the 
white blood cell levels. [16, 45] 
 In contrast to plasma levels, intracellular levels are difficult to measure because 
the intracellular MTX content consists of multiple MTX-PG species and specialty equipment 
like HPLC or LC-MS/MS is needed. Of the methods aimed towards the determination of 
intracellular methotrexate, a large part is devoted to the measurement of total intracellular 
MTX instead of the separate MTX-PGs.
 Total intracellular MTX can be assessed by fluorescence polarization immunoassay 
(FPIA), when adapted to measure in hemolysate. [46, 47] This utilises the cross reactivity 
between MTX species to measure all MTX-PGs. A specific problem that arises with 
immunoassay-based methods is the high cross reactivity of the assays. While this enables 
the measurement of the intracellular MTX-PGs, it also causes interference from other 
MTX metabolites such as DAMPA and 7-OH-MTX. [48, 49] Other methods generally break-
down the intracellular MTX-PGs by enzymatic hydrolysis to MTX, which is then measured. 
[26, 50, 51] This has as the benefit that it shortens run-time and simplifies interpretation. 
However, total intracellular MTX levels might be influenced by high amounts of MTX present 
in the plasma, as MTX can diffuse over the erythrocyte membrane. [52] This makes it very 
important to know when patients take their medication, in order to plan the blood sampling 
outside the window of high plasma MTX. 
 Intracellular MTX-PG concentrations can be determined by analytical techniques 
such as Radio ligand binding with fractioning of the eluate, [53] capillary-zone electrophoresis 
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[54] and high-performance liquid chromatography with post-column photo-oxidation. [43] 
However, these techniques are laborious, can be influenced by interference from endogenous 
folates, [44] and use equipment not generally available at a clinical lab. Therefore, they are 
less suitable for routine measurement in patients.
 Recently, two MS based methods have been described for the measurement of 
intracellular MTX-PGs. However, one method was designed for measuring in the Caco-2 cell-
line, and both sample preparation and chromatography is not convertable to erythrocytes. 
[55] The other method consists of an ion-pairing liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) assay. [44, 56] In multi-assay mass spectrometry (MS), the use 
of ion-pairing can lead to interference with the other assays and needs extensive clean-up 
between runs, which is not ideal for routine clinical application. Most importantly though, 
neither of these methods used stable-isotope-labelled internal standards for each MTX-PG, 
and are therefore not able to compensate for recovery and matrix-effects for the individual 
MTX-PG. 
Aims of this thesis
The aims of this thesis were:
1) To develop a quantitative method for the measurement of erythrocyte MTX-PG. 
2) To examine which clinical, genetic, socio-demographic, and biochemical factors 
 influence the erythrocyte MTX-PG levels in patients treated with low-dose MTX.
3) To examine the prospective accumulation of MTX-PGs in erythrocytes during 
 low-dose pulse MTX treatment and its association with response.
Outline of the thesis
In Chapter 2 we describe the development of a new bioanalytical assay to measure 
erythrocyte MTX-PGs in using a novel high-throughput rapid mass-spectrometric technology, 
which merges a high-repetition matrix-assisted laser desorption/ionization (MALDI) source 
with a triple quadruple mass analyzer. 
 Because the MALDI-MS/MS is a very specific and non-standard technology, it might 
not be possible for the routine clinical lab to obtain such a machine and a more ‘standard’ 
method would be useful. Therefore in Chapter 3 we show the development and clinical 
validation of a new LC-MS/MS based assay for the determination of the erythrocyte MTX-
PGs, and the subsequent application of the method in 50 samples from MTX treated 
patients.
 Although plasma levels are cleared within 24 hours and do not correlate  with 
response, being able to precisely measure the plasma levels may be important for 
pharmacokinetic studies and other disease types. An interference free method to measure 
plasma MTX is also important during glucarpidase treatment to rescue patients from toxic 
MTX levels. [57-59] Therefore we have adapted the method described in chapter 3 for the 
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measurement of MTX in plasma. Chapter 4 describes the development and validation of a 
new LC-MS/MS based method for the determination of MTX in plasma, and the subsequent 
comparison to the in-house immune-assay.
 As not every routine clinical lab will have an LC-MS/MS system available for the 
measurement of MTX-PGs, an easy and accessible method for the determination of total 
MTX-PGs in erythrocytes using a routine immune-analyser is described in Chapter 5. 
 The factors that influence the erythrocyte MTX-PGs levels are not clear yet, therefore 
in Chapter 6 we apply this method in two independent prospective study populations of 
MTX treated RA patients in order to determine the biological, genetic and behavioral factors 
that determine the intracellular levels of MTX-PGs.
 Because there is little information available about the effect of different MTX dosing 
schemes on the concentration, distribution and speed of accumulation of the intracellular 
MTX-PGs we examined the concentration profile of erythrocyte MTX-PGs over 9 months of 
treatment in 2 study populations of MTX treated patients in Chapter 7.
 There have been multiple studies that show a relation between erythrocyte MTX-
PGs and clinical response. However, no large prospective studies with a validation cohort 
have been performed. In Chapter 8, we show the association of erythrocyte MTX-PGs and 
disease activity using two independent prospective cohorts.
 Finally, in Chapter 9 we discuss the results and implications of our studies.
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Abstract
SUMMARY A new ultrafast quantitative and high-throughput mass spectrometric 
method using Matrix-Assisted Laser Desorption/Ionization-triple quadrupole-tandem 
mass spectrometry has been developed and validated for determination of intracellular 
erythrocyte concentrations of the antifolate drug methotrexate (MTX) and its polyglutamate 
metabolites. 
METHODS The method consist a solid phase extraction of MTX and MTX-polyglutamate 
metabolites from deproteinized erythrocyte lysates spiked with aminopterin as internal 
standard. The new developed method was validated according to the most recent FDA 
guidelines on linearity, recovery, within-run and between run accuracy and precision and 
stability of the analytes. The low limit of quantification (LLOQ) was 10 nmol/L for all analytes 
while the limit of detection (LOD) determined at a signal-to-noise ratio (S/N=3:1) in drug 
free erythrocyte lysate was 0.3 nmol/L. 
RESULTS After validation, the new method was used in the measurement of intracellular 
erythrocyte concentrations of MTX and MTX-polyglutamate metabolites (MTX-PG2 to 
MTX-PG7) in packed human erythrocyte samples collected from patients with rheumatoid 
arthritis receiving low-dose oral methotrexate therapy. Mean (SD) intracellular erythrocyte 
concentrations observed in patient samples were 12.8 (12.6), 12.4 (9.4), 44.4 (30.0), 33.6 
(35.9) and 9.4 (8.2) nmol/L for MTX to MTX-PG5, respectively in 106 erythrocytes. The 
highest observed glutamylation degree of MTX was MTX-PG5, the very long chain MTX-
polyglutamate metabolites MTX-PG6 and MTX-PG7 were not detected in the packed 
erythrocyte pellets from rheumatoid arthritis patients. 
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Introduction 
Methotrexate (N-[4[[(2,4-diamino-6-pteridinyl) methyl] methyl-amino] benzoyl]-L-glutamic 
acid; MTX) is a cytotoxic drug (folate antagonist) which is used to treat diseases such as 
leukemia, severe psoriasis and rheumatoid arthritis (RA). MTX inhibits competitively and 
reversibly the enzyme dihydrofolic acid reductase (DHFR) resulting in the inhibition of 
nucleic acid synthesis and in cell death[1]. MTX is applied in different doses depending 
on the disease; high dosage (up to 5000 mg/week) for treatment of different cancer 
types (e.g. leukemia) and in much lower doses for psoriasis [2] and rheumatoid arthritis 
(RA) [3] (5-25 mg/week). In RA, MTX is used as first-line drug. After admission of MTX, its 
plasma concentration decrease rapidly. MTX is transported into cells by the reduced folate 
carrier where it is retained, long after MTX has been eliminated from the plasma. MTX is 
metabolized intracellular by enzymatic polyglutamylation (folate-γ-glutamyl-tranferase) into 
MTX-polyglutamate metabolites by the addition of glutamate residues (max. 6 residues are 
added). Intracellular glutamylation increases the polarity of MTX resulting in intracellular 
retention prolonging drug action. MTX-polyglutamate metabolites can cause severe adverse 
events that can be counteracted by supplementation with folic acid (vitamin B9 or B11). Due 
to the low dose and the relatively short half life (8-15 hrs), it is no use measuring plasma MTX 
concentrations in low dose MTX therapy [4] and hence, MTX plasma levels do no correlate 
with disease activity [5]. In contrast, intracellular MTX-polyglutamates predict MTX response 
in RA patients especially the MTX-polyglutamates with three or more glutamic acid residues 
(MTX-PG3 to MTX-PG5) are associated with this therapeutic response while MTX and MTX-
PG2 are poorly associated with therapeutic efficacy [6].
 MTX and MTX-polyglutamate concentrations can be determined by analytical 
techniques such as high performance liquid chromatography (HPLC) with post column photo 
oxidation [4,6,7]. Total intracellular MTX can also be assessed after enzymatic hydrolysis 
of the polyglutamates followed by photometric measurement [8]. MTX-polyglutamate 
concentrations can also be determined by fluorescence polarization immunoassay (FPIA) 
[9] and capillary zone electrophoresis [10]. These techniques are laborious and influenced 
by interference from natural folates or other MTX related compounds. Recently, an ion-
pairing liquid chromatography-tandem mass spectrometry (LC-MS/MS) technique was 
described with increased specificity [11]. We decided to select a different analytical 
technology to determine intracellular polyglutamate concentrations. We applied a relative 
new mass spectrometric technology. This technology combines Matrix-Assisted Laser 
Desorption/Ionization (MALDI) and triple quadrupole (tandem) mass spectrometry 
(MALDI-QqQ-MS(/MS)) and was launched in 2008. It proved to be a robust and sensitive 
technology which can be applied for ultrafast and high-throughput analyses of small 
molecules because it does not necessarily require liquid chromatographic separation of 
samples prior to mass spectrometric analysis [12-14]. Omitting liquid chromatographic 
separation in combination with MALDI reduces analysis time considerably to approx. 10 
seconds per sample [13] or less. MALDI-QqQ-MS technology has been proven to be a versatile 
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quantitative tool in the ultrafast and high-throughput determination of concentrations of 
drugs  (extra-and intracellular) such as antiretroviral drugs (protease inhibitors) [12,14,15], 
anticancer drugs [13,16] but also other types of drugs [17-19] and as screening tool in 
enzyme kinetic studies [20]. Moreover, Volmer et al. [21] demonstrated that MALDI-QqQ-
MS technology has equal analytical performances in comparison to conventional LC-MS 
instrumentation using electrospray ionization (ESI)The aim of this study was to develop a new 
mass spectrometric method for measurement of intracellular MTX and MTX-polyglutamate 
concentrations in packed erythrocyte pellets from patients on low-dose MTX therapy.
Methods
Materials
4-amino-10-methylpteroylglutamic acid (MTX), 4-amino-10-methylpteroyldiglutamic 
acid (MTX-PG2), 4-amino-10-methylpteroyltriglutamic acid (MTX-PG3), 4-amino-10-
methylpteroyltetraglutamic acid (MTX-PG4), 4-amino-10-methylpteroylpentaglutamic 
acid (MTX-PG5), 4-amino-10-methylpteroylhexaglutamic acid (MTX-PG6),4-amino-10-
methylpteroylheptaglutamic acid (MTX-PG7) and internal standard 4-aminopteroylglutamic 
acid (Aminopterin; AO) were purchased from Schircks Laboratories (Jona, Switzerland). 
LC-MS grade methanol and water were obtained from Biosolve (Valkenswaard, the 
Netherlands) and all MALDI matrices and tricloroacetic acid (TCA) were purchased from 
Sigma Aldrich (Zwijndrecht, the Netherlands) and were Matrix-Assisted Laser Desorption/
Ionization time-of-flight mass spectrometric (MALDI-TOF) quality. The erythrocyte lysis 
buffer was purchased from Roche (Almere, the Netherlands. The 96-well SPE plates were 
purchased from Sigma Aldrich (DSC-C8 and DSC-C18; 25 mg) and from Waters (Oasis HLB-
30 mg, Breda, the Netherlands). Primary stock solutions of MTX and MTX-polyglutamate 
metabolites (MTX-PG2, MTX-PG3, MTX-PG4, MTX-PG5, MTX-PG6 and MTX-PG7) were 
prepared in potassium hydroxide solution (0.02 mol/L) at 44, 44, 44, 44, 58, 22, 22 µmol/L 
for MTX, MTX-PG2, MTX-PG3, MTX-PG4, MTX-PG5, MTX-PG6 and MTX-PG7, respectively. 
Chemical structures of MTX, MTX-polyglutamates and the internal standard aminopterin 
are illustrated in Figure 1.
 
MALDI-QqQ-MS/MS conditions
The MALDI-QqQ-MS/MS instrumentation used was a FlashQuant™ workstation containing 
a high repetition rate solid state UV-laser (FlashLaser; 349 nm, 1000 Hz) combined with a 
4000 API mass analyzer (AB Sciex, Concord, Canada) operating in positive ionization mode 
with selected reaction monitoring (SRM) of the selected analytes at unit resolution. SRM for 
MTX and MTX-polyglutamate metabolites corresponded to following transitions: [M+H]+ → 
[M-((C5H9NO4)n-(H2O)m)+H]+ with n=1 to 7 and m=(n-1) for MTX to MTX-PG7, respectively 
illustrating the loss of the polyglutamate chain. Optimized MALDI-QqQ-MS instrument 
parameters used were: laser power 55%, skimmer voltage 0V; CAD gas 8 arbitrary units (3.0-
3.33*105 torr, N
2
); source gas 10 arbitrary units (3.33-4.17*105 torr, N
2
), dwell time 10 ms 
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and laser raster speed of 1 mm/sec. Instrument control and data analyses were performed 
using Flashquant 1.0 software and Analyst 1.4.2 application software (AB Sciex, Concord, 
Canada). 
Figure 1. Chemical structures of Methotrexate (MTX), MTX-polyglutamate metabolites and internal standard 
Aminopterin and respective SRM transitions of protonated molecular ions [11].
Determination of MALDI ionization efficacy
The type of MALDI ionization matrix compound used can have a significant impact on 
sensitivity of the MALDI-QqQ-MS/MS measurements since the ionization efficacy of 
the analyte by selected MALDI matrix compound can be significant different. Therefore, 
we determined the influence of the MALDI matrix compounds on the ionization efficacy 
of MTX and all MTX-polyglutamate metabolites. We applied different MALDI matrix 
compounds which are frequently applied in MALDI-TOF. Tested were: 2,5-dihydroxy benzoic 
acid (2,5-DHB),7-hydroxy-4-(trifluoromethyl)-coumarin (HFMC) [22], super-DHB (SDHB; 
mixture of 2,5-DHB and 5-methoxysalicylic acid), 9-amino acridine (9-AA) and α-cyano-
hydroxy-cinnamic acid (α-CHCA). MALDI matrices such as 2,5-DHB and SDHB were used at 
a concentration of 30 mg/mL, HFMC and 9-AA at 10 mg/mL and α-CHCA at 6.2 mg/mL, 
respectively.
 The ionization efficacy of each individual MALDI matrix compound was determined 
by the measurement of the total counts per second (CPS) signal for all analytes at one 
concentration using each MALDI ionization compound, respectively. The CPS signal was 
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measured using following protocol: 20 µL of individual MTX and MTX-polyglutamate 
metabolite stock solutions (100 nmol/L in 50% (v/v) methanol/water) were mixed at a ratio 
of (1:1) with the different MALDI matrix solutions and subsequently five spots of 0.5 µL 
were spotted onto the MALDI target plate. Detection of the positive charged (protonated) 
ions were done in full scan mode (m/z= 450 to 1250) using a scan time of 1s. After the 
experiments, the MALDI matrix compound with the highest ionization efficacy was used for 
further fine-tuning of MALDI-QqQ-MS/MS instrument settings and the optimal sensitivity 
by determination the best mixing ratio between analyte solution and MALDI matrix solution 
and the maximum sample amount (µL) to be spotted onto the stainless steel MALDI target 
plate. 
Development of solid phase extraction procedure
A solid phase extraction (SPE) procedure was developed because MTX and MTX-
polyglutamate metabolite concentrations are very low (fmol/106 erythrocytes) [4, 6, 9, 
23]. At first, we determined the best SPE adsorbent material by determination of recovery 
rates for MTX and all MTX-polyglutamate metabolites applying 96-well SPE plates containing 
following adsorbents: octyl (C8), octadecyl (C18) and hydrophilic modified styrene polymer 
(HLB). The C8 and C18 well plates contained 25 mg adsorbent while the 96-well SPE-HLB 
plate contained 30 mg of adsorbent. The recovery rates of MTX and all other individual 
MTX-polyglutamate metabolites on the C8, C18 and HLB adsorbents were determined by 
spiking four different amounts of erythrocyte pellets (from healthy controls) with MTX 
and MTX-polyglutamate metabolites at one concentration (MTX, MTX-PG2, MTX-PG4; 44 
nmol/L, MTX-PG3; 58 nmol/L and MTX-PG5, MTX-PG6, MTX-PG7 at 22 nmol/L,respectively). 
Erythrocyte pellet volumes of 25, 50, 75 and 100 µL (in triplicate) were homogenized 
and lyzed with 65 µL water, 10 µL of internal standard (500 nmol/L) and 150 µL of the 
erythrocyte lysis buffer solution followed by deproteinized of the lysate by 50 µL TCA (50% 
w/v). Collected deproteinized supernatants were diluted with 1000 µL of water and further 
processed by SPE using the three different types of adsorbents and recovery rates for MTX 
and all MTX-polyglutamate metabolites were determined. 
 
Calibration curve of MTX and MTX-polyglutamate metabolites
The linear concentration ranges of the method for MTX and all MTX-polyglutamate 
metabolites were determined by applying calibrators prepared in whole blood by spiking 
MTX and MTX-polyglutamate metabolites at different concentrations. The whole blood 
applied for the preparation of calibrators was obtained from a healthy control (Sanquin Blood 
Supply Foundation, Rotterdam, the Netherlands) and calibrators were made by dilution of 
primarily stock solution containing MTX and MTX-polyglutamate metabolites (1000 nmol/L 
per analyte) with drug free whole blood yielding following calibrator concentrations: 1000, 
500, 250, 100, 50, 25, 10 and 0 nmol/L (blank). The calibration curves were prepared by 
spiking each calibrator (25µL in triplicate) with 10 µL of the internal standard aminopterin 
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(AO; 500 nmol/L) followed by lysis of the erythrocytes with 65 µL of water, 150 µL of 
erythrocyte lysis buffer (Roche, Almere, the Netherlands) and  deproteinization of the 
erythrocyte lysates by 50 µL of TCA. Precipitated proteins were removed by centrifugation 
for 5 min at 400 x g at ambient temperature.After collection of the supernatants, 1000 µL 
of water were added and analytes were extracted from the supernatants by solid phase 
extraction (SPE) using an Oasis HLB 96-SPE well plate (Waters, Etten-Leur, the Netherlands) 
containing 30 mg adsorbent. The SPE adsorbent was conditioned by washing the adsorbent 
with 1 mL of methanol followed by 2 x1 mL of water. After adsorption of the analytes 
and washing of the SPE adsorbent by 1 mL of water, elution of the analytes from the SPE 
adsorbent was achieved by 200 µL of methanol.Aliquots of 20 µL from collected SPE extracts 
were mixed with 40 µL of α-HCA-MALDI matrix solution and 0.5 µL were spotted in fivefold 
onto a 96-well stainless steel MALDI target plate (123 x 81 mm).Pipetted spots were let to 
dry and crystallize for 5 min at ambient temperature prior to MALDI-QqQ-MS/MS analysis. 
Calibration curves from all analytes were fit by linear regression of the ratio between the 
SRM peak areas of analyte and internal standard versus analyte concentrations by using 
GraphPad Prism software version 5.00 for Windows (GraphPad software, San Diego, USA).
Accuracy and precision 
Within-run and between run accuracy and precision were determined by analyzing 
erythrocyte lysates prepared from 25 µL of whole blood in threefold  spiked at three different 
concentration levels with all analytes at low, middle and high concentrations [24]. Within-
run accuracy and precision were assessed with 3 replicate erythrocyte lysates spiked at 500, 
100 and 20 nmol/L for each analyte, whereas between run accuracy and precision were 
assessed with 3 replicates of each concentration level analyzed on 3 subsequently different 
days. Accuracy was determined from the difference between measured concentrations and 
spiked nominal concentrations and was expressed as %error. Precision was determined by 
calculation of the coefficient of variation (%CV) of the replicate measurements (%CV). 
Application of method to RA patient samples
During MTX administration, 8 mL CPT cell preparation tubes (Becton Dickinson, Breda, the 
Netherlands) were collected on t=3 months (patients 1-7) and 9 months (patients 8-10) 
during therapy by venapuncture from RA patients receiving low dose MTX therapy (15-25 
mg MTX/week). The included patients had inflammatory joint complaints for less than 1 
year. Patient blood samples were collected in compliance with the Helsinki regulations and 
patients gave written consent (MEC-2006-252).
 Hematocrit, erythrocyte cell count, (differential) white blood cell count, 
hemoglobin concentration and platelet counts were determined from EDTA whole-blood 
using a Sysmex XE-5000 hemocytometer (Sysmex, Etten-Leur, The Netherlands). CPT tubes 
were centrifuged at room temperature for 20 minutes at 1500-1800 x g to separate blood 
cells (erythrocytes and monocytes) and obtained plasma was immediately stored at -80°C. 
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From all RA patients hematological parameters such as hematocrit, erythrocyte count 
(1012/L), hemoglobin concentration and platelet count were known, erythrocyte count and 
hematocrit values were used to determine the number of erythrocytes/µL in the packed 
erythrocyte pellet. Mean hematocrit (SD) was 0.43 (0.03) and and mean erythrocyte count 
(SD) was 4.56 x 1012/L (0.37). Collected erythrocyte pellets contained approx. 10 million 
erythrocytes/µL and for the measurement of the intracellular erythrocyte MTX and MTX-
polyglutamate metabolite concentrations in average 250 million erythrocytes were used. 
Results and discussion 
Method development
MALDI ionization efficacy and sensitivity 
The highest ionization efficacy for all MTX-polyglutamate metabolites was obtained using 
α-CHCA as MALDI matrix in combination with a sample/MALDI matrix solution ratio of 1:2 
and sample spots of 0.5 µL. Application of α-CHCA as MALDI matrix compound resulted 
in significant higher total ion counts (CPS) for all protonated molecular ions of MTX 
polyglutamates (Figure 2). 
Figure 2. Ionization efficiencies of studied MALDI ionization compounds on methotrexate and metothrexate 
polyglutamate metabolites. Applied MALDI-QqQ-MS instrument parameters (full scan m/z 450 to 1250) laser 
power 55%, skimmer voltage 0V; source gas 10 arbitrary units (3.33-4.17*105 torr, N
2
) and laser raster speed of 1 
mm/sec 
 Protonated molecular ions of MTX and MTX-polyglutamate metabolites using 
α-CHCA were used for further optimization of MALDI and MS instrument parameters such 
as plate voltage (V), collision energy (CE), collision cell exit potential (CXP), collision gas 
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(CAD), source gas, and skimmer voltage setting. Optimized MALDI-QqQ-MS/MS instrument 
settings for MTX and MTX-polyglutamate metabolites and the internal surrogate standard 
aminopterin are presented in Table 1. 
Mass spectrometric analysis of MTX and MTX-polyglutamate metabolites
Collision induced fragmentation (CID) of the protonated molecular ions from MTX and 
MTX-polyglutamate metabolites resulted in MS/MS spectra where one main high abundant 
fragment ion at a mass-to-charge ratio of m/z 308.2 was observed, although also few smaller 
fragment ions with lower abundance were observed; for the internal standard aminopterin, 
identical fragmentation behavior was observed with one difference that a high abundant 
fragment ion was observed at m/z 294.2. The high abundant fragment ions observed at m/z 
308.2 for all analytes were selected for SRM analyses. The formation of this high abundant 
fragment ion originate from an intermolecular cleavage of the amide bond in MTX and MTX-
polyglutamate metabolites situated between the first glutamyl-moiety and the 4-amino-
10-methylpteroyl-backbone of MTX-polyglutamate molecules (Figure 1). The cleavage of 
the amide bond resulted after hydrogen rearrangement in the loss of a neutral glutamate 
molecule (M-C
5
H
9
NO
4
; M-147) for MTX as well as the loss of neutral charged polyglutamyl-
peptide containing between two and seven glutamate moieties for MTX-PG2 until MTX-PG7, 
respectively as also reported by van Haandel et al. [11] using LC-ESI-MS/MS. 
Validation 
Significant different recovery rates for MTX and MTX-polyglutamate metabolites were 
observed for the three tested different SPE adsorbent materials. The lowest recoveries for 
all analytes were observed using the SPE-C8 adsorbent material, recovery ranges obtained 
applying this SPE adsorbent material ranged between 62.4% for MTX and 17.6% for MTX-
PG6. Higher recovery rates were obtained for the SPE-C18 material, recovery ranged here 
between 85.6% and 57.9 % for MTX and MTX-PG7, respectively. The highest recoveries were 
observed for the HLB-SPE material, recoveries observed were 71.3, 75.1, 96.7, 86.3, 88.5, 
90.3 and 97.7% for MTX to MTX-PG7, respectively.
 The recovery of the internal standard aminopterin was in the range of MTX and 
the MTX-polyglutamate metabolites, the recovery was 81.2%. After determination of the 
SPE adsorbent material with the highest recovery rates for all analytes, the maximum 
sample loading of this adsorbent was determined by applying different amounts of packed 
erythrocyte pellet, tested were 25, 50, 75 and 100 µL of packed erythrocyte pellet and 
recoveries of MTX and MTX-polyglutamate metabolites were determined. Highest recovery 
rates for all analytes were observed when 25 µL of lyzed erythrocyte pellets were applied. 
Higher loading amounts resulted in significant lower recovery rates for all analytes (Figure 3). 
Obviously, higher amounts of erythrocyte cell pellets overloaded the SPE adsorbent and 
caused desorption (breakthrough) of the analytes. 
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Table 1. MALDI-QqQ-MS/MS instrument settings for the quantitative measurement of 
MTX-PGsa,b
Analyte Abbr. SRM Plate Voltage CE CXP
(m/z) (V) (V) (V)
4-amino-10-methylpteroylglutamic acid MTX 455.2  308.2 45 25 10
4-amino-10-methylpteroyldiglutamic acid MTX-PG2 584.4   308.2 30 43 10
4-amino-10-methylpteroyltriglutamic acid MTX-PG3 713.4  308.2 35 43 10
4-amino-10-methylpteroyltetraglutamic acid MTX-PG4 842.4  308.2 45 60 10
4-amino-10-methylpteroylpentaglutamic acid MTX-PG5 971.6  308.2 60 70 15
4-amino-10-methylpteroylhexaglutamic acid MTX-PG6 1100.3  308.2 80 80 10
4-amino-10-methylpteroylheptaglutamic acid MTX-PG7 1229.4  308.2 75 90 25
4-amino-pteroyldiglutamic acid AO 441.2  284.2 50 28 15
aSkimmer voltage (0 Volts), bAs collision gas (CAD) N
2
 was applied
Figure 3. Recovery rates for individual MTX-polyglutamates in spkied erythrocyte pellets in relation to the 
erythrocyte pellet volume used for solid-phase extraction using Oasis HLB 96-well plates containing 30 mg 
adsorbent.
The selected concentration range using lysates produced from erythrocyte pellets based 
calibration standards indicated a linear relationship between the analyte peak area/
IS ratio of each individual MTX-polyglutamate metabolites and their concentration 
(MTX: y=1.3224x+0.3546, r2=0.9981; MTX-PG2: y=0.4042x-0.0443, r2=0.9936; MTX-
PG3: y=0.1649x-0.0317, r2=0.9905; MTX-PG4: y=0.0709x-0.0078, r2=0.9945; MTX-PG5: 
y=0.1137x-0.0189, r2=0.9912; MTX-PG6: y=0.2063-0.004, r2=0.9928 and MTX-PG7: 
y=0.01113x-0.0011, r2=0.9961). The LLOQ for each individual MTX-polyglutamate metabolite 
was defined as the calibrator with the lowest concentration used to calculate the calibration 
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curve which could be measured with an accuracy and precision of <20 %CV [24]; the LLOQ 
for the MTX-polyglutamate metabolites was 10 nmol/L for MTX to MTX-PG7, respectively. 
The upper limit of quantification (ULOQ) was defined as the highest concentration calibrator 
which could by measured with acceptable accuracy and precision of <15 %CV; the ULOQ was 
1000 nmol/L for all MTX-polyglutamates. 
 The limit of detection (LOD) defined as three times the signal-to-noise ratio (3:1) 
of drug free control whole blood was 1 nmol/L for MTX and MTX-PG2 and 3 nmol/L for 
MTX-PG3 to MTX-PG7, respectively. Validation of the method’s accuracy and precision by 
determination of with-run and between run accuracy and precision using quality control 
samples prepared at three different concentration levels (500, 100 and 20 nmol/l for each 
analyte) were in compliance with FDA criteria (CV and %error < 20%) (Table 2). Precision of 
the new method was expressed as %CV from within-run validation and ranged between 5.5 
and 14.4%, while within-run precision ranged between 4.9 and 14.6%, respectively. 
 
Figure 4. Stability of MTX and MTX-polyglutamate metabolites in a packed erythrocyte pellet spiked at a 
concentration of 100 nmol/L per analyte, illustrated are measured concentration of all analytes at day 0 and 
day 3 (mean ± SD).
Accuracy of the new method expressed as %error ranged for within-run validation between 
-8.5% and 9.8%, while the %error for the between run measurements were between -7.5% 
and 4.5%, respectively. The stability of MTX and its MTX-polyglutamate metabolites in 
erythrocyte matrix were tested by an erythrocyte pellet (25 µL) spiked with MTX and MTX-
polyglutamate metabolites at a concentration of 100 nmol/L by measuring at day 0 and day 
3. The stability of all analytes in the erythrocyte matrix was stable (expressed as %error) 
and were found to be <20 %error (Figure 4).Dervieux et al. [6] reported a mean sum of 
individual MTX- polyglutamate metabolite in seventy RA patients of 120 nmol/L (MTX to 
MTX-PG5). The intracellular concentrations were determined applying HPLC in combination 
with fluorescence detection of the MTX-polyglutamate metabolites. Van Haandel et al. [11] 
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used a LC-MS/MS assay for the determination of erythrocyte intracellular MTX and MTX-
polyglutamate metabolite concentrations and reported a concentration of 153 nmol/L (sum 
of MTX to MTX-PG6) for a JIA patient (Juvenile Idiopatic Arthritis) on MTX therapy. 
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Figure 5. Individual intracellular erythrocyte MTX and MTX-polyglutamate metabolite concentrations in ten 
RA patients; (a) MTX, (b) MTX-PG2, (c) MTX-PG3, (d) MTX-PG4 and (e) MTX-PG5, (f) observed concentrations of 
individual MTX-polyglutamates. The concentrations of the very long chain MTX-PG6 and MTX-PG7 were < LOD. 
Illustrated are mean concentrations and SD obtained from an analysis of 25 µL of a packed erythrocytes pellet in 
triplicate by MALDI-QqQ-MS/MS. (*) depicts concentration of this MTX-polyglutamate metabolite is <LOD.
 
In comparison to measured sum of individual MTX and MTX-polyglutamate metabolite 
concentrations (139 nmol/L; MTX to MTX-PG5) in our study of RA patients both publications 
are consistent with both publications. In contrast to reported concentrations we observed 
a concentration (SD) of the MTX-PG4 metabolite of 33.6 nmol/L (35.9) was almost equal to 
the MTX-PG3 metabolite concentration level which was 43.6 nmol/L (30.0). An unambiguous 
explanation is difficult to give since many parameters could cause this significant difference. 
These include differences in pharmacokinetics between patients, time point of sample 
collection, and storage of samples [7]. The time reaching steady state concentrations for 
MTX and MTX-polyglutamate metabolites can be significant different, especially for MTX-
PG4 time ranges between 16 and 832 weeks (mean 146 weeks) were observed with patients 
while for MTX to MTX-PG3 metabolite 6, 11 and 41 weeks and for MTX-PG5 140 weeks were 
reported [7]. Depending on the point of the sample collection 
higher or lower concentrations can be expected [7]. Higher MTX-PG4 concentrations were
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reported as being associated with improved MTX efficacy in RA patients [23]. In general, 
our findings are consistent with previously reported intracellular concentrations [6,26,27] 
although also a large variation in individual MTX-polyglutamate metabolite concentrations 
between our ten included RA patients per MTX-polyglutamate metabolite was observed 
(Figure 5). This large variation in individual MTX-polyglutamate metabolite concentrations 
was also observed by Dalrymple et al. [7] who reported a large interpatient variability of 
erythrocyte MTX and MTX-polyglutamate metabolite accumulation and elimination in 
adults with RA. 
Conclusion
The newly developed MALDI-QqQ-MS/MS method allows a sensitive and accurate 
measurement of therapeutically relevant concentrations of MTX and MTX-polyglutamate 
metabolites in erythrocytes from patients receiving low dose MTX therapy. This new 
technology is comparable to other analytical methods such as fluorescence polarization 
immunoassay (FPIA) and HPLC in combination with fluorescence detection after photo-
oxidation or LC-MS/(MS) is that it is ultrafast and therefore can be applied for high-
throughput measurements of large number of samples of large patient population studies. 
A major advantage of the MALDI-QqQ-MS instrumentation is that the instrumentation is 
directly available for analysis of other substances without downtime of the instrumentation 
compared with common LC-MS instrumentation due to exchange of separation columns 
and equilibration of the applied instrumentation. 
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Abstract
BACKGROUND: The folate antagonist methotrexate (MTX) is the anchor drug in the 
treatment of rheumatoid arthritis. The therapeutic effects of MTX are attributed to the 
intracellular levels of MTX, present in the cell as polyglutamates (MTX-PGs). We developed 
a new LC-ESI-MS/MS based assay to separately quantitate MTX-PGs in red blood cells using 
stable isotope internal standards.
METHODS: Samples were analysed by LC-ESI-MS/MS using a Waters Acquity UPLC BEH 
C18 column with a 5-100% organic gradient of 10 mM ammonium bicarbonate (pH10) and 
methanol. The analysis consisted of simple sample preparation and 6 minute run time. 
Detection was done using a Waters Acquity UPLC coupled to a Waters Quattro Premier XE 
with electrospray ionization operating in the positive ionization mode. Assay validation was 
performed following recent FDA guidelines. 
RESULTS: The method was linear from 1-1000 nmol/L for all MTX-PGs (r2 >0.99). The 
coefficient of variation ranged from 1-4% for intraday precision and 6-15% for interday 
precision. Samples were stable for at least 1 month at −80°C. Recovery ranged from 98-100% 
and the relative matrix-effect varied from 95-99%. The LLOQ was 1 nmol/L for each MTX-PG. 
50 patients samples from the tREACH study were analyzed. The MTX-PG concentration and 
distribution of these samples were comparable with values reported in literature.
CONCLUSIONS: The developed LC-ESI-MS/MS method for the quantitative measurement of 
MTX-PGs in erythrocytes is both sensitive and precise within the clinically relevant range. 
The method can be easily applied in clinical laboratories due to the combination of simple 
pre-treatment with robust LC-ESI-MS/MS.
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Introduction
Although low-dose methotrexate (MTX) is the most widely used treatment for rheumatoid 
arthritis (RA), approximately 30% of patients do not reach sufficient response or suffer from 
adverse events [1]. There is no therapeutic drug-monitoring based model for predicting 
response or adverse events during low-dose MTX treatment. 
 Although MTX levels can be measured easily in plasma, low-dose MTX is rapidly 
cleared from plasma and is therefore not routinely measured. The therapeutic effects of 
MTX are thought to be mediated by its intracellular levels [2], which in contrast to plasma 
levels is difficult to measure and is not performed clinically.
 MTX is transported into the cell primarily by the reduced folate carrier. In the cell 
it is rapidly converted by folylpolyglutamate synthase to MTX polyglutames (MTX-PGs) by 
γ-linked sequential addition of glutamic acid residues. In a competing reaction, the MTX-PGs 
are deconjugated by γ-glutamyl hydrolase, leading to a variety of chain-lengths (MTX-PG2-7) 
[2, 3]. In low-dose MTX treatment, the pentaglutamate (MTX-PG5) is the highest order of 
glutamylation detected, while the triglutamate form (MTX-PG3) of MTX predominates [4, 
5]. Polyglutamylation retains MTX in the cell because MTX-PGs are a poor substrate for the 
MTX efflux proteins. Assessment of intracellular MTX-PG levels might predict how patients 
respond to treatment [6-10] and can also be used to assess adherence to MTX therapy. 
 Intracellular MTX-PG concentrations can be determined by analytical techniques 
such as capillary-zone electrophoresis [11] and high performance liquid chromatography 
(HPLC) with post-column photo-oxidation [4, 8]. Total intracellular MTX can also be assessed 
by fluorescence polarization immunoassay [12, 13] or after enzymatic hydrolysis of the 
polyglutamates, followed by photometric measurement [8]. However, these techniques 
are laborious, influenced by interference from endogenous folates [5] or other MTX-related 
compounds [14, 15] and therefore not suitable for routine measurement in patients. 
 Recently, an ion-pairing LC-MS/MS technique with increased specificity was 
described [16]. However, it did not use stable-isotope-labelled internal standards for each 
MTX-PG, and is therefore unable to compensate for recovery and matrix-effects for the 
individual MTX-PG. Also, the use of ion-pairing on a multi-assay MS can lead to interference 
with the other assays, which is not ideal for routine clinical application. We recently 
developed an ultrafast MALDI-MS/MS method to measure MTX-PGs [17]. Although this 
method is ideal for large cohort studies, stable isotopes were not used, it lacks the precision 
needed for routine clinical monitoring, and the equipment is not routine for hospital 
laboratories. Because of these issues, we developed a new LC-ESI-MS/MS based assay to 
separately determine individual MTX-PGs in erythrocytes using stable-isotope internal 
standards for the quantitation of intracellular MTX-PGs to ensure the method is specific, 
robust and precise in order to be used in clinical laboratories.
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Methods
Materials
MTX-PG1-5 standards were purchased from Schircks Laboratories (Jona, Switzerland). 
Stable isotope labeled internal standards (13C
5
, 15N), MTX-PG1-5(M+6), were purchased 
from Pepscan (Lelystad, the Netherlands). The chemical structures of MTX and the stable 
isotope labeled standards are illustrated in Figure 1. LC-MS grade methanol and water 
were obtained from Biosolve (Valkenswaard, the Netherlands). Ammonium bicarbonate 
(NH
4
HCO
3
) and perchloric acid (HClO
4
 70%) were purchased from Sigma (Zwijndrecht, 
Netherlands). Ammonium hydroxide (NH
4
OH, 25% v/v) was purchased from Merck 
(Schiphol-Rijk, Netherlands). 
 Blinded drug-free K2–ethylenediaminetetraacetic acid (EDTA) erythrocyte pellets 
were used for development and validation. The drug-free erythrocyte pellets were obtained 
by centrifugation of EDTA whole-blood tubes at 2700 × g and removing the supernatant. 
Pellets were pooled per 10 ml and stored at −80°C until further use. As these patient samples 
were leftover from routine analysis at the department of clinical chemistry, no medical-
ethical approval was necessary for this study.
Equipment
Analyses were performed on an LC-MS/MS system consisting of a Waters Acquity UPLC with 
a 20 µl sample loop and a Quattro Premier XE (Waters Corporation, Etten-Leur, Netherlands) 
triple quadrupole mass spectrometer with an electrospray ionization source (ESI) operated 
in the positive mode.
Chromatographic conditions
Chromatography was done using partial-loop injection of 10 µl sample on a Waters Acquity 
BEH C18 column (2.1 × 100 mm, 1.7 µmol/L) at 35°C. The mobile phase consisted of (A) 10 
mM ammonium bicarbonate adjusted to pH 10 with 25% ammonium hydroxide and (B) 
methanol. A flow rate of 0.3 ml/min was maintained and the analytes were eluted using 
the following program: 0-0.5 min isocratic hold 5% B, 0.5-4 min linear gradient 5–40% B; 
4.0–4.25 min linear gradient 40–100% B; 4.25–4.75 min isocratic 95% B; 4.75–5 min linear 
gradient 100–5% B; 5–6 min, isocratic 5% B.
MS detection
The ESI was operated in the positive mode with the following fixed settings: capillary voltage 
1.00 kV, desolvation temperature 350°C at a gas flow of 1000 l/hr nitrogen, and cone gas 
flow of 50 l/hr nitrogen. Argon was used as collision gas at a flow rate of 0.20 ml/min. MTX-
PG specific settings were as follows; dwell time was 0.1s for all MTX-PGs, cone voltage was 
30, 30, 50, 60 and 55V for MTX-PG1-5, respectively. Collision energy was set at 20, 20, 40, 40 
and 50eV for MTX-PG1-5, respectively. Mass transitions are shown in Figure 1.
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Preparation of standards
Stock solutions were prepared in 0.1 mol/L ammonium hydroxide at 88.75 μmol/L, 64.48 
μmol/L, 85.7 μmol/L, 40.71 μmol/L and 51.28 μmol/L for MTX-PG1-5 respectively, and 
10 µmol/L for each IS. Stock solutions were stored at -80°C. For Each analysis the IS stock 
solutions were diluted with LC-MS grade water to a working solution containing 100 nmol/L 
of each MTX-PG(M+6).
Figure 1. (A) MTX-PG structure, the glutamate group is indicated in brackets. Cirkels denotate stable isotope 
labels. (B) A typical total ion count chromatogram obtained from spiked erythrocyte samples (50 nmol/L). Dwell 
time was 0.1s for all MTX-PGs, cone voltage was 30, 30, 50, 60 and 55V for MTX-PG1-5 respectively. Collision 
energy was set at 20, 20, 40, 40 and 50eV for MTX-PG1-5, respectively. ainternal standard (MTX-PG mass+6 13C
5
, 
15N) denoted between brackets
Preparation of calibrators and quality control samples
A batch of frozen pooled drug-free erythrocyte pellet was thawed at room temperature 
while rotating and spiked with 500 nmol/L of each MTX-PG. A ten-point calibration curve 
was obtained by a 1:1 serial dilution with drug-free erythrocyte pellet resulting in 0.97, 1.95, 
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3.91, 7.81, 15.63, 31.25, 62.5, 125 and 250 nmol/L of each MTX-PG and a blank (0 nmol/L) 
calibrator. A fresh calibration curve was prepared for each run.
Quality-control (QC) samples were prepared in drug-free erythrocyte pellet at four different 
concentrations: 5, 25, 50 and 100 nmol/L of each individual MTX-PG. Aliquots were stored 
at -80 °C and thawed on ice. QC samples were prepared with every 50 patient samples. A 
run was considered successful if the QC samples did not deviate more than 15% from the 
nominal value, as indicated by the FDA guidelines for industry [18]. 
Sample preparation
Patient samples were obtained by centrifuging EDTA whole-blood tubes at 2700 × g. 
Patient and validation samples were all prepared as follows; 200 µL erythrocyte pellet 
was supplemented with 200 µL cold IS solution (100 nmol/L MTX-PG1-5). Protein was 
precipated by adding 320 µl cold 16% perchloric acid to the diluted sample while vortexing 
and incubating on ice for 30 min, after which they were centrifuged for 15 min at 2700 × g. 
The clear supernatant was transferred to a sample vial and placed in the autosampler at 4°C 
until analysis. 
Validation procedures
Method validation was adapted from the 2001 FDA guidelines [18] and Matuszewski et al. 
[19]. It consisted of selectivity, IS integrity, carry-over, linearity, stability (freeze/thaw, short-
term storage), recovery, matrix-effects, lower limit of quantitation (LLOQ), and precision 
(interday/intraday) and accuracy. All samples were measured in duplicate unless otherwise 
specified
Selectivity and IS integrity
Selectivity was determined by measuring 20 different drug-free erythrocyte pellets without 
addition of MTX-PGs or IS. The average background signal was calculated for each MTX-PG 
and IS, and used as noise for the signal/noise ratio. The IS was also tested for the presence of 
MTX-PG, MTX-PG mass+1 and MTX-PG mass +2 in drug-free erythrocyte pellet spiked with 
50 nmol/L IS to determine isotope interference. 
Carry-over
Carry-Over was assessed by triplicate measurement of a spiked sample with high 
concentration (250 nmol/L of each MTX-PG) directly followed by triplicate measurement 
of a sample with low (5 nmol/L) concentration and calculated as ((Low1 – Low3)/(High3 − 
Low3)) × 100% [20]. Carry-over was considered acceptable if it was less than 0.5%.
Linearity
Linearity was determined by spiking a batch of pooled drug-free erythrocyte pellet with 12 
different concentrations of MTX-PGs in a range of 0.97-1000 nmol/L and containing a blank (0 
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nmol/L) sample. Each concentration was measured five times. This was repeated in a second 
drug-free erythrocyte pellet. Linearity was expressed as the expected concentration against 
the measured concentration and was considered acceptable if the squared correlation 
coefficient (R2) was >0.99 for each calibration curve. 
Recovery
Recovery of the sample preparation was determined by spiking ten different batches of 
pooled drug-free erythrocyte pellets with 50 nmol/L of each MTX-PG and 50 nmol/L IS 
before, and after sample preparation. The recovery was calculated as: recovery (%) = (peak 
area of an analyte spiked into erythrocyte pellet before sample preparation / peak area 
of an analyte spiked into the supernatant obtained from erythrocytes subjected to sample 
preparation) × 100%. After correction with internal standard, the relative recovery should 
be approximately 100% and reproducible; the CV% of the ten batches should be <10%.
Matrix-effects
Matrix-effects can have a detrimental effect on MS-based analysis [21], and both absolute 
and relative matrix-effects can occur [19]. Absolute matrix-effect is defined as the difference 
in response between analyte in sample matrix and analyte in pure solvent. Relative matrix-
effect is defined as the variation in response between different samples in a similar matrix, 
and can be expressed as the CV% of the slopes of reference curves in different samples 
of the same matrix. The evaluation of matrix-effects was performed according to the 
recommendations of Matuszewski et al. [19]. Ten different batches of pooled drug-free 
erythrocyte pellet were spiked with five concentrations (6.25 nmol/L, 12.5 nmol/L, 25 
nmol/L, 50 nmol/L and 100 nmol/L) of each MTX-PG after sample preparation. The slopes 
of these reference curves were compared with the slope of a reference curve prepared in 
pure solvent as a measure of absolute matrix-effect: Absolute matrix-effect = (slope pooled 
erythrocyte pellet/slope distilled water) × 100%. The relative matrix-effect was calculated as: 
100% − CV% of the slopes of the ten drug-free pellets calibration lines. We also calculated 
the maximum slope difference between the lowest and highest slope of the 10 standard 
lines, which was expressed as %difference. Matrix-effects were calculated with and without 
correction by the internal standard. Slopes were calculated by linear regression analysis. A 
relative matrix-effect of <5% was considered acceptable.
Stability
The stability of MTX-PGs in stored erythrocytes was studied by measuring the stored QC 
samples after 1 week at -80 °C, 4 weeks at -80 °C, and 3 months at -80 °C. Stability after 
sample preparation was studied by preparing a concentration range of MTX-PGs (1-250 
nmol/L of each MTX-PG and a blank sample) and measuring this directly and after storage in 
the autosampler at 4 °C for up to 2 weeks. 
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 Freeze/thaw stability was investigated by measuring QC samples after three 
successive cycles of freezing at -80 °C and unassisted thawing on ice. All results from these 
experiments were compared with results from freshly prepared and measured samples.
Lower limit of quantitation (LLOQ)
LLOQ was determined by spiking drug-free erythrocyte pellet with different levels of MTX-
PGs covering a range of 0.97-1000 nmol/L of each MTX-PG and containing a blank (0 nmol/L) 
sample. Each sample was measured ten times. This experiment was repeated in separate 
drug-free erythrocyte pellet. The LLOQ was defined as the lowest concentration with a 
CV<20% and having a signal-to-noise ratio of >10:1. To calculate the signal-to-noise ratio, 
the result of the selectivity experiment was used.
Precision and Accuracy
Interday precision was determined by measuring QC samples five times consecutively per 
day for twenty successive working days. For each day a fresh batch of QC samples was 
prepared. The intraday precision was assessed by measuring one set of QC samples 20 times 
on the same day. This was repeated on a different day in a different batch of QC samples. 
The samples were prepared as described in 2.7. Precision was expressed as CV%.
 Due to the lack of reference material and reference methods, accuracy could not 
be determined with samples of known concentration. However, accuracy was determined 
according to FDA guidelines for industry and expressed as the bias (%error) from a known 
concentration which should not deviate more than 15% from the known concentration.
Patient samples
To compare our measurements with previously reported erythrocyte MTX-PG levels in RA 
patients, 50 samples were obtained from RA patients enrolled in the treatment in Rotterdam 
Early Arthritis CoHort (tREACH) study [22, 23]. These patients were treated with a similar 
amount (median 25 mg/wk, range 10-25 mg/wk) of MTX for the same period (median 
97 days, range 50-121 days). Patient consent was obtained for the tREACH study and the 
study was approved by the local ethics committee. Samples were prepared as described in 
paragraph 2.7.
Statistics
Quantitation was performed using peak-area ratio of analyte to internal standard. Microsoft 
Excel and Analyse-it for Microsoft Excel (version 2.20) were used to assess linearity according 
to CLSI EP-6 (matrix-effects studies and linearity studies)[24]. Precision was expressed as 
coefficient of variation (CV): CV% = (SD/mean) × 100%. Accuracy was expressed as %bias 
and calculated as the %error.
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Results
MS optimization
To establish the appropriate MS conditions for each individual MTX-PG, a 1 μmol/L standard 
solution was directly infused into the MS system. Collision-induced dissociation of the 
protonated molecules was performed and the product ion with the highest abundance was 
chosen for selected reaction monitoring (SRM) analysis. All MTX-PGs and MTX-PGs(M+6) 
had an identical fragment ion of m/z 308.2 (Figure 1). Other mass transitions were detected 
but their S/N ratio was too low to be used for quantitation. 
Selectivity and IS integrity
When 20 drug-free erythrocyte pellets were measured, the signal of the MTX-PG and MTX-
PG(M+6) mass transition did not rise above the noise, showing good selectivity of the assay. 
Individual MTX-PG(M+6) IS were tested for the presence of MTX-PG and MTX-PG(n+1) 
and were not found to contain significant traces of MTX-PG (<0.044% MTX-PG; <0.026% 
MTX-PG(M+1); <0.025% MTX-PG(M+2)).  Injecting 1 μM clean standard solution of each 
MTX-PG(M+6) yielded a background signal <1.1% for each of the MTX-PGs. When drug-
free pellets were spiked with 50 nmol/L of each of the MTX-PGs, there was a small amount 
of background for MTX-PG1-4 (~0.5 nmol/L for each MTX-PG). The blank standard in the 
calibration line was used to correct for this background. 
Carry-over and Linearity
No significant carry-over was detected for any of the MTX-PGs (mean carry-over 0.04% 
range 0.0-0.1%). The method was linear for all MTX-PGs from 0.975-1000 nmol/L (R2>0.99 
for all MTX-PGs, Table 1). 
Table 1. Linearitya
R2 ± SDb Slope ± SDb
MTX-PG1 0.9995 ± 0.0001 0.9996 ± 0.0003
MTX-PG2 0.9972 ± 0.0037 0.9973 ± 0.0038
MTX-PG3 0.9969 ± 0.0045 0.9991 ±0.0007
MTX-PG4 0.9991 ± 0.0003 0.9994 ± 0.0006
MTX-PG5 0.9996 ± 0.0001 0.9997 ± 0.0002
aLinearity based on a 1-1000 nmol/L calibration curve including a blank sample.
bR2 and slope represent the average of 3 linearity experiments in 3 different batches of pooled erythrocytes.
Recovery
Recovery was measured in 10 batches of pooled pellet and ranged from 54-98% (mean 
recovery 80% ± 11%) with a CV% of 14%. After correction with the internal standard, 
recovery ranged from 89-108% (mean recovery 100 ± 3%) with a CV% of 5% for all MTX-PGs 
at all concentrations tested. 
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Matrix-effects
When not corrected for the IS, a noticeable absolute matrix-effect was present for each of 
the MTX-PGs (63-105%) with a prominent relative matrix-effect (87-95%, maximum slope 
difference of 15-47%) for all MTX-PGs. After correction with the IS, the absolute matrix-
effect was compensated for all MTX-PGs but to a lesser extent for MTX-PG4. However, the 
relative matrix-effect was low for each of the MTX-PGs, with an acceptable maximum slope 
difference (3-17%, Table 2). All slopes that were used to determine matrix-effects were 
linear (R2>0.995).
Table 2. Matrix-effects
IS corrected (response) Not IS corrected (Area)
Absolute 
Matrix-effecta 
(CV)
Min/Maxb Relative  
Matrix-effect
Absolute 
Matrix-effect
(CV)
Min/Max Relative  
Matrix-effect
MTX-PG1 102% (2%) 4% 98% 65% (13%) 47% 87%
MTX-PG2 100% (1%) 4% 99% 63% (12%) 42% 88%
MTX-PG3 101% (3%) 11% 97% 82% (5%) 16% 95%
MTX-PG4 84% (5%) 17% 95% 74% (5%) 15% 95%
MTX-PG5 100% (1%) 3% 99% 105% (10%) 34% 90%
All slopes were r2>0.999 when corrected for IS.
aMatrix-effect is expressed as % recovery and calculated by comparing the slopes of reference curves made in 10 
different plasma matrices with the slope of a reference curves made in water.
bThe maximum slope difference shows the % difference between the largest and smallest slope, indicating the 
variance between slopes in different matrices.
Stability
When storing untreated QC samples at −80°C, a 10% loss in recovery was observed (mean 
recovery: 90% range 89-98%). However, no further loss was observed for at least 3 months 
at −80°C (Table 3). Pre-treated QC samples were stable when kept in the autosampler at 4°C 
for up to 2 weeks (mean recovery: 101% range 96-113%) (Table 3). Three subsequent freeze-
thaw cycles did not influence the recovery of MTX-PGs in erythrocytes (mean recovery 
100%, range 93%-107%). 
Lower limit of quantitation (LLOQ)
LLOQs were determined as the lowest concentration that resulted in a CV% <20% and S/N 
>10:1. However, as all concentrations tested had a CV% <20% and an S/N ratio >10:1, the 
LLOQ was set at 1 nmol/L for all MTX-PGs. At this concentration there was always a visual 
and distinguishable peak in every calibration curve, and a response at least five times higher 
than the response of the lowest sample of the calibration curve (0 nmol/L). 
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 Table 3. Stability 
Before sample preparation stored at −80°Ca After sample preparation stored at 4 °Cb
1 week 
(Recovery % ± SD)
1 month
(Recovery % ± SD)
3 months
(Recovery % ± SD)
1 week
(Recovery % ± SD)
1 month
(Recovery % ± SD)
MTX-PG1 90 ± 3% 91 ± 3% 92 ± 4% 99 ± 3% 99 ± 3%
MTX-PG2 98 ± 5% 86 ± 5% 87 ± 3% 101 ± 3% 99 ± 6%
MTX-PG3 89 ± 7% 89 ± 8% 95 ± 6% 98 ± 3% 103 ± 8%
MTX-PG4 89 ± 2% 96 ± 10% 92 ± 11% 96 ± 4% 98 ± 2%
MTX-PG5 95 ± 2% 87 ± 1% 86 ± 1% 113 ± 4% 106 ± 6%
aThe mean recovery represents the recovery of the different QC sample concentrations, measured in fivefold and 
compared to the results of the freshly prepared QC samples.
bThe mean recovery represents the recovery of a prepared calibration curve, measured in twofold and compared 
to the results of the freshly prepared calibration curve
Precision and Accuracy
The median CV for intraday precision was 2.1% (range 1.0-4.3%), whereas for interday 
precision the median CV was 8.4% (range 5.9-14.7%) for all MTX-PGs at all concentrations. 
The bias was <15% for all MTX-PGs at all concentrations (Table 4). 
Table 4. Precision
Intraday precisiona Interday precisionb
Concentration
(nmol/L)
Mean ± SD
(nmol/L)
CV% Bias 
(%)
Mean ± SD
(nmol/L)
CV% Bias 
(%)
MTX-PG1 5 5.9 ± 0.19 3.0 -5.5 5.2 ± 0.43 8.3 -3.6
50 52.3 ± 0.83 1.6 -1.3 49.8 ± 3.12 6.3 0.5
100 98.6 ± 1.91 1.9 5.6 93.5 ± 6.03 6.4 6.5
MTX-PG2 5 5.68 ± 0.12 1.9 4.1 5.1 ± 0.47 9.2 -1.5
50 51.4 ± 1.23 2.3 -2.4 50.1 ± 3.54 7.1 -0.2
100 99.6 ± 1.46 1.4 5.1 94.9 ± 7.94 8.4 5.1
MTX-PG3 5 5.4 ± 0.17 2.8 -9.7 4.8 ± 0.51 10.6 3.4
50 48.7 ± 0.88 1.8 -1.6 47.5 ± 4.14 8.7 5.1
100 92.2 ± 1.62 1.7 -5.3 90.8 ± 6.66 7.3 9.2
MTX-PG4 5 5.1 ± 0.2 3.4 -10.0 4.5 ± 0.67 14.7 9.1
50 46.0 ± 0.77 1.7 -1.6 47.3 ± 4.66 9.8 5.4
100 89.1 ± 0.91 1.0 5.5 92.3 ± 10.61 11.5 7.7
MTX-PG5 5 4.8 ± 0.21 4.3 7.0 4.6 ± 0.56 12.1 7.1
50 44.7 ± 0.62 1.4 8.0 46.7 ± 2.75 5.9 6.6
100 84.9 ± 1.46 1.7 15.0 87.2 ± 6.76 7.7 12.8
aThe intraday precision summarizes 20 replicate measurements at each concentration of MTX during one day.
bThe interday precision summarizes 20 different experiments from 20 consecutive days with measurement done 
in fivefold each day.  
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Patient samples
The 50 patient samples obtained from the tREACH study contained a mean concentration of 
139.0 ± 54.3 nmol/L of total MTX and an average of 35.3 ± 28.1 nmol/L MTX-PG1, 21.3 ± 9.2 
nmol/L MTX-PG2, 51.4 ± 19.6 nmol/L MTX-PG3, 23.4 ± 17.1 nmol/L MTX-PG4 and 7.7 ± 10.4 
nmol/L MTX-PG5 respectively (Figure 2). The pre-dominant glutamate form of MTX in 
erythrocytes was MTX-PG3, which constituted 37% of the total erythrocyte MTX content. 
MTX-PG5 was <LLOQ in 5 out of 50 samples.
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Figure 2. MTX-PG content of 50 RA patients treated with MTX for 3 months (mean treatment duration 
93.0 ± 13.1 days). Mean MTX dose was 24.0 ± 3.4 mg/week. MTX was administered orally in all patients
Discussion
We developed a simple LC-MS/MS-based method for the separate quantitation of individual 
MTX-PGs in human erythrocytes. To our knowledge this is the first method using stable 
isotope internal standards for the measurement of MTX-PG1-5. 
 While other methods have been reported for measuring MTX-PGs in erythrocytes, 
most have longer sample-preparation and analysis times, and most do not use mass 
spectrometry for detection [4, 11, 25]. Therefore, these methods might be less specific and 
prone to interference by compounds similar to MTX, such as folates [5]; this translates to 
lower sensitivity and higher limits of quantitation. 
 The described method has a linear range of 1-1000 nmol/L, which contains the 
known clinical range of the different MTX-PGs [6, 10]. At 1 nmol/L the LLOQ is comparable 
to [16], or lower than previously reported methods [4, 5, 17]. This is especially important for 
the longer-chain MTX-PGs as these are present in lower concentrations than the short-chain 
MTX-PGs [6, 10]. Improvements in LLOQ can still be achieved by better sample clean-up 
such as SPE, but this would increase the cost and preparation time of the method.
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 As shown in our validation experiments, recovery and matrix-effects differ strongly 
for each MTX-PG and between different erythrocyte pellets. The use of a stable-isotope 
labeled IS is important for a reliable quantitation in a complex matrix such as erythrocytes. 
 The stable-isotope IS compensates for absolute matrix-effect in all MTX-PGs except 
MTX-PG4, where the internal standard did not fully compensate for absolute matrix-effect 
even after correction with the IS. However, this was not considered a problem, as the stable 
isotope IS compensates sufficiently for the relative matrix-effects.  
 Recovery based on peak area was moderate with high variance, which was 
compensated by the stable-isotope-labeled IS. As this resulted in more reproducible 
measurements and a recovery of approximately 100%, it emphasizes the need for a proper 
internal standard.
 QC samples were stable for at least three months at −80°C with approximately 90% 
recovery. Although no freeze-thaw effect was found, the stability study suggests there is 
indeed a small freeze-thaw effect as QC samples stored at −80°C had a stable 90% recovery 
at 4 weeks, 8 week and 12 weeks. QC samples stored after sample preparation were stable, 
with approximately 100% recovery.
 The intraday CV of <2.5% and interday CV of <12.0% are improved over our previous 
method (intraday CV<13.2%, interday CV<12.1% [17]) and are well within acceptable limits 
[18]. Moreover, our precision is better than the ion-pairing-based MS method reported 
recently (intraday <20.0%, interday <23.7% [16]). 
 We used our method to analyze the erythrocyte MTX-PG content of 50 patient 
samples obtained from the tREACH study [22]. The concentrations and distribution of MTX-
PG1-5 as measured by our method were in line with those previously reported [4, 5, 7, 10, 
26]. 
 Theoretically, MTX-PG6 and MTX-PG7 are also present in the erythrocyte. However, 
these have not been proven conclusively. As analysis of multiple patients in literature and 
in our patient samples did not reveal detectable amounts of MTX-PG6 and MTX-PG7 [4, 
10], and because of the prohibitive cost of the MTX-PG6 and MTX-PG7 stable-isotopes, we 
decided not to focus on MTX-PG6 and MTX-PG7. 
 In conclusion, we describe an LC-MS/MS-based method to measure MTX in 
erythrocytes with minimal sample pretreatment, relatively short analysis time, and good 
diagnostic performance that can be applied in routine clinical TDM. The method is validated 
for the clinical lab and is currently the only method that measures MTX-PG1-5 separately 
using stable isotope internal standards.
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Abstract:
BACKGROUND: High dose methotrexate (MTX) is used in the treatment of proliferative 
diseases such as acute lymphoblastic leukemia. Therapeutic drug monitoring of plasma MTX 
is important to monitor efficacy and adverse events. The authors aimed to develop a new 
mass spectrometry based method for determining MTX in plasma for patient diagnosis and 
pharmacokinetic studies. 
METHODS: Samples were analysed using a Waters Acquity U-HPLC and Quattro Premier 
XE.  A Waters Acquity U-HPLC BEH C18 column (2.1 mm x 100 mm, 1.7 µm) was used 
running an isocratic mobile phase of 21% methanol and 10 mM ammonium bicarbonate. 
The electrospray was operated in the positive ionization mode monitoring the following 
mass transitions: m/z 455.2>308.2 for MTX and m/z 458.2>311.2 for MTX-d3. The 
analysis combines straightforward sample preparation, consisting of dilution and protein 
precipitation, with a 3 minute run time. 
RESULTS: The method was linear up to 50 µmol/L (r2>0.99) and a coefficient of variation 
(CV) of <6% for intraday and <10% for interday precision was found. Average recovery was 
99%. There were no significant matrix effects. The lower limit of quantitation, defined as the 
lowest concentration where CV<20% and S/N>1:10, was 5 nmol/L. Method comparison with 
the Abbott TDx FPIA immunoassay showed excellent agreement and a small but significant 
negative constant bias was detected (LC-MS/MS=0.98 × FPIA-7.3).
CONCLUSIONS: The authors developed a specific and sensitive stable isotope dilution LC-
ESI-MS/MS method to monitor MTX levels in plasma within the clinically relevant range. The 
method can be easily applied in clinical laboratories because it combines straightforward 
sample pre-treatment with LC-MS/MS. 
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Introduction 
Methotrexate (MTX) is a folate antagonist that has been used in clinical practice for five 
decades. It is used in the treatment of proliferative diseases such as acute lymphoblastic 
leukemia (ALL) [1, 2], which is the most frequent cancer in children aged less than 15 years, 
[3] and other proliferative diseases [4]. Treatment is often limited due to severe toxicity [5] 
and monitoring of plasma MTX is important to assess efficacy and adverse events [3, 6, 7].
 Plasma MTX is commonly measured using immunoassays like the Fluorescent 
Polarization Immuno Assay (FPIA) and Enzyme Multiplied Immunoassay Technique (EMIT) 
[8], from Abbott and Siemens, respectively. Immunoassays need limited sample preparation 
and relatively fast measuring times can be achieved, which make them suitable for routine 
clinical application. 
 However, immunoassays are expensive and are hampered by interference such 
as cross reaction of folates and MTX metabolites leading to low specificity [9-12]. While 
immunoassays are easy to implement and run, the large concentration range of MTX plasma 
in high-dose (HD) MTX treated patients (20 nmol/L to 100 µmol/L) imposes the need for 
testing samples in serial dilution [12, 13]. This compromises the assay’s throughput unless 
an extensive infrastructure is present. Furthermore, immunoassays generally display little 
sensitivity [9]; the lower limit of quantitation (LLOQ) of most immunoassays for MTX lies in 
the 20 nmol/L range. While this range is below the clinically relevant levels (therapeutic drug 
monitoring (TDM) of MTX plasma levels generally stops below 100 nmol/L) pharmacokinetic 
studies might benefit from a lower LLOQ.
 Several high performance liquid chromatography (HPLC) based methods have 
been developed to improve specificity and sensitivity of plasma MTX detection. Commonly 
used detection methods include fluorescence detection [6, 14-16], UV detection [17] and 
mass spectrometry [18-21]. While HPLC based methods have many advantages, most HPLC 
methods rely on UV detection of fluorescence which makes these methods subject to 
interference by other compounds, most notoriously folates and the deconjugated MTX form 
DAMPA [22], leading to poor specificity and lower sensitivity (high LLOQ). 
 Liquid chromatography tandem mass spectrometry (LC-MS/MS) is becoming a 
more routine method in the clinical laboratory [23]. LC-MS/MS is generally more specific 
than either conventional HPLC or immuno-assay methods. In addition, these LC-MS/MS 
based methods will in most cases result in shorter analysis times than HPLC methods, 
leading to higher throughput [24]. Therefore, we aimed to develop and validate a new LC-
MS/MS method for the measurement of MTX in plasma.
Methods
Chemicals and blood specimens
MTX was purchased from Schircks Laboratories (Jona, Switzerland). Deuterium labeled 
MTX (MTXd3) was used as internal standard (IS) and was purchased from Toronto Research 
Chemicals Inc. (North York, Canada). Chemical structures of MTX and the deuterated 
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analogue are illustrated in Figure 1. LC-MS grade methanol and water were obtained from 
Biosolve (Valkenswaard, the Netherlands). Ammonium bicarbonate and perchloric acid 
(70% v/v) were purchased from Sigma (Zwijndrecht, the Netherlands). Ammonia (25% v/v) 
was purchased from Merck (Schiphol-Rijk, the Netherlands). 
 Blinded drug-free and patient blood samples were used for development and 
validation of the method. Blinded samples were left-over from routine analysis at the 
department of Clinical Chemistry and the Hospital Pharmacy and hence, no medical-ethical 
approval was necessary for this study.
Instruments
Analyses were performed on a LC-MS/MS system consisting of a Waters Acquity UPLC 
(Waters Corporation, Etten-Leur, the Netherlands) equipped with a 20 µl sample loop and 
a Quattro Premier XE (Waters Corporation, Etten-Leur, the Netherlands) triple quadrupole 
mass spectrometer with an electrospray ionization source (ESI) operated in the positive 
ionization mode.
Chromatographic conditions
Chromatography was done using partial loop injection of 10 µl sample on a Waters Acquity 
UPLC BEH C18 column (2.1 mm x 100 mm, 1.7 µm) maintained at 35°C. The mobile phase 
consisted of (A) 10 mM ammonium bicarbonate adjusted to pH 10 with 25% ammonia and 
(B) methanol. The system was maintained at a flow rate of 0.3 ml/min. keeping an isocratic 
concentration of 21% B. After every 80 samples, the column was flushed 10 min with 100% 
methanol at a flow rate of 0.3 ml/min followed by re-equilibration with 21% B at a flow rate 
of 0.3 ml/min.
MS detection
The ESI was operated in the positive mode with the following selected reaction monitoring 
mass transitions: m/z 455.2>308.2 for MTX and 458.2>311.2 for MTXd3 (Figure 1). Other 
mass spectrometer settings were: capillary voltage 1.00 kV, cone voltage 30 V, collision 
energy 20 eV, source temperature 120°C desolvation temperature 350°C at a gas flow of 700 
l/hr and cone gas flow 50 l/hr. Argon was used as collision gas at a flow rate of 0.20 ml/min.
Preparation of standards
Stock solutions were prepared in 0.1 mol/L ammonia at concentrations of 1836.6 µmol/L 
for MTX and 10 µmol/L for MTXd3. Both stock solutions were stored at −80°C. The stock 
solution of MTXd3 was diluted with LC-MS grade water to a working solution of 100 nmol/L 
to serve as internal standard (IS). The working solution was prepared freshly for each batch 
of prepared samples.
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Preparation of calibrators and quality control samples
Frozen drug-free plasma was thawed at room temperature while rotating and spiked with 
MTX to a final concentration of 50 µmol/L. A sixteen point calibration range was obtained by 
1:1 serial dilution, containing 3.05, 6.10, 12.21, 24.41, 48.83, 97.66, 195.31, 391.63, 781.25, 
1562.5, 3125, 6250, 12500, 25000 and 50000 nmol/L MTX as well as a blank sample (0 
nmol/L). A fresh calibration curve was prepared for each run.
 Quality control (QC) samples were prepared in drug-free plasma at five different 
concentrations: 10, 50, 500, 5000 and 50000 nmol/L MTX. Aliquots were stored at −80 °C 
and thawed at 4°C while rotating.
Sample preparation
Plasma was obtained by centrifuging K
2
-EDTA whole-blood tubes at 2700 × g. A 50 µl plasma 
aliquot was added to 450 µl drug-free plasma and then supplemented with 500 µl cold IS 
solution (100 nmol/L MTXd3 in H2O). Protein precipitation was done by the addition of 
800 µl cold 16% perchloric acid to the diluted sample while vortexing. The samples were 
placed on ice for 30 min to enhance precipitation, after which they were centrifuged for ten 
minutes at 2700 × g. The clear supernatant was transferred to a sample vial and placed in 
the autosampler of the LC-MS/MS system maintained at 4°C. The injection volume was 10 
µl. Calibrators and QC samples were also prepared as described above. Concentrations were 
multiplied by 10 to correct for dilution.
Validation procedures
Method validation was adapted from the 2001 FDA guidelines [25] and Matuszewski et al. 
[26]. It consisted of selectivity, IS integrity, carry-over, stability (short/long term storage, 
freeze/thaw), recovery, matrix effects, linearity, LLOQ, precision (interday/intraday) and 
accuracy in comparison to FPIA (gold standard). All samples were measured in duplicate 
unless otherwise specified.
 Selectivity of the detection was determined by measuring 20 different drug-free 
samples, which were prepared as described in the “materials and methods” section but 
replacing MTX and IS solution with LC-MS grade water. The average background signal was 
calculated for both MTX and MTXd3 and was used as noise when calculating the signal/
noise ratio. 
 IS integrity was tested by measuring the presence of MTX, MTX mass+1, MTX 
mass+2 and MTX mass+3 in LC-MS/MS grade water spiked with 100 nmol/L IS.
Carry-Over was assessed by triplicate measurement of a spiked plasma sample with high 
concentration (50 μM) directly followed by triplicate measurement of a sample with low (50 
nmol/L) concentration and calculated as ((Low1 – Low3)/(High3 − Low3)) × 100% [27]. This 
was repeated in 3 different plasma batches. 
 Stability of MTX in plasma was studied by measuring the stored QC samples after 
1 week, 6 weeks and 6 months at −80 °C. The stability of MTX after sample preparation was 
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studied by storing a prepared concentration range (3-50,000 nmol/L) in the autosampler 
at 4 °C for 16 days. Freeze/thaw stability was investigated by measuring QC samples after 
three successive cycles of freezing at −80 °C and unassisted thawing on ice. All samples were 
measured five times from the same vial and the results from these stability experiments 
were compared with freshly prepared and directly measured samples.
 Recovery of the sample preparation was determined by spiking ten different blank 
plasma samples with three different MTX concentrations (50, 500, 5000 nmol/L) and IS 
(100 nmol/L) before and after sample preparation. The recovery was calculated with the 
following formula: Recovery (%) = (MTX spiked before sample prep/MTX spiked after sample 
prep) × 100%.
 Matrix effects can have a detrimental effect on MS based analysis [28] and both 
absolute and relative matrix effects can occur [26].  Absolute matrix effect was defined as 
the difference in response between analyte spiked in sample matrix versus analyte spiked 
in pure solvent. A relative matrix effect is described as the variation in response between 
different samples in a similar matrix and can be expressed as the coefficient of variation 
(CV%) between the slopes of reference curves made in different samples of the same 
matrix. The evaluation of matrix effects was performed according to the recommendations 
of Matuszewski et al. [26]. Ten reference curves were prepared by spiking ten different drug-
free plasma batches with five concentrations (10 nmol/L, 50 nmol/L, 500 nmol/L, 5 μmol/L 
and 50 μmol/L) of MTX after sample preparation. The slopes of these reference curves in 
the different drug-free plasma batches were compared with the slope of a reference curve 
prepared in purified water to determine the absolute matrix-effect. The absolute matrix-
effect was defined as: Absolute matrix effect = (mean slope plasma sample/slope distilled 
water) × 100%. By comparing the reference curves of the ten standard lines from the ten 
different plasma samples the relative matrix-effect was calculated, which was expressed as: 
Relative matrix-effect = 100% - CV% of the slopes of the ten reference curves. Furthermore, 
the maximum slope difference was calculated as the difference in percentage between the 
lowest slope and highest slope of the ten reference curves. All matrix effects were calculated 
with and without correction by the internal standard. Slopes were calculated by linear 
regression analysis. 
 Linearity of the method was determined by spiking drug-free plasma with 22 
different concentrations of MTX in a range of 3-250 µmol/L. This range reflects the full 
clinical range of MTX concentrations reported the past year at the Hospital Pharmacy of the 
Erasmus MC. Samples were measured five times from the same vial and the experiment and 
the experiment was repeated in a second drug-free plasma batch. Linearity was considered 
acceptable if the coefficient of determination (R2) was >0.99 for each calibration curve and 
if the lack of fit was <3.75. 
 LLOQ was determined by spiking drug-free plasma samples with different levels of 
MTX covering a range of 3-50000 nmol/L. These were measured ten times from the same 
vial for each concentration level and the experiment was repeated in a second drug-free 
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plasma batch. The LLOQ was defined as the lowest concentration of a serial dilution with a 
CV<20%, while having an area of at least ten times the average area of the drug-free plasma 
samples used for the selectivity experiment and five times the area of the blank sample (0 
nmol/L). 
 Precision and accuracy were determined by measuring QC samples five times on 
twenty consecutive working days for interday precision. The QC samples were thawed and 
prepared as described in the “materials and methods” section. Everyday a new batch of 
drug-free plasma was used for the dilution of the QC samples. The intraday precision was 
assessed by measuring QC samples twenty times in one run. This was repeated on a different 
day with another drug-free plasma batch for the dilution of the QC samples. Precision was 
expressed as CV% and accuracy as bias (%error).
Method comparison 
Blood samples from ALL patients were collected in K
2
-EDTA tubes from November, 2009 
to March 2011 by the Hospital Pharmacy of the Erasmus MC. These were used for routine 
measurement of plasma MTX using the fluorescence polarization immunoassay (FPIA) on 
an Abbott TDx FLx Immunology Analyzer (Abbott Diagnostics, Hoofddorp, the Netherlands). 
 In total, 194 plasma samples from 34 ALL patients receiving 2-5 g/m2 MTX for 24 
h were measured both with FPIA and with LC-MS/MS. After measurement by the Hospital 
Pharmacy, left over plasma was kept at -20 °C before measurement on the LC-MS/MS. All 
samples were measured twice from the same vial on the LC-MS/MS to be able to detect 
carry-over. 
 Samples were measured in random order to reduce sample selection bias. Samples 
were re-measured by LC-MS/MS when: i) duplicate measurements differed more than 15%, 
ii) samples were below the LLOQ or iii) above the upper limit of quantitation (ULOQ). All 
samples that were re-measured were both obtained from the original prepared sample 
as well as from freshly prepared sample. Samples that were below LLOQ were repeated 
undiluted, whereas samples that were above ULOQ were diluted 1:100 in drug-free plasma 
before preparation.
Statistics
Quantitation was performed using peak area ratio of analyte to internal standard. Microsoft 
Excel and Analyse-it for Microsoft Excel (version 2.20) were used to perform linear regression 
(matrix effects studies, calibration lines, linearity). Validation studies were done according to 
CLSI EP-6 and Passing & Bablok regression analysis with 95% confidence intervals (method 
comparison). Precision was expressed as coefficients of variation (CV): CV% = (mean/stdev) 
× 100%. MassLynx software (Waters) was used for the analysis of chromatograms.  The 
processing of MS data was done using QuanLynx software (Waters).
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Results
Method performance
To establish the appropriate MS conditions, a standard solution was directly infused into 
the MS for optimization. Collision induced dissociation of the protonated molecules was 
performed and the product ions with the highest abundance were selected for selected 
reaction monitoring (SRM) analysis. Mass transitions obtained in positive mode were: 
455.2>308.2 for MTX and 458.2>311.2 for MTXd3 (Figure 1). Other mass transitions were 
detected but their S/N ratio was too low to be used for quantitation. 
 When measuring 20 drug-free samples the signal did not rise above the noise, 
showing good selectivity of the assay and that no interferences were detected. 100 nmol/L 
MTXd3 in water yielded 0%, 0%, 3% and 97% for MTX, MTX mass+1, MTX mass+2 and MTX 
mass+3 respectively, showing good integrity and purity. Mean carry-over was 0.021%.
Figure 1. Chromatograms and chemical structures of methotrexate and internal standard (MTXd3). The location 
of the deuterium enriched methyl-group is highlighted.  The SRM for both MTX and MTXd3 are depicted above 
the molecule.
 The results for the stability experiments are presented in Table 1. Untreated 
plasma samples were stable when stored for 1 week at −80 °C (mean recovery: 106%), 6 
weeks at −80°C (mean recovery: 106%), or 6 months at −80 °C (mean recovery: 107%).  After 
preparation samples were stable when kept in the autosampler at 4 °C for up to 16 days 
(mean recovery: 102%). Furthermore, this was confirmed in 11 patient samples that were 
re-measured after one week at 4 °C (mean recovery: 110%). Three subsequent freeze-thaw 
cycles did not significantly influence MTX concentration. The observed decrease in response 
after freeze-thaw was 3%. 
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Table 1. Recovery MTX in plasma (n=10)
Sample concentration 
(nmol/L)
Measured concentration
(nmol/L ± SD)
Average recovery
( ± SD)
CV%
50 nM 50.4 ± 2.5 101% ± 5% 5%
500 nM 503.2 ± 14.6 99% ± 5% 5%
5000 nM 5001.6 ± 175.7 98% ± 6% 6%
 
 Average recovery ranged from 96-102% for all concentrations (50 nmol/L, 500 
nmol/L, 5000 nmol/L) of MTX with a CV% of <15% for each concentration when based on 
the area of the MTX peaks. After correction with the IS, average recovery ranged from 98-
101% for all concentrations with a CV% of <6% for each concentration (Table 2). 
 The absolute matrix effect calculated without correction for the IS was 71% with 
a relative matrix effect of 81% and a maximum slope difference of 67%, showing large 
variation between the different samples. After correction with the IS, the absolute matrix 
effect improved to 94% with a relative matrix effect of 98% and a maximum slope difference 
of 7%. All slopes showed an r2 >0.999. Matrix effects tested in sample without dilution in 
drug-free plasma yielded similar results (Table 3).
Table 2. Stability of stored spiked plasma
Conditions Average recovery (range)
Before sample preparationa 1 week -80 °C 106% (95-115%)
6 weeks -80 °C 106% (100-115%)
6 months -80 °C 107% (103-114%)
Freeze/Thawa (3 cycles -80 °C) 97% (92-99%)
After sample preparationb 1 day 4 °C 102% (93-115%)
1 week 4 °C 102% (91-110%)
2 weeks 4 °C 102% (93-113%)
aThe average recovery represents the recovery of the different QC sample concentrations, measured in fivefold 
and compared to the results of the freshly prepared QC samples.
bThe average recovery represents the recovery of a prepared calibration curve, measured in twofold and 
compared to the results of the freshly prepared calibration curve
 The method was linear up to 50 µmol/L (y=-0.326 + 0.997x) and subsequent 
validation samples and QC samples were done using calibration curves of 3 nmol/L – 50 
µmol/L (supplementary data 1). These were linear (r2>0.998, lack-of-fit <0.85) throughout 
the validation.
 When determining the LLOQ the CV% did not become larger than 20% at any 
concentration other than the blank (0nmol/L) sample (supplementary data 2). In all samples 
the signal to noise ratio was better than 10:1. The LLOQ was set at 5 nmol/L because at 
this concentration there was always; 1) a visual and distinguishable peak present in every 
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calibration curve and 2) a response five times higher than the response of the lowest sample 
of the calibration curve (0 nmol/L). The precision profile of the method is shown in Table 4. 
Precision ranged between 2.1 and 6.5% for intraday variation and between 5.8 and 11.0% 
for interday variation for the total range of tested MTX concentrations. The mean bias 
(%error) ranged from −11.3 to 14.5% for intraday precision and −9.7% to 14.4 for the total 
range of tested MTX concentrations.
 
Table 3. Matrix effects of 10 different plasma samplesa
Sample concentration Average 
Matrix effect
CV% Relative 
matrix effect
Maximum slope 
differenceb
Diluted plasma
(1:10 in drug-free plasma)
With IS 94% 2% 98% 7%
Without IS 71% 19% 81% 67%
Undiluted plasma With IS 96% 2% 98% 6%
Without IS 72% 17% 93% 67%
All slopes were r2>0.999 when corrected for IS.
aMatrix effect is expressed as % recovery and calculated by comparing the slopes of reference curves made in 10 
different plasma matrices with the slope of a reference curves made in water.
bThe maximum slope difference shows the % difference between the largest and smallest slope, indicating the 
variance between slopes in different matrices.
Table 4. Intraday and interday precision
Expected concentration
(nmol/L)
Measured concentration intraday 
precision (nmol/L; n=20)a
Measured concentration interday 
precision (nmol/L; n=20)b
Mean ± SD CV% Bias 
(%error)
Mean ± SD CV% Bias 
(%error)
10 11.4 ± 0.76 6.5 14.5 11.6 ± 1.27 11.0 14.4
50 54.9 ± 1.95 3.5 9.7 53.5 ± 3.13 5.8 7.5
500 543.9 ± 17.84 3.3 8.8 536.3 ± 40.43 7.5 7.1
5000 4947.4 ± 168.85 3.4 −1.1 5073.1 ± 465.15 9.2 1.3
50000 44335.1 ± 918.77 2.1 −11.3 45413.0 ± 3322.88 7.3 −9.7
aThe intraday precision summarizes 20 replicate measurements at each concentration of MTX during one day.
bThe interday precision summarizes 20 different experiments from 20 consecutive days with measurement done 
in fivefold each day.  
Method comparison 
194 HD-MTX patient plasma samples were compared between methods. Duplicate 
measurements on the LC-MS/MS always showed a CV <10% with the exception of 14 
samples, of which 10 samples were below the LLOQ of either the FPIA or the LC-MS/MS 
and were therefore excluded from the comparison. The other 4 samples contained low 
concentrations of MTX (20-36 nmol/L) and were preceded by high samples (35088-146851 
nmol/L). The observed difference between duplos (6-45 nmol/L) was similar to the expected 
carry-over (7-31 nmol/L) assuming the 0.02% found previously, suggesting carry-over as the 
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cause. Another 9 samples were excluded because MTX plasma concentrations were below 
the LLOQ of the FPIA and therefore not reported as numerical data but as “<20 nmol/L” by 
the FPIA.  All samples where the CV was >10% were re-measured both from the original 
original prepared sample and from freshly prepared samples after which all samples had 
duplicates with a CV<10%. 
 The comparison of the remaining 175 samples showed good agreement between 
methods: (LC-MS/MS=0.98 [95% CI: 0.95 to 1.02]×FPIA - 7.3 nmol/L [95% CI: -10.96 to -5.34]) 
(Figure 2, insert). A slight, non-significant proportional bias was present and a small but 
significant constant bias of -7.3 nmol/L was found for the complete sample set. Changing 
the method comparison to the low (0-500 nmol/L), high (500-50000 nmol/L) or complete 
sample concentration range did not give a significant difference in slope or bias. For the 
lower concentration range (0-500 nmol/L), which contained 75% of all patient samples, 
good agreement was obtained (LC-MS/MS=1.00 [95% CI: 0.94 to 1.06] × FPIA -8.51 nmol/L 
[95% CI: -11.06 to -5.88]) (Figure 2).
Discussion
We developed a straightforward and robust LC-MS/MS based method for the measurement 
of MTX in human EDTA plasma. While other mass spectrometry based methods have been 
reported for the detection of MTX in plasma, most methods do not use stable isotope 
labeled IS. Furthermore, these methods generally have higher LLOQs [29-31], or use more 
expensive and work-intensive sample preparation and machinery [18, 32]. Compared with 
traditional methods of MTX TDM (such as FPIA), our method has improved LLOQ and a large 
dynamic range.  
 The presented method does not require expensive and time-consuming sample 
preparation, such as solid phase extraction, and because of the use of a stable isotope labeled 
internal standard, it is a very useful method for implementation within a clinical laboratory. 
The short analysis time of 3 minutes makes the method attractive for high-throughput 
settings and clinical studies. Improvements in LLOQ can be made with the addition of better 
sample clean-up like SPE, but this would also drive up the cost and preparation time of the 
method. Alternatively, LLOQ may be improved by reducing the dilution factor. However, due 
to the dilution of patient sample in drug-free plasma, less volume is needed making the 
method suitable for use in very small sample volumes such as in pediatric samples.
 Although carry-over is only 0.02%, the difference in maximum plasma levels in HD-
MTX treatment can be as high as 100 fold. When measuring very low samples (<100 nmol/L) 
after very high samples (>50 µmol/L) this could lead to falsely increased MTX levels in the 
low concentration range as was seen when patient samples were measured in random 
order. Samples with a low concentration of MTX measured directly after samples with a 
high concentration of MTX had a discrepancy between duplicates that fitted roughly with 
the 0.02% carry-over that was determined. The use of duplicate measurement is important 
to detect and counter this. For most TDM purposes, this will not pose any problems as the 
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clinical cut-off for TDM is usually ~200 nmol/L. However, when dealing with samples in the 
setting of carboxylase-G2 treatment, carry-over might present a problem due to the large 
difference in MTX concentration between patient samples as a result of MTX breakdown by 
the enzyme. [12, 13, 33]
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Figure 2. Comparison of plasma MTX between the Abbott FPIA on the TDx analyzer (x-axis) compared to the 
LC-MS/MS method (y-axis) (n=175). Samples shown are in the range of 0-500 nmol/L MTX which contains 75% 
of all patient samples (n=131). A) Passing & Bablok regression was used to compare both methods. The insert 
shows the comparison of the whole concentration range (0-170 µmol/L MTX). B) Bland-Altman plot of differences 
between observed MTX concentrations by FPIA and LC-MS/MS methods. Solid line represents bias (-9.02 nmol/L), 
and dotted lines represent 95% limits of agreement (-70.13 to 52.08)
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 Recovery based on peak area was moderate with high variance, but this was 
corrected for by the use of the stable isotope labeled IS, leading to more reproducible 
measurements and a recovery of approximately 100%. The use of a deuterium labeled IS 
also compensated for matrix effects. When using the peak areas to calculate matrix effects, 
a prominent absolute matrix effect was detected, which was almost completely corrected 
for by the use of the IS. The relative matrix effect caused by using different plasma batches 
is also corrected for by use of the internal standard. Both the recovery and matrix effect 
experiments emphasize the need for a proper IS when working with complex matrices such 
as biological samples in an LC-MS/MS setting. 
 Matrix effects in undiluted samples were also very low after correction for the 
IS which indicates that the dilution step in drug-free plasma is optional and leads to the 
possibility of measuring very low samples concentration (<LLOQ) without dilution. 
As shown by the method comparison, good agreement was found with the FPIA analysis. 
This correlation was somewhat unexpected due to reports about the a-specificity of the FPIA 
method [9, 11, 33]. The few outliers that were found and the observed small constant bias 
might be caused by several reasons. First, the FPIA might measure higher concentrations 
because of its a-specific measurement of MTX metabolites like DAMPA. Second, differences 
might exist in the calibration between methods (traceability chain). Third, calibration errors 
within the laboratory might also have caused the constant bias between FPIA and LC-MS/
MS. Because there is neither reference method nor standard reference material for MTX 
in plasma it is difficult to speculate about the accuracy of methods. However, in line with 
FDA guidelines our LC-MS/MS method showed small positive bias (%error <7.1 for interday 
and <8.8 for intraday) in the clinically relevant concentration range based on the spiked 
samples and the intraday recovery (see Table 4). In the higher concentration range the bias 
was slightly negative (%error −9.7 for interday and −11.3 for intraday).  In certain situations, 
immunoassays like the FPIA method may be hampered by interference of MTX metabolites. 
For example, the presented method was able to measure the rapid disappearance of plasma 
MTX in patients treated with carboxylase-G2 for adverse events whereas the FPIA method 
was hampered by falsely high MTX levels due to interference from the methotrexate 
metabolite DAMPA (data not shown). This observation was confirmed by literature [12, 13]. 
 In conclusion, we describe a LC-MS/MS based method to measure MTX in plasma 
with minimal sample pretreatment, relative short analysis time, and good diagnostic 
performance that can be applied in routine clinical TDM. 
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Supplementary data 2. LLOQ determination of MTX in plasma as measured by LC-MS/MS.
Each point represents the CV% of a ten-fold measurement of drug-free plasma samples spiked with MTX. 
The concentration of the standards are represented on the x-axis, the CV% on the y-axis.
Supplementary data 1. Linearity of plasma MTX 
MTX concentration as measured by LC-MS/MS (y-axis) is plotted against the spiked concentrations of the samples 
(x-axis). Linearity was determined by five-fold measurement of a 0-50 µmol/Lconcentration range, R2 was always 
>0.99.
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Abstract
BACKGROUND: The folate antagonist methotrexate (MTX) is the anchor drug in the 
treatment of rheumatoid arthritis. The therapeutic effects of MTX are attributed to the 
intracellular levels of MTX, present in the cell as polyglutamates (MTX-PG). We aimed to 
validate an immunoassay for the measurement of MTX-PG in erythrocytes.
METHODS: Samples were analysed by an adapted fluorescent polarisation immune assay 
(FPIA) method on the FLx analyser (Abbott). Cross-reactivity was determined in both plasma 
and erythrocyte pellet. In erythrocyte pellet, the imprecision, linearity, and lower limit of 
quantitation (LLOQ) was determined. The method was compared to our in-house LC-MS/
MS method for total MTX-PG.
RESULTS: For the adapted FPIA method, a linear range of 25-1000 nmol/L (R2 = 0.993) 
was obtained for total MTX-PG in erythrocytes. A coefficient of variation (CV) of <17% for 
interday and <8% for intraday imprecision was found and average recovery was 91%. LLOQ 
was determined at 50 nmol/L total MTX-PG with a CV of 15%. There was no significant 
proportional bias of the FPIA assay compared with our in-house LC-MS/MS method but 
a (non-significant) constant positive bias was present [FPIA = 1.00 (95% CI: 0.60 - 1.95) 
× LC-MS/MS + 31.00 nmol/L (95% CI: -11.83 - 61.00)]. Results could be very different for 
individual patients as reflected in the poor R2 of 0.419. 
CONCLUSIONs: The FPIA method can be used to measure total MTX-PG in erythrocytes.. 
Although there was no significant bias detected compared with the LC-MS/MS method, 
the FPIA method showed constant positive bias, probably due to interference from folates 
and MTX metabolites DAMPA and 7-OH-MTX. The correlation between both methods was 
average and resulted in large differences in individual patients, most likely due to problems 
during sample preparation.
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Introduction
Methotrexate (MTX) is the anchor drug in the treatment of arthritic diseases due to its 
safety and efficacy. In low-dose MTX treatment, plasma-MTX is eliminated from plasma 
within 24 hours[1] and is unrelated to response.[2] Therefore, plasma MTX is not a reliable 
tool for therapeutic drug monitoring in low-dose MTX treatment.[3] However, methotrexate 
polyglutamates (MTX-PGs) accumulate intracellularly, which are related to clinical response 
and have been proposed to be of use for TDM purposes.[4-7] In low-dose MTX treatment, 
the pentaglutamate (MTX-PG5) is the highest order of glutamylation detected, while the 
triglutamate form (MTX-PG3) of MTX predominates.[5, 8] Polyglutamylation retains MTX in 
the cell because MTX-PGs are a poor substrate for the MTX efflux proteins. 
 While methods for the measurement of plasma MTX are commercially available, 
methods for measuring intracellular MTX-PG are not and require more complex procedures 
and equipment such as HPLC[5, 9] or mass spectrometry.[8, 10, 11] However, measurement 
of intracellular total MTX-PG concentration is also possible by adaptation of commercial 
plasma methods.[12, 13] 
 Although the individual MTX-PG species are good predictors of response, we have 
recently shown that total MTX-PG concentration at three months of treatment can also be 
used to predict clinical response in rheumatoid arthritis (RA)[14] and juvenile idiopathic 
arthritis (JIA).[15] In RA, a threshold of 74 nmol/L of total erythrocyte MTX-PG was able to 
differentiate between responders and non-responders over 9 months of treatment.  
 Cross-reactivity of the antibody against all MTX-PG species in the MTX fluorescent 
polarisation immune assay (FPIA) can be used for the measurement of erythrocyte total 
MTX-PG from RA patients.[12] Cross reactivity was shown by comparing erythrocytes spiked 
with MTX-PG7 to those spiked with equal amounts of MTX-PG1.[12] However, the authors 
did not assess bias of the method by comparing with more specific methods to measure 
intracellular MTX-PG species such as mass spectrometry. 
 Therefore, the aim of our study was to compare the adapted Abbott FLx MTX 
FPIA assay to measure erythrocyte total MTX-PG with the more specific measurement of 
erythrocyte MTX-PG species measurement as described by us earlier.[11]
Material and methods
Materials and samples
MTX-PG1-5 were purchased from Schircks Laboratories (Jona, Switzerland). 
Dichloromethane, 10 mol/L ammonium hydroxide, sodium hydroxide, 70% perchloric acid 
were bought at Merck (Schiphol-Rijk, the Netherlands). Protease K was bought at Qiagen 
(Venlo, the Netherlands). Methotrexate II Reagent Pack for FPIA, calibrators and controls 
were purchased from Abbott Laboratories (Hoofdorp, The Netherlands) and the assay was 
performed on an Abbott FLx analyzer. 
 For both methods erythrocyte pellets were obtained by centrifuging 
K
2
-ethylenediaminetetraacetic acid (EDTA) whole-blood tubes for 10 minutes at 2700 × g. 
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Pellets were not washed. Blinded, drug-free erythrocyte pellets were used for development 
and validation. Drug-free pellets were pooled per 10 ml and stored at −80 °C until further 
use. After thawing, samples were vortexed vigorously before handling. Positive displacement 
pipettes (Gilson, den Haag) were used for pipetting the erythrocyte pellets. 20 samples of 
patients treated with MTX were used to compare the adapted FPIA method with LC-MS/MS. 
All samples were blinded after selection. Patient samples were pelleted by centrifugation for 
10 minutes at 2700 × g and stored at −80 °C until analysis. As these patient samples were 
leftover from routine analysis at the department of clinical chemistry, no medical-ethical 
approval was necessary for this study.
Sample preparation
For the FPIA assay, sample preparation was based on Hayashi et al.[12] and was adapted 
where the article did not specify or optimization was needed in our hands. Briefly, samples 
were prepared by adding 40 µl of proteinase K to 275 µl of erythrocyte pellet, incubated for 
15 minutes at 50 °C and cooled on ice. 60 µl 1 mol/L NaOH and 500 µl methylene chloride 
were added to the sample and vortex mixed for 30 seconds at room temperature. Samples 
were then incubated at –30 °C for one hour followed by centrifugation at 20000 × g for 15 
minutes; 200 µl clear supernatant was transferred and mixed with 4 µl of 10% perchloric 
acid. Samples were kept on ice during the sample preparation unless mentioned otherwise. 
Samples for LC/MS-MS analyses were prepared as described earlier.[11]
Preparation of calibrators and control samples
Stock solutions of MTX-PG were prepared in 0.1 M ammonium hydroxide at 88.75 μmol/L 
(MTX-PG1), 64.48 μmol/L (MTX-PG2), 85.7 μmol/L (MTX-PG3), 40.71 μmol/L (MTX-PG4) and 
51.28 μmol/L (MTX-PG5). A batch of frozen pooled drug-free erythrocyte pellet was thawed 
at room temperature while rotating and spiked with 0, 40, 80, 120, 160 or 200 nmol/L of 
each MTX-PG standard, yielding a total MTX-PG calibration curve of 0, 200, 400, 600, 800 
and 1000 nmol/L. A fresh calibration curve was prepared for each run.
 Quality-control (QC) samples were prepared in drug-free erythrocyte pellet at three 
different concentrations: 200, 500, and 800 nmol/L of each individual MTX-PGn. Aliquots 
were stored at −80 °C and thawed on ice. QC samples were prepared for every run. LC-MS/
MS calibrators and QC samples were prepared as published earlier.[11]
LC-MS/MS analysis
Sample preparation and LC-MS/MS analysis were performed as published previously [11].
Validation of the adapted FPIA assay
Cross reactivity of the FPIA assay was determined by comparing drug-free plasma samples 
spiked with 200, 400, 600, 800 and 1000 nmol/L of the separate MTX-PGs with samples 
spiked with the same concentrations of MTX-PG1. To test cross reactivity in erythrocytes, 
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drug-free erythrocyte pellets were spiked with 200, 400, 600, 800 and 1000 nmol/L of 
either MTX-PG1 or MTX-PG5.  Cross reactivity was expressed as (concentration MTX-PG/
concentration MTX-PG1) × 100%. 
 Linearity of the method was determined by spiking a batch of drug-free erythrocyte 
pellet with 9 different concentrations of MTX-PG1-5 in a range of 12.5–1000 nmol/L. The 
samples were measured 5 times from the same vial. Linearity was considered acceptable if 
the squared coefficient of correlation (R2) was >0.99 for each calibration curve.
 Lower limit of quantitation (LLOQ) was determined by spiking a batch of drug-free 
erythrocyte pellets with 9 different concentrations of MTX-PG1-5 in a range of 12.5–1000 
nmol/L. These were measured 5 times from the same vial for each concentration level. The 
LLOQ was defined as the lowest concentration with a coefficient of correlation (CV) <20%.
MTX-PG interday imprecision was determined by measuring quality control samples 10 
consecutive working days. Intraday imprecision was determined by measuring a set of 
quality control samples 5 times on a single day. Imprecision was expressed as CV% (mean/
standard deviation × 100%).
 Recovery of the sample preparation was determined by spiking 3 different batches 
of pooled drug-free erythrocyte pellets with 40, 100, and 160 nmol/L of each MTX-PGn 
before and after sample preparation. The recovery was calculated as recovery (%) = (sample 
spiked before preparation/ sample spiked after sample preparation)×100 %. 
Method Comparison.
The methods were compared using two sets of samples, one set of calibration samples 
(n=10), and one set of 20 blood samples of RA patients treated with MTX which were left 
over from routine analysis. These samples were measured on the same day with both the 
adapted FPIA method and our in-house LC-MS/MS method which is capable of measuring 
the separate MTX-PGs. In the LC-MS/MS method, total erythrocyte MTX-PG was calculated 
by summing up all individual MTX-PG species. Passing and Bablok regression analysis was 
used to compare both methods. The patients received 15-25 mg/week oral MTX. 
Results
When the MTX-PGs were separately spiked into drug-free plasma samples, we found 
103 ± %, 102 ± 4%, 100 ± 2%, and 106 ± 6% cross reactivity for MTX-PG2 to MTX-PG5 
respectively when compared to MTX-PG1 in plasma, demonstrating the high cross reactivity 
of this assay (Table 1). In erythrocyte samples, a cross reactivity of 98 ± 8% for MTX-PG5 
was found. When the 5 MTX-PGs were added in equimolar amounts, the measured amount 
of total MTX-PG did not differ from equal amounts of MTX-PG1 (Table 1). Using a dilution 
of equimolar amounts of MTX-PG1-5 spiked into erythrocyte pellet, the method was linear 
from 25 nmol/L to 1000 nmol/L (R2 = 0.993; y= x + 9 nmol/L), which reflects most of the 
clinically relevant range. LLOQs were determined as the lowest concentration that resulted 
in a CV% <20%, and was set at 50 nmol/L total MTX-PG. 
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Table 1. Cross-reactivity of MTX-PGs in the Abbott FPIA assay for spiked plasma and 
erythrocyte samples.
MTX-PG measured in plasma (nmol/L)
Concentration (nmol/L) 200 400 600 800 1000
MTX-PG1 (nmol/L) 195 390 584 793 1002
MTX-PG2 (nmol/L) 208 403 611 806 1000
MTX-PG3 (nmol/L) 209 386 611 805 998
MTX-PG4 (nmol/L) 188 393 598 802 990
MTX-PG5 (nmol/L) 226 403 613 823 1000
Crossreactivity (%)
MTX-PG2 107% 103% 105% 102% 100%
MTX-PG3 107% 99% 105% 101% 100%
MTX-PG4 96% 101% 102% 101% 99%
MTX-PG5 116% 103% 105% 104% 100%
MTX-PG measured in spiked erythrocyte samples (nmol/L)a
MTX-PG1 (nmol/L) 233 481 652 776 1040
MTX-PG5 (nmol/L) 231 432 601 863 987
Crossreactivity (%)
MTX-PG5 99% 90% 92% 111% 95%
MTX-PG1 (nmol/L) 198 350 517 700 1065
MTX-PG1-5 (nmol/L) 228 404 596 772 1035
Crossreactivity (%)
MTX-PG1-5 115% 115% 115% 110% 97%
aErythrocyte samples were measured in two batches of pooled drug-free erythrocytes, one batch to asses cross-
reactivity of MTX-PG5, and the other batch to assess cross-reactivity of the combined MTX-PGs at equimolar 
concentration.
 The CV% for interday imprecision was 17%, 6% and 5% for the 200, 500 and 800 
nmol/L samples respectively, For intraday imprecision the CV% was 8%, 2% and 1% for for 
the 200, 500 and 800 nmol/L samples, respectively for the combined MTX-PGs in erythrocyte 
pellets. Recovery was measured in 3 batches of spiked pooled pellet and ranged from 80-
100% (mean recovery 91±7%) with a CV% of 8%. Figure 1 and 2 show the results for the 
method comparison of the 10 calibration samples and the 20 patient samples, respectively. 
The FPIA method showed no proportional bias but a (non-significant) constant positive bias 
compare to LC-MS/MS, both in the calibrator samples [FPIA = 0.99 (95% CI: 0.96-1.09) × LC-
MS/MS + 22.23 nmol/L (95% CI: −23.21-34.18)] and the patient samples [FPIA = 1.00 (95% 
CI: 0.60 - 1.59) x LC-MS/MS + 31.00 nmol/L (95% CI: -11.83 - 61.00)]. 
 Of the 20 patient samples, 1 sample was excluded because it did not mix properly 
during the sample preparation for the FPIA assay. The squared correlation coefficient was 
excellent in the calibration samples (R2 = 0.998) whereas it was average in the 19 patient 
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samples (R2 = 0.419). The results in individual patients samples could be very different, 
which was reflected by the average correlation (Figure 2).
Figure 1
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Figure 2. Passing-Bablok comparison of MTX-PGs determined by the adapted Abbott FPIA assay on the FLx 
analyzer (y-axis) and the LC-MS/MS method (x-axis) using erythrocyte samples from patients treated with MTX 
(n=19). Solid line (grey) represents an x=y comparison, Solid line (Blue) represents Passing and Bablok comparison, 
dotted lines represent the 95% CI. Right panel shows the measured values in nmol/L per liter erythrocyte pellet.
Figure 1. Passing-Bablok comparison of MTX-PGs in spiked erythrocyte pellets between the adapted Abbott FPIA 
on the FPIA analyzer (y-axis) and LC-MS/MS method (x-axis) (n=19). Solid line (grey) represents an x=y comparison, 
Solid line (Blue) represents Passing and Bablok comparison, dotted lines represent the 95% CI. Right panel shows 
the measured values in nmol/L per liter erythrocyte pellet.
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Discussion
Due to the increasing evidence of the relation between methotrexate polyglutamates and 
response in RA and JIA it would be beneficial to have a quick, easy-to-use assay for the 
measurement of the total MTX-PG content in erythrocytes that utilizes an existing, robust 
platform like the FLx in order to enhance the clinical availability of this measurement. We 
tried to utilize the adapted FLx based FPIA MTX-PG assay published previously,[12] which 
makes use of the assay’s high cross-reactivity between MTX-PG species in order to measure 
total erythrocyte MTX-PG. We were able to replicate this high cross-reactivity and we did 
not find a notable difference in specificity for any of the MTX-PGs compared to MTX-PG1 
which is the analyte for which the FPIA method has originally been developed. 
 In our hands, the method performed well during validation using spiked erythrocyte 
samples. When comparing patient samples measured with both the FPIA method and our 
in-house validated LC-MS/MS assay,[11] Passing and Bablok analysis showed no significant 
proportional bias. However, while no proportional bias was found, the plot shows a 
substantial constant bias (31 nmol/L) between both methods; FPIA measured samples 
generally yielded higher concentrations of total MTX-PG than the same samples measured 
on LC-MS/MS. The constant bias found with Passing and Bablock analysis will likely be 
significant when more samples are included.
 Overestimation by the FPIA assay has been reported before [16, 17] and is likely 
to be partially due to cross-reactivity of the FPIA assay to folate or the MTX metabolites 
7-hydroxy-MTX (7-OH MTX) and  2,4-diamino-N10-methylpteroic acid (DAMPA)[18, 19] 
reflecting the lower specificity. In theory part of the overestimation might be due to the 
very long chain MTX-PGs (MTX-PG6 and MTX-PG7) as our total MTX-PG measurement on 
the LC-MS/MS does not take these into account. However, these have not been conclusively 
shown in low-dose MTX treatment and we have never encountered these MTX-PG species 
before.
 In a previous publication, we reported a significant bias of 7.3 nmol/L MTX in plasma 
when samples were measured with the FPIA assay. The cross-reactivity for MTX metabolites 
might be the reason for the observed constant positive bias for the FPIA assay. Furthermore, 
we showed that the correlation between FPIA and LC-MS/MS in patients samples was much 
poorer than for calibration samples (R2 = 0.419 vs 0.998), which sometimes generated large 
differences in total erythrocyte MTX-PG levels in individual patients for both methods (Figure 
2). The difference in MTX levels measured by both methods might be partially due to the 
colour and turbidity of the samples measured using the FPIA assay because the concentration 
of the patient samples was calculated using calibration samples from a separate batch of 
erythrocyte pellet. The colour and turbidity of these batches was as variable as the colour 
and turbidity of the patient samples. Although FPIA is less influenced by colour and turbidity 
differences than other immune assays, the preparation of the erythrocyte pellets for the 
FPIA assay did not yield colourless samples or samples of consistent colour and turbidity and 
these sample to sample differences may contribute to the discrepancy between methods. 
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These sample to sample differences  might also reflect a difference in extraction efficiency, 
yielding varying amounts of extracted total MTX-PG from the erythrocytes. 
 During the initial method comparison there was good agreement between methods 
when using spiked samples which did not contain intracellular MTX and were obtained from 
a single batch of pooled erythrocytes (Figure 1). Although a clear, though non-significant 
bias was present, these samples exhibited similar behaviour. However, patient samples 
containing intracellular MTX did not compare favourably between methods (Figure 2). 
The sample preparation might therefore not be able to extract all intracellular MTX-PG, 
combined with differences between patients in cross-reacting metabolites such as 7-OH 
MTX and DAMPA might have led to the discrepancy between methods. These differences 
between methods might in fact reflect variations in folate metabolism between individual 
patients and it might be useful to compare these differences with clinical response or 
adverse events. 
 Compared with the in-house LC-MS/MS method for the measurement of MTX-PG 
in erythrocytes, the FPIA assay has higher CV% for interday and intraday imprecision, as 
well as a higher LLOQ and a smaller linear range,[11] making the FPIA assay less suitable for 
patients with low levels of erythrocyte MTX-PG. 
 One other method for the measurement of total MTX-PG in erythrocytes with the 
FPIA assay has been published, using a different sample preparation. However, that method 
uses solid phase extraction (SPE) to obtain a clean supernatant,[13] although this should 
prevent inter-sample variation in colour, it is very difficult to compensate for the recovery 
rate of the SPE, which is known to be very variable. Both FPIA based assays that have been 
published were not compared with a reference method to test if the newly developed 
method does indeed measure consistently and correctly. 
 While the FPIA assay seems promising, sample preparation needs to be further 
optimized before it can be utilised in a clinical setting and it cannot be translated directly 
from the original articles. We strongly advice laboratories to do a cross-validation with a 
(reference) method on a different platform using real patient material when adapting similar 
methods. 
 In conclusion, we demonstrate that an adapted FPIA assay can be used to measure 
erythrocyte total MTX-PG levels but that the method in general shows a positive bias and 
low specificity, probably due to interference MTX metabolites DAMPA and 7-OH-MTX. 
Furthermore, due to problems in the sample preparation FPIA results may substantially 
deviate between individual patients. 
84
Chapter 5
References
1 Hornung N, Ellingsen T, Attermann J, Stengaard-Pedersen K, Poulsen JH. Patients with rheumatoid 
arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate 
to plasma concentrations and clinical efficacy. J Rheumatol. 2008 Sep;35(9):1709-15.
2 Dalrymple JM, Stamp LK, O’Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral 
methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008 Nov;58(11):3299-308.
3 Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse 
methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996 Mar;30(3):194-210.
4 Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of 
methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985 Sep;76(3):907-12.
5 Dervieux T, Orentas Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, et al. HPLC determination of 
erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with 
rheumatoid arthritis. Clin Chem. 2003 Oct;49(10):1632-41.
6 Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate 
with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide 
transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid 
arthritis. Arthritis Rheum. 2004 Sep;50(9):2766-74.
7 Becker ML, Gaedigk R, van Haandel L, Thomas B, Lasky A, Hoeltzel M, et al. The effect of genotype 
on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug 
response. Arthritis Rheum. 2011 Jan;63(1):276-85.
8 van Haandel L, Becker ML, Leeder JS, Williams TD, Stobaugh JF. A novel high-performance liquid 
chromatography/mass spectrometry method for improved selective and sensitive measurement of 
methotrexate polyglutamation status in human red blood cells. Rapid Commun Mass Spectrom. 2009 
Dec;23(23):3693-702.
9 Hroch M, Tukova J, Dolezalova P, Chladek J. An improved high-performance liquid chromatography 
method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile 
idiopathic arthritis. Biopharm Drug Dispos. 2009 Apr;30(3):138-48.
10 Meesters RJ, den Boer E, de Jonge R, Lindemans J, Luider TM. Assessment of intracellular 
methotrexate and methotrexate-polyglutamate metabolite concentrations in erythrocytes by ultrafast 
matrix-assisted laser desorption/ionization triple quadrupole tandem mass spectrometry. Rapid 
Commun Mass Spectrom. 2011 Oct 30;25(20):3063-70.
11 den Boer E, Meesters RJ, van Zelst BD, Luider TM, Hazes JM, Heil SG, et al. Measuring methotrexate 
polyglutamates in red blood cells: a new LC-MS/MS-based method. Anal Bioanal Chem. 2013 
Feb;405(5):1673-81.
12 Hayashi H, Fujimaki C, Tsuboi S, Matsuyama T, Daimon T, Itoh K. Application of fluorescence 
polarization immunoassay for determination of methotrexate-polyglutamates in rheumatoid arthritis 
patients. Tohoku J Exp Med. 2008 May;215(1):95-101.
13 Inoue S, Hashiguchi M, Kawai S, Mochizuki M. Erythrocyte methotrexate-polyglutamate assay using 
fluorescence polarization immunoassay technique: application to the monitoring of patients with 
rheumatoid arthritis. Yakugaku Zasshi. 2009 Aug;129(8):1001-5.
14 de Rotte MC, den Boer E, de Jong PH, Pluijm SM, Bulatovic Calasan M, Weel AE, et al. Methotrexate 
polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid 
arthritis. Ann Rheum Dis. 2013 Dec 5.
15 Bulatovic Calasan M, den Boer E, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, et al. Methotrexate 
polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic 
arthritis patients. Ann Rheum Dis. 2013 Nov 28.
16 Najjar TA, Matar KM, Alfawaz IM. Comparison of a new high-performance liquid chromatography 
method with fluorescence polarization immunoassay for analysis of methotrexate. Ther Drug Monit. 
1992 Apr;14(2):142-6.
Chapter
5
85
Measuring erythrocyte MTX-PGs using FPIA
17 den Boer E, Heil SG, van Zelst BD, Meesters RJ, Koch BC, Te Winkel ML, et al. A U-HPLC-ESI-MS/MS-
based stable isotope dilution method for the detection and quantitation of methotrexate in plasma. 
Ther Drug Monit. 2012 Aug;34(4):432-9.
18 Al-Turkmani MR, Law T, Narla A, Kellogg MD. Difficulty measuring methotrexate in a patient with high-
dose methotrexate-induced nephrotoxicity. Clin Chem. 2010 Dec;56(12):1792-4.
19 Pesce MA, Bodourian SH. Evaluation of a fluorescence polarization immunoassay procedure for 
quantitation of methotrexate. Ther Drug Monit. 1986;8(1):115-21.

Chapter 6
Clinical, metabolic and genetic determinants 
of erythrocyte methotrexate-polyglutamate 
concentrations at 3 months of treatment in 
rheumatoid arthritis
E. den Boer 
M.C.F.J. de Rotte
S.M.F. Pluijm 
S.G. Heil 
J.M.W. Hazes 
R. de Jonge
Provisonally  accepted by the Journal of Rheumatology
88
Chapter 6
Abstract
BACKGROUND: Low-dose methotrexate (MTX) is the anchor drug in the treatment for 
rheumatoid arthritis. Response to MTX is related to the intracellular MTX-polyglutamate 
(MTX-PG) levels and little is known about its determinants. We aimed to define the 
determinants of erythrocyte MTX-PG concentrations in two prospective cohorts of RA 
patients.
METHODS: MTX treated RA patients from two longitudinal cohorts were included: 93 from 
the MTX-R study (derivation cohort), and 247 from the tREACH study (validation cohort). 
MTX-PG concentrations were measured at 3 months of treatment using LC-MS/MS. The 
MTX-PGs were used as outcome measure. Various socio-demographic, clinical, biochemical, 
and genetic factors were assessed at baseline. Associations with MTX-PG levels were 
analyzed using multivariate regression analysis.
RESULTS: Age was positively associated with MTX-PG1 (stβ 0.23; p=0.033) and total MTX-
PGs (stβ 0.23; p=0.018) in the derivation cohort, and with all MTX-PGs in the validation 
cohort (PG1: stβ 0.13, p=0.04; PG2: stβ 0.21, p=0.001; PG3: stβ 0.22, p<0.001; PG4+5: 
stβ 0.25, p<0.001; and total: stβ 0.32, p<0.001). Erythrocyte folate levels were positively 
associated with MTX-PG3 (stβ 0.32; p=0.021) and total MTX-PG levels (stβ 0.32; p=0.022) in 
the derivation cohort, which was replicated for MTX-PG3 (stβ 0.15, p=0.04) in the validation 
cohort. Patients with the FPGS rs4451422 wildtype-genotype had higher concentrations of 
MTX-PG3 (p<0.05), MTX-PG4+5 (p<0.05) and total MTX-PG (p<0.05) in both cohorts. In the 
combined cohort, MTX dose was positively associated with levels of MTX-PG3 (stβ 0.23; 
p<0.001), MTX-PG4+5 (stβ 0.30; p<0.001), and total Total MTX-PG (stβ 0.20; p=0.002), but 
negatively associated with MTX-PG2 levels (stβ -0,22; p<0.001).
CONCLUSIONS: This prospective study shows that higher age, higher MTX dose, higher 
erythrocyte folate status and the FPGS rs4451422 wildtype genotype are associated 
with higher MTX-PG concentrations. While only up to 21% of inter-patient variability 
can be explained by these determinants, this knowledge may aid in the development of 
personalized treatment in RA.
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Introduction
Low dose methotrexate (MTX) is the most widely used treatment for rheumatoid arthritis 
(RA) and other arthritic diseases. Although MTX is effective and save, approximately 
30% of RA patients do not reach sufficient response or suffer from adverse events [1]. A 
pharmacogenetic model for the prediction of MTX efficacy has been proposed previously 
[2]. However, at the moment there is no therapeutic drug-monitoring (TDM) based model 
for predicting compliance, response or adverse events during low-dose MTX treatment.
 While MTX plasma levels can be measured easily, low-dose MTX is rapidly cleared 
from plasma and is not routinely measured. Hence, plasma MTX levels do not correlate with 
response in RA patients [3]. The therapeutic effects of MTX are thought to be mediated by 
its intracellular levels [4], which are difficult to measure. Intracellular levels of methotrexate 
can predict treatment response, making intracellular MTX an interesting target for TDM 
[5-13]. We recently developed a stable isotope dilution LC-MS/MS assay to measure 
erythrocyte MTX-PGs [14].
 MTX is transported into the cell primarily by the reduced folate carrier. Once in the 
cell, MTX is converted by folylpolyglutamate synthase (FPGS) to MTX polyglutamates (MTX-
PGs) by γ-linked sequential addition of glutamic acid residues. In a competing reaction, the 
MTX-PGs are deconjugated by γ-glutamyl hydrolase (GGH), leading to a variety of chain-
lengths (MTX-PG2-7). In low-dose MTX treatment, the pentaglutamate (MTX-PG5) is the 
highest order of glutamylation detected, while the triglutamate form (MTX-PG3) of MTX 
predominates [15, 16]. Polyglutamylation retains MTX in the cell because the MTX-PGs are 
a poor substrate for the MTX efflux proteins. 
 In low dose MTX, the median time to reach steady-state erythrocyte MTX levels 
is highly variable between patients and increases with the number of PGs attached to MTX 
[17]. For example, MTX-PG3 has a median time to reach steady-state of 41.2 weeks (range 
19.8-66.7 weeks) compared to 139.8 weeks (range 15.5-264.0 weeks) for MTX-PG5 [17]. 
Steady-state levels also are highly variable between patients: total erythrocyte MTX-PG 
concentration varied between 90.9-351.5 nmol/8*1012 erythrocytes [17]. The mechanisms 
behind the highly variable intracellular MTX-PG levels are still not known.
 Previous research has shown that increased age, higher dose, route of 
administration and decreased renal function [18, 19] are associated with higher MTX-PG 
levels, as well as multiple single nucleotide polymorphisms (SNP) in MTX pathway genes [8, 
13]. However, these studies used cross-sectional cohorts with a wide range of treatment 
duration between patients. Therefore, the aim of this study was to examine clinical, genetic, 
socio-demographic, and biochemical determinants of erythrocyte MTX-PG concentrations 
in patients treated with low-dose oral MTX using two different prospective cohorts.
Methods
Patients
This study includes data of RA patients treated with MTX from two prospective cohorts:  For 
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the derivation cohort, patients from the methotrexate in Rotterdam, Netherlands cohort 
(MTX-R) were used. The MTX-R is a longitudinal prospective cohort of patients diagnosed 
with RA who started MTX between January 2006 and March 2011 in the department of 
Rheumatology, University Medical Center Rotterdam (Erasmus MC), Netherlands. The 
validation cohort consisted of patients from the treatment in Rotterdam Early Arthritis 
Cohort (tREACH). The tREACH is a clinical multicentre, stratified single-blinded trial 
(ISRCTN26791028) and was described earlier.[20] Patients were included in the validation 
cohort if they met the 2010 ACR/EULAR criteria for RA. The medical ethics committee from 
the Erasmus MC approved both studies and patients gave written informed consent before 
inclusion. Patients from the derivation and validation cohorts were included in our study 
if they were prescribed MTX at baseline and three months of treatment and had at least 
one MTX-PG measurement at three months of treatment. All patients were MTX naïve at 
inclusion.
 In the derivation cohort, dosage and co-medication was chosen by the physician. 
MTX was generally given orally. Patients from the validation cohort started with 25 mg/
week MTX per os (dosage reached after 3 weeks) and were randomized to treatment with 
or without sulfasalazine, hydroxychloroquine and glucocorticosteroids. Patients in both 
cohorts received folic acid (10 mg/week) during MTX treatment as recommended by the 
Dutch Rheumatology Society [21]. In both cohorts, patients were assessed at baseline and 
after 3 months.
Patient material
During the first and second study visits, an extra EDTA tube was drawn from the patient. The 
sample from the first visit was used for DNA isolation, whereas the sample from the second 
visit was immediately put on ice after collection and centrifuged for 10 min at 1700 x g and 
4 °C. Plasma and erythrocyte cell-pellet aliquots were stored at -80 °C. 
MTX-PG quantification
 MTX-PGs were measured in the cell-pellet aliquots sampled at 3 months of 
treatment using a recently developed LC-MS/MS method [14]. MTX-PG1 and MTX-PG2 
are considered as short chain, MTX-PG3 as medium chain and MTX-PG4 and MTX-PG5 as 
long chain. The sumscore of MTX-PG2 to MTX-PG5 was used as the total MTX-PG content. 
Considering the finding that MTX-PG1 can diffuse over the erythrocyte membrane, [22] we 
decided to remove MTX-PG1 out of the model for total MTX-PGs.
SNP selection
SNP in genes involved in MTX transport and polyglutamylation were selected based on the 
following criteria: minor allele frequency (MAF) > 0.10 in the Hapmap and National Center 
for Biotechnology Information (NCBI) SNP database [23, 24] or a proven functionality in 
relation to MTX, JIA, RA, or folate metabolism[25-33]. If no information was known for a 
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particular gene, we selected tagging SNP by Hapmap database and Haploview (version 4.2, 
29 April 2008) . Preferably, 2 SNP were selected per gene, which were located in different 
haplotype blocks. 
 The following 28 SNP in 19 genes were selected: ABCB1 rs1128503, rs2032582, 
rs1045642; ABCC1 rs35592, rs3784862; ABCC2 rs4148396, rs717620; ABCC3 rs4793665, 
rs3785911; ABCC4 rs868853, rs2274407; ABCC5 rs2139560; ABCG2 rs13120400, 
rs2231142; ADA rs7359874; ADORA2A rs5751876; AMPD1 rs17602729; ATIC rs2372536; 
FPGS rs4451422; FOLR2 rs514933; GGH rs10106587, rs3758149; ITPA rs1127354; MTHFR 
rs1801131, rs1801133; MTRR rs1801394;  SLC46A1 rs2239907; and SLC19A1 rs1051266. 
The major allele was analysed as wild-type allele. 
Genotyping
SNP genotyping has been described earlier [34].
Clinical, biochemical and socio-demographic parameters
Various clinical, biochemical and socio-demographic parameters were assessed at baseline. 
In the derivation cohort, the use of other DMARDs, hydroxychloroquine, sulfasalazine, 
corticosteroids, biological, route of administration of corticosteroids, dose of methotrexate, 
and route of administration of methotrexate were reported by patients using question 
forms. In the validation cohort, these items were scored by research nurses. The eGFR-
MDRD was calculated using the 4-variable MDRD formula and body surface area (BSA) was 
calculated using the Mosteller formula. During the study visit, blood was obtained from 
patients to determine rheumatoid factor, anti-cyclic citrullinated peptide antibody (Anti-
CCP), C-reactive protein (CRP), one-hour erythrocyte sedimentation rate (ESR), albumin, 
enzymatic creatinine, erythrocyte folate, serum folate, vitamin B12, vitamin B6, and 
homocysteine. Questionnaires were used to determine smoking habit and the consumption 
of alcohol, cola, coffee, tea and cigarettes (amount per day).  
Statistics
Comparison of patient characteristics between cohorts was made by Student t-test, X2 test 
or the Mann-Withney u-test where appropriate. Multivariate multiple linear regression 
analysis, stratified by cohort, was used to examine the associations between these potential 
determinants and the different MTX-PG concentrations. First, univariate linear regression 
was performed for all potential determinants with the MTX-PG concentrations as outcome 
measure. The strength of the associations was expressed as standardized beta’s. Univariate 
relations between variables and any MTX-PG with a p-value less than 0.2 were entered in 
subsequent multivariate multiple regression analyses with adjustment for age, gender and 
other potential determinants that had a p-value of less than 0.2 in the univariate analysis. 
 Continuous determinants were analyzed as continuous variable and transformed 
into quintiles to examine possible non-linear associations. In order to establish non-linear 
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associations the quintiles were plotted against the total MTX-PG levels were used.  Variables 
with a non-linear association were transformed into categorical variables and categories 
were combined where appropriate. This was done for ESR, GFR, creatinine, alcohol 
consumption, tea consumption and days of treatment. Dummy variables were used to 
analyze categorical variables with more than two categories in linear regression using the 
first category as reference. Non-normal distributed variables were transformed using the 
natural logarithm (ln) for linear regression; this was done for homocysteine, erythrocyte 
folate and C-reactive protein.
 SNPs were divided into dominant, recessive or additive models depending on the 
distribution of the total MTX-PG levels per genotype to ensure pre-analysis selection of an 
analysis model.  ANCOVA was used to determine significant associations between SNPs and 
MTX-PG levels. For SNPs, estimated marginal means + standard error are reported. SNPs 
in dominant model were ITPA rs1127354, AMPD1 rs17602729, ABCC4 rs2274407, ABCC2 
rs717620. SNPs in recessive model were ABCC1 rs35592, ABCC4 rs868853, FPGS  rs4451422, 
SLC19A1 rs1051266. Other SNPs were analyzed as an additive model. All SNPs were corrected 
for age and gender
 It was not possible to test the influence of MTX dose in the separate cohorts 
because MTX dose was protocolled at 25 mg/wk in the validation cohort and there was 
low variation in the derivation cohort. To evaluate dose as potential determinant, both 
cohorts were combined. MTX dose was entered in an ANCOVA together with age, gender, 
erythrocyte folate, and FPGS rs4451422.
 Multiple testing was not corrected for as the included variables in the study were 
carefully chosen for an expected relation to MTX-PG based on literature and physiology. 
Statistical analyses were done with SPSS PASW 20.0.0.1 for Windows (SPSS Inc., Chicago, IL, 
USA) unless stated otherwise. P values less than 0.05 were considered significant. 
 
Results
Patient characteristics
93 out of 102 patients from the derivation cohort and 247 out of 285 patients from the 
validation cohort could be included into our study, the remaining patients were excluded 
because there was no erythrocyte pellet sample for MTX-PG measurement at three months.
 The derivation and validation cohorts were very similar for most baseline 
characteristics (table 1). In the derivation cohort, a smaller percentage of patients used 
hydroxychloroquine (44.7% vs 58.4%; p=0.32), sulfasalazine (35.3% vs 58.4%; p<0.001) and 
corticosteroids (12.9% vs 89.1%; p<0.001). DAS28 was lower in the derivation cohort (4.1 vs 
4.7) and the derivation cohort had slightly higher eGFR-MDRD (88.1 ml/min/1.73m2 vs 80.7 
ml/min/1.73m2; p<0.05) and erythrocyte folate content (1075.7 nmol/L vs 925.5 nmol/L; 
p<0.001) than the validation cohort. Treatment dose of MTX was significantly different 
between both cohorts (p<0.001). Patients in the derivation were treated with 15 mg/wk 
and patients in the validation were treated with 25 mg/wk as per study protocol.
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MTX-PG levels 
After 3 months of MTX treatment, median [IQR] MTX-PG concentrations in the derivation 
cohort were: 33.8 [22.7-61.6], 23.1 [17.2-31.6], 39.8 [24.8-53.6], 8.4 [4.2-17.3], 1.0 [0.0-2.8] 
nmol/l for MTX-PG1 to MTX-PG5 respectively, and 79.0 [49.3-106.0] nmol/l for total MTX-PG 
(Figure 1a). In the validation cohort, median [IQR] MTX-PG concentrations were: 30.0 [19.8-
47.4], 21.2 [15.9-27.4], 49.0 [36.5-61.4], 20.0 [11.4-30.2], 4.7 [2.0-9.3] nmol/l for MTX-PG1 
to MTX-PG5, respectively (Figure 1a), and 97.9 [71.6-125.3] for total MTX-PG. MTX-PG1 did 
not differ between the derivation cohort and the validation cohort despite the difference 
in MTX dose between cohorts (table 1). Median MTX-PG2 concentrations were slightly, 
but significantly higher in the derivation cohort than in the validation cohort (p=0.015). In 
contrast, median MTX-PG3, MTX-PG4, MTX-PG5 and total MTX-PG were significantly lower 
in the derivation cohort than in the validation cohort (p<0.001 for MTX-PG3-5 and total 
MTX-PG, Figure 1a). 
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Figure 1. A) Concentrations of the separate MTX-PGs in the derivation (white bars, n=93) and validation (grey 
bars, n=247) cohorts. Brackets denote significant differences between cohorts, p-values are noted above the 
brackets. MTX-PG2 is significantly lower in the validation cohort, while MTX-PG3, MTX-PG4, and MTX-PG5 are 
higher in the validation cohort. Significant differences were tested with Mann-Whitney U-test.
B) Effect of MTX dosage on the concentration of total MTX-PG in the combined cohort. Increased dose of MTX leads 
to increased total MTX-PG. ANCOVA was adjusted for age, gender, erythrocyte folate, and rs4451422 in the FPGS 
gene.  p-values are from the confounder adjusted data, boxplots are from unadjusted data.
*p<0.05, **p<0.001
Determinants of MTX-PGs
All variables listed in Table 1 were entered into a univariate linear regression model 
(Supplementary Table 1). Variables that obtained a p-value <0.2 in univariate linear 
regression were entered into a multivariate linear regression model (Table 2). 
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Table 1. Baseline characteristics of MTX-R and tREACH cohorts.
Derivation cohort Validation cohort
Patient demographics N=93 N=247
Age, years, mean (SD) 51.2 (16.1) 52.8 (14.2)
Female (%) 72.0 69.2
BSA, m3, mean (SD) n/a 1.9 (0.3)
DAS28esr, mean (SD)* 4.1 (1.4) 4.7 (1.2)
Rheumatoid factor positive (%)* 37.3 56.1
Anti-CCP positive (%)* 38.6 59.6
Days of treatment at study visit, mean (SD) 91.2 (11.8) 92.9 (9.0)
Medication
Methotrexate Dose* 247
10mg/wk (%) 7.5 0.0
15mg/wk (%) 91.6 0.4
25mg/wk (%) 1.1 99.6
Intramuscular administration of methotrexate (%) 7.1 0.0
Other DMARD use (%) 51.8 58.4
Hydroxychloroquine use (%)* 44.7 58.4
Sulfasalazine use (%)* 35.3 58.4
Biological use (%) 1.1 0.0
Corticosteroid use (%)* 12.9 89.1
Corticosteroid route of administration (%)
No Corticosteroid 87.1 10.9
Subcutaneous 2.4 29.0
Oral 10.6 60.2
Laboratory parameters
C- reactive protein, mg/L, median (IQR) 7.0 (3.0-13.0) 8.0 (4.0-20.0)
Erythrocyte sedimentation rate, mm/hr, mean (SD) 23.3 (18.9) 28.0 (21.4)
Albumin, (g/L), mean (SD) 44.1 (3.6) 43.6 (3.2)
Creatinine, mmol/L, mean (SD) 70.8 (16.5) 75.9 (16.8)
Erythrocyte folate, nmol/L, median (IQR)* 1075.7 (845.7-1323.0) 925.5 (679.8-1172.5)
Serum folate, nmol/L median (IQR) 17.3 (13.0-24.1) 17.3 (13.4-23.9)
eGFR-MDRD, ml/min/1.73m2, mean (SD)* 88.1 (23.8) 80.7 (18.0)
Vitamin B12, pmol/L, median (IQR) 281.6 (225.5-376.8) 290.2 (234.5-403.9)
Vitamin B6, nmol/L, median (IQR) 76.0 (66.0-104.0) 81.0 (65.0-98.0)
Homocysteine umol /l, median (IQR) 12.4 (9.9-14.6) 11.3 (9.5-14.4)
Lifestyle parameters
Alcohol consumption, drinks/month, median (IQR) 6.0 (0.0-32.0) 8.0 (2.0-32.0)
Cola consumption, drinks/month, median (IQR) 0.0 (0.0-24.0) 0.0 (0.0-8.0)
Coffee consumption, drinks/month, median (IQR) 56.0 (24.0-168.0) 112.0 (40.0-112.0)
Tea consumption, drinks/month, median (IQR) 56.0 (1.5-56.0) 40.0 (0.0-56.0)
* signifies a difference between groups that is p<0.05
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Determinants of eryhrocyte MTX-PG levels
 In multivariate analysis, in the derivation cohort, there was a positive association 
between age at start of treatment and levels of MTX-PG1 (stβ 0.23; p=0.033), and total 
MTX-PGs (stβ 0.23; p=0.018), while exhibiting a trend for MTX-PG2 (stβ 0.18; p=0.098) 
and borderline significance for MTX-PG3 (stβ 0.21; p=0.052) (Table 2). This finding was 
replicated in the validation cohort for all MTX-PGs (MTX-PG1: stβ 0.13, p=0.04; MTX-PG2: 
stβ 0.21, p=0.001; MTX-PG3: stβ 0.22, p<0.001; MTX-PG4+5: stβ 0.25, p<0.001; and total 
MTX-PG: stβ 0.28, p<0.001) (Figure 2a). Erythrocyte folate was positively associated with 
levels of MTX-PG3 (stβ 0.32, p=0.021) and total MTX-PG (stβ 0.32, p=0.022), while exhibiting 
a trend for significance for MTX-PG4+5 (stβ 0.24, p=0.099) in the derivation cohort. This 
was replicated in the validation cohort for MTX-PG3 levels (stβ 0.15, p=0.04) and there was 
a trend towards significance for MTX-PG4+5 levels (stβ 0.13, p=0.087) and total MTX-PG 
levels (stβ 0.14, p=0.053) (Figure 2b). Also, in the derivation cohort, there were positive 
associations between serum folate concentration and MTX-PG1 levels (stβ 0.32, p=0.002), 
and between CRP concentration and levels of MTX-PG1 (stβ 0.29, p=0.043) and MTX-PG2 
(stβ 0.32, p=0.022). These findings were not replicated in the validation cohort.
 In the validation cohort, male patients had higher total MTX-PG levels than female 
patients (0.14, p=0.027), and homocysteine levels were positively associated MTX-PG4+5 
levels (stβ 0.20, p=0.007). These findings were not found in the derivation cohort. 
SNP analysis
 A total of 28 SNPs in 18 MTX pathway genes were assessed for their contribution 
to MTX-PG levels (Table 3, Supplementary Table 2). With the exception of ABCB1 rs2032582 
(χ2=299.36, p<0.001) and MTHFR rs1801133 (χ2=5.46, p=0.019), all SNPs were in Hardy-
Weinberg-Equilibrium. SNPs not in Hardy-Weinberg-Equilibrium were entered into linear 
regressions as normal. 
 In the derivation cohort, patients with the FPGS rs4451422 wildtype genotype 
had significantly higher levels of MTX-PG3 (p=0.001), MTX-PG4+5 (p=0.004) and total MTX-
PG (p<0.001; Table 3, Figure 2c). This was replicated in the validation cohort for MTX-PG3 
(p=0.049), MTX-PG4+5 (p=0.043), and total MTX-PG (p=0.015) (Table 3, Figure 2c). Also, 
patients with the SLC46A1 rs2239907 wildtype or heterozygous genotype had significantly 
lower MTX-PG2 (p=0.031) levels in the derivation cohort; this was replicated in the validation 
cohort for MTX-PG1 (p=0.012).
 In the derivation cohort, significant positive correlations were also found for 
ITPA rs1127354 and  MTX-PG4+5 levels (p=0.024); ABCC5 rs2139560 and MTX-PG1 levels 
(p=0.001), and MTX-PG2 levels (p=0.022); ATIC rs2372536 and MTX-PG1 levels (p=0.008); 
ABCB1 rs1045642 and MTX-PG1 (p=0.029), MTX-PG2 (p=0.001), MTX-PG3 (p=0.012), and 
total MTX-PG (p=0.011) levels. A significant negative correlation was found for ABCC1 
rs35592 and MTX-PG3 (p=0.021). None of these results were replicated in the validation 
cohort. In the validation cohort, significant positive associations were found for AMPD1 
rs17602729 and MTX-PG2 levels (p=0.015); ABCC1 rs3784862 and MTX-PG1 levels 
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Figure 2. A) Linear regression of age and total MTX-PG. Solid line represents a trendline with its 95% confidence 
interval (dotted line). In both cohorts age is positively associated with total MTX-PG. Regression analysis is plotted 
from the unadjusted data, Stβ and p-values are from the confounder adjusted data.
B) Linear regression of erythrocyte folate and total MTX-PG. Solid line represents a trendline with its 95% confidence 
interval (dotted line). In both cohorts, age is positively associated with total MTX-PG. Regression analysis is plotted 
from the unadjusted data, Stβ and p-values are from the confounder adjusted data.
C) Effect of the FPGS rs4451422 variant allele on the concentration of total MTX-PG. Patients of the FPGS rs4451422 
heterozygous and homozygous genotype have significantly lower concentrations of total MTX-PG. ANCOVA was 
adjusted for age and gender. Wt: wildtype carriers, het/var: heterozygous combined with homozygous variant 
carriers. Brackets denote significant differences groups, p-values are noted above the brackets. *p<0.05, **p<0.001
(p=0.014); MTHFR rs1801131 and MTX-PG1 levels (p=0.031); ABCC3 rs3785911 and MTX-
PG4+5 (p=0.004), and total MTX-PG levels (p=0.029); ABCC3 rs4793665 and MTX-PG1 levels 
(p=0.038). A significant negative correlation was found for ABCC4 rs868853 and MTX-PG1 
levels (p=0.038). These results were not observed in the derivation cohort.
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Table 4. Multivariate regression model of the three strongest determinants.
MTX-PG1 MTX-PG2 MTX-PG3 MTX-PG4+5 MTX-PG2-5
St.β p St.β p St.β p St.β p St.β p
Derivation Cohort
Age 0.21 0.06 0.20 0.09 0.24 0.03 0.20 0.08 0.28 0.01
Erythrocyte folate -0.19 0.13 0.04 0.75 0.21 0.08 0.18 0.15 0.19 0.10
FPGS  rs4451422 
wt vs. het/var
-0.08 0.47 -0.17 0.13 -0.36 <0.001 -0.33 0.003 -0.38 <0.001
R2 0.14 0.04 0.21 0.11 0.21
Validation Cohort
Age 0.13 0.08 0.22 0.002 0.23 0.001 0.22 0.002 0.28 <0.001
Erythrocyte folate 0.05 0.53 0.03 0.66 0.12 0.09 0.10 0.16 0.11 0.099
FPGS rs4451422  
wt vs. het/var
0.01 0.84 -0.07 0.30 -0.08 0.25 -0.09 0.18 -0.10 0.12
R2 0 0.03 0.07 0.07 0.10
Combined Cohort
Dose -0.07 0.26 -0.22 <0.001 0.23 <0.001 0.30 <0.001 0.2 <0.001
Age 0.15 0.013 0.20 0.001 0.23 <0.001 0.21 <0.001 0.27 <0.001
Erythrocyte folate 0.03 0.65 0.03 0.66 0.15 0.01 0.11 0.06 0.13 0.024
FPGS rs4451422  
wt vs. het/var
-0.01 0.80 -0.09 0.106 -0.16 0.003 -0.15 0.005 -0.18 <0.001
R2 0.01 0.08 0.15 0.15 0.16
Variables which, after correction for confounders, had a significant correlation in both cohorts were included 
in one multivariate regression model.  FPGS (folylpolyglutamate synthetase) rs4451422 was dichotomized into 
wild type versus heterozygous/variant. Correlations with p<0.05 are considered significant. Confounders are 
not shown and were serum folate (for erythrocyte folate) and gender (for FPGS rs4451422).
Combined multivariate model
The significant variables present in both cohorts and their confounders were included in 
one multivariate regression model. The included variables were age,  erythrocyte folate and 
FPGS rs4451422. Confounders included were gender and serum folate. In the derivation 
cohort, this combined model explained 14% of MTX-PG1 variability, 4% of MTX-PG2 
variability, 21% of MTX-PG3 variability, 11% of MTX-PG4+5 variability, and 21% of total MTX-
PG variability (Table 4). However, in the validation cohort, the model only explained 0% 
of MTX-PG1 variability, 3% of MTX-PG2 variability, 7% of MTX-PG3 variability, 7% of MTX-
PG4+5 variability, and 10% of total MTX-PG variability.
MTX Dose
As the variation in MTX dosage in each cohort was insufficient to adequately determine the 
influence of treatment dose on MTX-PG concentration, the effect of dosage was studied by 
grouping both cohorts and comparing the different treatment doses. Multivariate regression 
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analysis was performed using age, gender, erythrocyte folate and FPGS rs4451422 as co-
variables. Treatment dose did not have a significant association with MTX-PG1. However, 
treatment dose had a positive association with MTX-PG3 levels (stβ 0.23; p<0.001), MTX-
PG4+5 levels (stβ 0.30; p<0.001), and total MTX-PG levels (stβ 0.20; p=0.002; Figure 1b). 
Strikingly, there was a negative association with MTX-PG2 levels (stβ -0.22; p<0.001). The 
model including dose explained 1% of MTX-PG1 variability, 8% of MTX-PG2 variability, 15% 
of MTX-PG3 variability, 15% of MTX-PG4+5 variability, and 16% of total MTX-PG variability 
in the combined cohort.
Discussion
To the best of our knowledge, we are the first to report clinical, genetic, socio-demographic 
and biochemical determinants of erythrocyte MTX-PG accumulation at three months of 
low-dose MTX treatment in a prospective study, using a derivation and validation cohort. In 
our study, we found age, MTX dosage, erythrocyte folate content and the FPGS rs4451422 
SNP as the major determinants of MTX-PG levels in both cohorts. 
 MTX is the ‘anchor drug‘  in the treatment of pediatric and adult arthritis due to 
its high efficacy, low cost and good safety profile. Its use is hampered because 20-40% of 
patients are non-responsive to treatment and 30% of patients suffer from adverse events. 
 To further improve efficacy and reduce toxicity personalized treatment is mandatory 
by prescribing patients the right drug in the right concentration. [2, 35] The dosage of MTX, 
required to suppress disease activity, varies between patients and as of yet therapeutic drug 
monitoring of low-dose MTX therapy is not possible because plasma MTX is rapidly cleared 
and is unrelated to response. [4, 36] This has led to a trial and error approach in finding the 
right MTX dose for RA patients. However, intracellular MTX can be measured [15, 37, 38] 
and we have shown previously that erythrocyte MTX-PG levels predict reponse in the first 
nine months of treatment in three prospective cohort studies in RA and JIA. [39, 40] Knowing 
the determinants of MTX-PG accumulation and the cutoff concentration that predicts good 
response with good sensitivity and specificity might help with targeting treatment at the 
individual patient in order to reach the optimal MTX-PG level. TDM of MTX therapy may also 
help to identify patients that do not or partially comply with treatment. 
 In concordance with previous findings [18], we found age as the predominant 
determinant for erythrocyte MTX-PG levels with increasing age leading to increased 
concentrations of long-chain and total MTX-PGs (Figure 2a). Although reduced renal function 
is likely an important part of this complex interaction, eGFR-MDRD and creatinine levels 
did not have a significant effect on MTX-PG levels in either of our cohorts. More extensive 
research is needed to find out the underlying interactions. 
 Previous studies have shown that dose is a driving factor for the accumulation of 
MTX-PGs [18, 19, 41]. In our study, the validation cohort had elevated MTX-PG3, MTX-PG4 
and MTX-PG5 levels, but lower MTX-PG2 levels than the derivation cohort (Figure 1a). This 
difference in MTX-PG levels between cohorts is likely caused by the difference in dose as the 
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cohorts had significantly different dosing regimes (Table 1).
 However, in our cohorts, there was too little variation in dosage to be able to 
demonstrate and validate a relation between MTX dosage and erythrocyte MTX-PG 
accumulation in each cohort. Therefore, we studied the effect of MTX dosage on erythrocyte 
MTX-PG accumulation by grouping both cohorts and comparing the treatment doses. Using 
multivariate analysis we confirmed that the differences in MTX-PG concentration between 
our cohorts were largely due to the difference in dose. Patients treated with 25 mg/wk 
had 61% higher concentrations of long-chain MTX-PGs, and 18% higher concentrations of 
total MTX-PG (Figure 1b) than patients treated with 15 mg/wk or less. Interestingly, the 
group that was treated with higher MTX dosage had 21% lower short-chain MTX-PG levels, 
possibly indicating that the addition of glutamate groups occurs at a higher rate than the 
removal of the glutamate groups, which would lead the high exposure to MTX to push the 
equilibrium towards long-chain MTX-PGs. 
 In our validation cohort, co-medication was strictly protocolized (Table 1). 
Therefore, we cannot conclusively dismiss the effect of co-medication on the accumulation 
of MTX-PG. Corticosteroid supplementation especially was very strongly correlated to MTX 
dose. However, none of the co-medications had significant associations with MTX-PG levels 
and when entered as co-variable in multivariate linear regression they had no effect on the 
association.
 In addition to dose of treatment, route of administration has been shown to effect 
MTX-PG levels as well.[12, 19] The effective dose of subcutaneous administration would 
be substantially higher because of the increased bio-availability. In our cohorts, only 7% 
of the derivation cohort and none of the patients from the validation cohort received 
subcutaneous methotrexate and we did not see an effect of route of administration on the 
MTX-PG levels. This is likely due to the small amount of patients that received subcutaneous 
methotrexate and we expect this to have a stronger effect when more patients are treated 
with subcutaneous methotrexate.
 Folic acid use during MTX treatment has no, or negative effects on MTX efficacy.
[42, 43] suggesting that higher concentrations of folate during MTX treatment facilitate 
lower effectiveness of MTX due to competition with folate for transporter proteins, 
polyglutamylation proteins and target enzymes. However, we showed in two prospective 
RA cohorts that high baseline erythrocyte folate was related to response to MTX.[44] We 
speculated that patients with higher concentrations of baseline erythrocyte folate may be 
more effective in accumulating intracellular MTX because of the high structural similarity of 
MTX to folate; MTX uses the same cellular machinery for uptake, transport and metabolism. 
Baseline erythrocyte folate might be viewed as a functional marker for the capacity to 
take up and accumulate folates, thereby predicting MTX accumulation during treatment. 
In support of this hypothesis, we show that higher baseline erythrocyte folate levels are 
associated with higher levels of MTX-PGs.  We also found that higher baseline serum folate 
levels were associated with higher MTX-PG1 levels in the derivation cohort,  although not 
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in the validation cohort, which may reflect improved take-up of MTX from the  intestine. It 
might be speculated that the observed relation between age and MTX-PG levels is caused 
by changes in folate with age. However, although age and baseline erythrocyte folate levels 
are correlated in both cohorts (derivation cohort r=0.229, validation cohort r=0.177), the 
relation between age and MTX-PG did not change when erythrocyte folate or serum folate 
was included in the model as variable, suggesting that age has a distinct effect on MTX-PG 
accumulation. In the present study, baseline erythrocyte folate was significantly lower in 
the validation cohort whereas this cohort accumulated the highest MTX-PG levels due to 
the much higher dosis (25 mg/week). The difference in baseline erythrocyte folate between 
cohorts might be explained by the slightly higher disease activity in the validation cohort; 
the higher activity of the immune system in patients with higher disease activity might lead 
to higher folate use leading to a lower baseline erythrocyte folate in the validation cohort. 
 Folylpolyglutamate synthetase (FPGS) has a central role in the metabolism of 
methotrexate, as it is the enzyme that attaches the glutamate groups to methotrexate, 
creating the methotrexate polyglutamates. Any changes in function might therefore 
dramatically decrease the longer chain MTX-PGs, thereby leading to a slower build-up of MTX-
PGs and lower steady-state concentrations, which in turn can lead to decreased response 
to medication [45]. In our study, we see this effect most strongly in the derivation cohort, 
where medium chain and long chain MTX-PGs, as well as total MTX-PGs are significantly 
lower (Table 3) in patients with the heterozygous or homozygous variant genotype of FPGS 
rs4451422. In the validation cohort, the effect is less prominent, with smaller differences 
in concentrations between genotypes. The higher MTX dosage in the validation cohort 
might partially override the genetic determinants [46], leading to a decreased influence 
of this genotype. This could indicate that patients with the homozygous variant genotype 
would benefit from an increase in MTX dose, thereby possibly lowering the time needed for 
patients to achieve optimal treatment and might prevent needless switching to the more 
expensive biological.
 We also found SLC46A1 rs2239907 to be significantly associated with MTX-PGs 
in both cohorts. SLC46A1 is a proton-coupled folate transporter that is responsible for 
the intestinal uptake of folate. Patients with the SLC46A1 rs2239907 homozygous variant 
allele have significantly higher concentrations of short-chain MTX-PGs than patients with 
the wildtype allele. This could correspond to an increased uptake of MTX, which would 
lead to higher plasma MTX levels and increased exposure of the bone marrow to MTX. 
Similar to previous studies the associations of SNPs to MTX-PGs are weak. In other studies, 
polymorphisms in the GGH and SLC19 genes have been found to influence the long chain 
MTX-PG levels [6, 8]. In our cohorts, there was no significant association of GGH or SLC19 
SNPs in the derivation cohort, although there was an effect on long-chain MTX-PGs in the 
validation cohort. To our knowledge we are the first to publish an extensive overview of the 
effect of SNPS in the MTX pathway on intracellular MTX accumulation using a prospective 
derivation and validation cohort and linking FPGS rs4451422 and SLC46A1 rs2239907 to 
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MTX-PG accumulation in both cohorts.
 Previous research also found dose of MTX, route of administration, age and renal 
function [15, 18, 19, 41] to be strongly associated with MTX-PG levels. In concordance with 
this data, we found MTX dose and age to be strong determinants. However, renal function 
was not significantly associated with MTX-PG levels in our cohorts. The discrepancy between 
results from previous studies and our study can be partially explained by the cross-sectional 
cohorts that were used in previous studies. In our study, patients were prospectively followed 
while other studies used patients that were treated with MTX for up to 19 years [6, 8, 18, 
19, 41]. The MTX-PG accumulation over such a long period of time would be very different, 
mostly in steady state, and possibly controlled by different determinants. Previous studies 
also used patients treated with a relatively low dose of MTX, comparable to the derivation 
cohort in our study. The validation cohort uses an almost two-fold higher MTX dose, which 
might override some of the biological and genetic determinants, thereby leading to other 
significant determinants of MTX-PGs. Despite strong correlations, the determinants found 
in this study only explained up to 21% of the variability in the derivation cohort, and even 
less in the validation cohort (up to 10%). This was also seen in the combined cohort, where 
only up to 16% of variability (MTX-PG2-5) was explained by the model including dose of 
treatment. This indicates that there are other, as of yet undiscovered factors that influence 
the MTX-PG status. One possibility could be alternative splicing of FPGS, which has been 
shown to influence response to MTX in leukemia cell lines [47]. Alternative splicing leads 
to loss of function of FPGS, resulting in a different polyglutamation status and loss of 
MTX retention in the cell. Another possibility could be differences in methylation, causing 
differences in expression of the folate pathway genes thereby leading to variation in MTX 
uptake, or polyglutamation. 
 In conclusion, our study is the first prospective study investigating the determinants 
of intracellular MTX-PGs using a derivation and validation cohort. We found that higher age, 
higher erythrocyte folate concentration, higher MTX dose and the FPGS rs4451422 wildtype 
variant all lead to higher accumulation of medium and long chain MTX-PGs. Knowing these 
determinants might help targeting treatment at the individual patient.
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Determinants of eryhrocyte MTX-PG levels
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ABSTRACT 
BACKGROUND: Low-dose methotrexate (MTX) is the gold standard in the treatment 
of rheumatoid arthritis (RA). Response to MTX is very variable and is related to the 
intracellular MTX-polyglutamate (MTX-PG) levels. Similar to response, the intracellular MTX-
PG concentrations are very variable. There is little information on the effect of different 
MTX dosing schemes on the speed of accumulation and concentration and intracellular 
distribution of intracellular MTX-PGs.
OBJECTIVES: The aim of this study was to measure the speed of erythrocyte MTX-PG 
accumulation as well as the concentration and distribution of MTX-PG species in RA patients 
on two different MTX dosing regimens.
METHODS: Erythrocyte MTX-PG concentrations were prospectively measured at 3, 6 and 
9 months of treatment. Adult RA patients from two longitudinal cohorts were included. 
Patients in the MTX-R received 15 mg/week MTX, whereas patients from the tREACH 
received 25 mg/week MTX.  Patients were included if they were treated with MTX during the 
whole observation period and had at least one MTX-PG measurement. A recently developed 
LC-MS/MS assay was used for the measurement of the separate MTX-PG levels. 
RESULTS: The largest part of the accumulation of the MTX-PGs occurred during the first 3 
months of treatment with only marginal increase in the months thereafter. Steady state 
levels for all MTX-PGs were reached after 6 months of treatment in both cohorts. Patients 
from the MTX-R needed a longer time to accumulate similar levels of MTX-PGs than patients 
from the tREACH and after 9 months of treatment the MTX-R group still had lower levels of 
the long-chain MTX-PGs. Strikingly, during the early phase of treatment, patients from the 
MTX-R had higher levels of the short-chain MTX-PGs (p=0.02), but lower levels of long-chain 
MTX-PGs (p=0.006). In the MTX-R cohort, the distribution of MTX-PGs was biased towards 
short-chain MX-PGs whereas in the tREACH cohort the distribution was biased towards 
long-chain MTX-PGs even though the total MTX-PG levels were not different. 
CONCLUSIONS Higher treatment dose of MTX led to a faster accumulation and higher 
concentrations of long-chain MTX-PGs resulting in a selective distribution towards long-
chain MTX-PGs. As the long-chain MTX-PGs are considered to be the more active MTX-
species this study suggests that more intensive treatment may be more efficient. This is 
supported by a shift towards higher treatment doses and extended co-medication over time 
in the MTX-R, whereas in the tREACH medication stayed more or less stable. In contrast to 
previous findings, the main bulk of MTX-PG accumulation takes place during the first three 
months of treatment and steady states are reached at six months of treatment. 
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INTRODUCTION
Because of its high efficacy and good safety profile the folate antagonist methotrexate (MTX) 
is the medicine of choice for the treatment of multiple diseases. High-dose MTX treatment 
is used for proliferative diseases such as acute lymphoblastic leukemia, whereas low-dose 
methotrexate is used for arthritic diseases such as rheumatoid arthritis (RA). In low-dose 
treatment, MTX is eliminated from the plasma within 24 hours and plasma MTX is unrelated 
to response.[1] Therefore, plasma MTX is not a reliable tool for the monitoring of treatment 
in low-dose MTX treatment.  However, MTX polyglutamates accumulate intracellularly over 
time and these are more stable than plasma MTX, making intracellular MTX an interesting 
target for therapeutic drug monitoring (TDM).[2-7]
 After MTX is transported into the cell, it is rapidly converted to MTX polyglutames 
(MTX-PGs) by the sequential addition of glutamic acid residues. In a competing reaction, 
the MTX-PGs are deconjugated, leading to a variety of chain-lengths (MTX-PG2-7), the 
concentration and distribution of which varies widely per patient and is influenced by 
multiple factors such as dose, treatment duration and genetics.[2, 5, 6, 8-12] In low-dose 
MTX treatment, the pentaglutamate (MTX-PG5) is the highest order of glutamylation 
detected, while the triglutamate form (MTX-PG3) of MTX predominates.[8-10, 12, 13] 
Polyglutamylation retains MTX in the cell because the MTX-PGs are a poor substrate for the 
MTX efflux proteins. 
 The time to reach steady-state intracellular MTX levels is highly variable between 
patients and increases with the number of PGs attached to MTX.[9, 11, 14] In low dose 
MTX, the median time to reach steady-state erythrocyte-MTX levels is highly variable 
between patients and increases with the number of PGs attached to MTX.[9, 14] While 
the short-chain MTX-PGs quickly reach steady state levels, the time to steady state for the 
medium and long-chain MTX-PGs ranges from 3 months to multiple years.[9] Steady-state 
levels also are highly variable between patients and can differ up to four-fold.[3, 6, 9, 10, 15] 
The mechanisms behind the highly variable intracellular MTX-PG levels and accumulation 
have still not been completely elucidated. Previous research has shown that increased age, 
higher treatment dose, route of administration and decreased renal function are associated 
with higher MTX-PG levels, as well as multiple single nucleotide polymorphisms (SNP) in 
MTX pathway genes.[7, 8, 12, 14, 16] 
 The erythrocyte MTX-PGs have been shown to correlate with response in 
multiple studies. In fact, the efficacy of MTX is thought to increase with the elongation of 
the polyglutamate chain, confirming their potential use in TDM.[2, 11, 17, 18] In a cross-
sectional study in RA patients, a cut-off value for response of >60 nmol/L MTX-PG3 has been 
proposed,[2] and in a recent prospective study in two RA cohorts, we determined a cut-off 
value for response of >74 nmol/L total MTX-PG.[17] 
 Although erythrocyte MTX-PG levels have been shown to be a valid target for 
TDM in RA patients, little is known about the effect of different dosing regimens on the 
accumulation and previous studies are either cross-sectional[6, 8, 19] or consist of small 
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sample groups.[9, 14] The use of these cut-off values would be greatly increased if it is clear 
how to reach them. 
 In this study, we aim to prospectively measure the speed of erythrocyte MTX-PG 
accumulation as well as the concentration and distribution of MTX-PG species over the 
course of treatment in RA patients on two different MTX dosing regimens.
 
METHODS
Patients
This study includes data of RA patients treated with MTX from two prospective cohorts:
 1) the methotrexate in Rotterdam, Netherlands cohort (MTX-R), a longitudinal 
prospective cohort of patients diagnosed with RA who started MTX between January 2006 
and March 2011 in the department of Rheumatology, University Medical Center Rotterdam 
(Erasmus MC), Netherlands. 2) the treatment in Rotterdam Early Arthritis Cohort tREACH), 
a clinical multicentre, stratified single-blinded trial (ISRCTN26791028) and was described 
earlier.[20] Patients were included in the tREACH if they met the 2010 ACR/EULAR criteria 
for RA.[21] 
 The medical ethics committee of the Erasmus MC approved both studies and 
patients gave written informed consent before inclusion. For both cohorts, an extra EDTA 
tube was drawn from the patient at 3, 6 and 9 months of treatment. This sample was 
immediately put on ice after collection and centrifuged for 10 min at 1700g and 4 °C. Plasma 
and erythrocyte cell-pellet aliquots were stored at -80 °C.
 Patients from the MTX-R and tREACH cohorts were included in this study if they 
were prescribed MTX at baseline, 3 and 6 months of treatment, and had at least one MTX-
PG measurement at either 3, 6 or 9 months of treatment. Patients were excluded if they 
were prescribed parenteral MTX, had MTX-PG levels lower than 15 nmol/L erythrocytes, 
which is our threshold for compliance to treatment. Also, we chose to include only patients 
whose blood had been drawn within 4 weeks of the time-points. All patients were MTX 
naïve at inclusion and were newly diagnosed with RA according to the 2010 classification 
criteria. 
MTX dosage
In the MTX-R cohort, dosage and co-medication were decided by the physician at each 
visit. Patients from the tREACH cohort started with 17.5 mg/week MTX per os, which 
was escalated to 25 mg/week in 3 weeks. Patients in the tREACH were randomized to 
treatment with or without sulfasalazine (2 g/day), hydroxychloroquine (400 mg/day) and 
intramuscular (methylprednisolone 120 mg or triamcinolone 80 mg) or oral (tapering 
scheme; week 1-4: 15 mg/day, week 5-6: 10 mg/day, week 7-8 5 mg/day, week 9-10: 2.5 
mg/day) glucocorticosteroids,[20] which were In both cohorts, patients received folic acid 
(10 mg/week) during MTX treatment. All patients were assessed at baseline, after 3 months, 
6 months and 9 months of treatment.
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MTX-PG quantification
MTX-PGs were measured in the cell-pellet aliquots using a recently developed LC-MS/MS 
method.[22] MTX-PG1 and MTX-PG2 are considered as short-chain MTX-PGs; MTX-PG3 is 
considered as medium-chain MTX-PG; MTX-PG4 and MTX-PG5 are considered as long-chain 
MTX-PGs.
Statistics
Comparison of patient characteristics between cohorts was made by Student t-test, X2 test 
or the Mann-Withney u-test where appropriate. Statistical analyses were done with SPSS 
PASW 20.0.0.1 for Windows (SPSS Inc., Chicago, IL, USA) unless stated otherwise. P-values 
less than 0.05 were considered significant. Cubic splines were made in R version 3.0.1 (R 
Foundation for Statistical Computing, Vienna, Austria).
 
RESULTS
Patient characteristics
Out of all patients, there were 98, 81 and 73 patients where MTX-PG levels had been 
measured in the MTX-R at t3, t6 and t9 respectively. In the tREACH, MTX-PG levels had 
been measured in 270, 232, 222 patients at t3, t6 and t9 respectively. Of these 76, 58 and 
34 patients of the MTX-R could be included in the study at t3, t6 and t9, respectively, and 
222, 133 and 99 patients of the tREACH could be included in the study at t3, t6 and t9, 
respectively. 
 The remaining patients were excluded because patients did not use MTX at all the 
time points prior to sampling, did not have an MTX-PG measurement, or patients did not 
have MTX-PG levels above our threshold for compliance (15 nmol/L total MTX-PG). Patients 
receiving parenteral MTX were also excluded.
 At baseline, both cohorts were very similar (Table 1). In the MTX-R, disease activity 
was slightly lower (DAS: 4.2 vs 4.7; p<0.01), and less patients were positive for rheumatoid 
factor (38.7% vs 62.5%, p<0.001) and anti-CCP (40.0% vs 67.3%; p<0.001). Also, patients in 
the MTX-R had slightly higher eGFR-MDRD (88.4 ml/min/1.73m2 vs 81.2 ml/min/1.73m2; 
p<0.05) and erythrocyte folate content (1041.0 nmol/L vs 892.4 nmol/L; p<0.001) than the 
tREACH cohort. 
MTX dose
Treatment dose of MTX was significantly different between both cohorts (p<0.001, Table 
2) at baseline. Patients in the MTX-R were treated with median 15 mg/wk (range 10-25 
mg/week) and patients in the tREACH were treated with median 25 mg/wk (range 15-25 
mg/week) as per study protocol. Also, in the MTX-R, a smaller percentage of patients used 
hydroxychloroquine (45.6% vs 58.5%; p<0.05), sulfasalazine (36.7% vs 58.5%; p<0.001) and 
corticosteroids (12.2% vs 89.5%; p<0.001). 
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Table 1. Baseline characteristics of MTX-R and tREACH cohorts.
MTX-R tREACH
N N
Patient demographics
Age, years, mean (SD) 82 50.7 (16.3) 232 52.7 (14.0)
Female (%) 82 72.0 232 66.8
BSA, m3, mean (SD) n/a 229 1.9 (0.3)
DAS28esr, mean (SD)** 75 4.2 (1.3) 232 4.7 (1.3)
Rheumatoid factor positive (%)**** 75 38.7 208 62.5
Anti-CCP positive (%)*** 75 40.0 208 67.3
Days of treatment at study visit, mean (SD)t 80 91.6 (12.2) 219 93.3 (8.5)
Medication
Methotrexate Dose*** 82 232
10mg/wk (%) 4.9 0.0
15mg/wk (%) 93.9 0.4
25mg/wk (%) 1.2 99.6
Other DMARD use (%) 79 53.2 229 58.5
Hydroxychloroquine use (%)* 79 45.6 229 58.5
Sulfasalazine use (%)*** 79 36.7 229 58.5
Biological use (%)t 79 1.3 229 0.0
Corticosteroid use (%)*** 79 12.7 229 89.5
Corticosteroid route of administration (%)*** 79
No Corticosteroid 87.3 229 10.5
IM 2.4 27.9
Oral 10.1 61.6
Laboratory parameters
C- reactive protein, mg/L, median (IQR)t 82 7.0 (3.0-13.0) 231 8.0 (4.0-19.0)
Erythrocyte sedimentation rate, mm/hr, mean (SD) 82 23.5 (19.5) 232 27.7 (20.6)
Albumin, (g/L), mean (SD) 78 44.0 (3.6) 213 43.7 (3.2)
Creatinine, mmol/L, mean (SD)t 82 70.7 (16.7) 96 75.6 (17.0)
Erythrocyte folate, nmol/L, median (IQR)*** 78 1041.0 (837.5-1288.3) 207 892.4 (666.2-1157.1)
eGFR-MDRD, ml/min/1.73m2, mean (SD)* 82 88.4 (24.2) 96 81.2 (17.9)
Lifestyle parameters
Alcohol consumption, drinks/month, median (IQR) 37 4.0 (0.0-32.0) 219 10.0 (2.0-32.0)
Cola consumption, drinks/month, median (IQR) 76 0.0 (0.0-24.0) 217 2.0 (0.0-8.0)
Coffee consumption, drinks/month, median (IQR) 76 96.0 (40.0-168.0) 217 112.0 (40.0-140.0)
Tea consumption, drinks/month, median (IQR) 79 56.0 (0.5-56.0) 215 24.0 (0.0-56.0)
*p<0.05; **p<0.01; ***p<0.001; tp<0.1
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 At t3, patients in the MTX-R study received a lower dose of MTX (median: 15, range 
5-25 mg/week vs 25, range 12.5-25 mg/week p<0.001) and a smaller percentage of patients 
used biologicals (0% vs 19.5%; p<0.001). 
 At t6, patients in the MTX-R study were treated with a lower dose of MTX (median 
20 range 10-25 mg/week vs median 25 range 2.5-25 mg/week, p<0.001) and biological use 
was lower in the MTX-R group (2.9% vs 28.6%; p<0.001). 
 Over the course of treatment, patients in the MTX-R were switched to higher 
dosages of MTX, with approximately 30% of patients receiving more than 15 mg/week from 
t3 and approximately 60% receiving more than 15 mg/week MTX from t6. Co-medication 
was increased over time for MTX-R patients as was the percentage of patients that received 
intramuscular MTX (Table 5).
 In the tREACH cohort, medication was slowly decreased over time, with patients 
receiving 25 mg/week decreasing from approximately 100% at t0 to approximately 90% at 
t3 and approximately 80% at t6.  Co-medication was also decreased over time in the tREACH 
(Table 2), except for biological, which increased to up to 28.6% over the course of treatment.
Table 2.  Medication over time in both cohorts.
MTX-R tREACH
t0 t3 t6 t0 t3 t6
N=82 N=65 N=34 N=222 N=175 N=110
Methotrexate Dose (mg/wk, %) *** *** ***
2.5 1.0
5 1.6
7.5 1.6 1.0
10 4.9 8.2 14.7 0.4 0.7
12.5 0.7 4.0
15 93.9 59.0 29.4 4.4 7.1
17.5 2.2 5.1
20 8.2 14.7 2.2 3.0
22.5 2.0
25 1.2 21.3 41.2 99.6 89.7 76.8
Other DMARD use (%) 53.2 62.3 67.6 58.5 57.1 54.1
Hydroxychloroquine use (%) 45.6* 54.1 58.8 58.5 57.1 51.0
Sulfasalazine use (%) 36.7*** 41.0 41.2 58.5 51.1 46.9
Biological use (%) 1.3 0*** 2.9** 0.0 19.5 28.6
Corticosteroid use (%) 12.7*** 4.9 5.9 89.5 6.0 7.1
Corticosteroid route of administration (%)
No Corticosteroid 87.3*** 95.1 94.1 10.5 94.0 92.9
Intramuscular 2.5 0.0 0.0 27.9 2.3 4.1
Oral 10.1 4.9 5.9 61.6 3.8 3.1
* p<0.05; ** p<0.01; *** p<0.001
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Disease activity
Disease activity was measured using the DAS28esr and is presented in table 3 and Figure 1. 
Patients in the MTX-R started treatment with significantly lower DAS28esr than patients in 
the tREACH (p=0.002). However, at the other time-points the DAS28esr did not differ. In the 
MTX-R, the DAS28esr lowered significantly between t0 and t3 (p<0.001), but not between 
t3 and t6 or t6 and t9, although a trend towards lower DAS28esr was observed from t6 to 
t9 (p=0.063). In the tREACH the DAS28esr lowered from t0 to t3 (p<0.001) and from t6 to t9 
(p=0.002). From t3 to t6 the decrease in DAS28 was almost significant (p=0.050). 
 The change in DAS28esr (deltaDAS28esr), relative to t0, was less pronounced in 
the MTX-R and differed significantly between both cohorts at all time-points (p<0.005). In 
both individual cohorts, the change in DAS28esr was largest from t0 to t3. In the MTX-R, the 
change in DAS28esr was significant from t0 to t3 (p<0.001) and from t6 to t9 (p=0.046). In 
the tREACH, the change in the DAS28esr was significant from t0 to t3 (p<0.001) and from t6 
to t9 (p=0.002).
Table 3. Disease activity during treatment
t0 t3 t6 t9
 MTX-R n=75 n=76 n=58 n=33
DAS28esr
 (median [IQR])
4.15** 
[3.07-5.09]
2.93# 
[1.98-3.85]
2.59 
[1.84-3.69]
2.64¥ 
[1.69-3.35] 
deltaDAS28esr  
(median [IQR])
-1.03# 
[-1.75 -0.67]
-1.09 
[-2.14 -0.02]
-1.26# 
[-2.69 -0.18]
tREACH n=232 n=222 n=133 n=99
DAS28esr  
(median [IQR])
4.67 
[3.75-5.49]
2.81# 
[2.15-3.89]
2.79 
[1.98-3.54]
2.20# 
[1.50-3.25]
deltaDAS28esr 
(median [IQR])
-1.66**# 
[-2.45 -0.74]
-1.84**¥ 
[-2.76 -1.02] 
-2.29**# 
[-3.34 -1.2]
DAS, disease activity score; IQR, inter quartile range; deltaDAS28esr, change in  DAS28esr relative to t0
* p<0.05, ** p<0.01, *** p<0.001, between cohorts
# p<0.05, ¥ p<0.1, compared to previous time-point 
Erythrocyte MTX-PG levels and differences between cohorts
The erythrocyte MTX-PG concentrations in both cohorts are presented in Table 4 and Figure 
1. When looking at the difference in MTX-PG levels between both cohorts, patients in the 
MTX-R cohort accumulated higher levels of short-chain MTX-PG1+2 at t3 (p=0.033), t6 
(p=0.020) and t9 (p=0.012). However, medium-chain MTX-PG3 was lower in the MTX-R at t3 
(p=0.001), but not at t6 (p=0.056) or t9 (p=0.399). Long-chain MTX-PG4+5 levels were lower 
in the MTX-R at t3 (p=0.000) and t6 (p=0.006) but not at t9 (p=0.303). The total MTX-PG1-5 
levels did not differ significantly between both cohorts.
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Accumulation in each cohort during treatment
In the MTX-R cohort, medium-chain MTX-PG3 concentration increased from t3 to t6 
(p<0.001), but not from t6 to t9 (p=0.256). Similarly, long-chain MTX-PG4+5 concentrations 
increased over time from t3 to t6 (p<0.001), but not from t6 to t9 (p=0.248). Total MTX-
PG1-5 levels also increased from t3 and t6 (p=0.010), but not from t6 to t9 (p=0.153). 
 In the tREACH, the medium-chain MTX-PG3 levels increased significantly from t3 
to t6 (p<0.001), but not from t6 to t9 (p=0.051). Long-chain MTX-PG4+5 levels increased 
significantly from t3 to t6 (p=0.031) but not from t6 to t9 (p=0.263). The total MTX-PG1-5 
levels increased significantly between t3 and t6 (p=0.012), but not between t6 and t9 
(p=0.390). The short-chain MTX-PG1+2 levels did not differ significantly between time-
points in either cohort.
Table 4.  Erythrocyte MTX-PG concentrations and distribution in patients using oral 
methotrexate
MTX-R tREACH
Concentration nmol/L [IQR] Concentration nmol/L [IQR]
t3 t6 t9 t3 t6 t9
N=76 N=58 N=34 N=222 N=133 N=99
Short-chain 
MTX-PG1+2
61.4 
[42.1-96.3]*
68.8 
[47.9-99.4]*
71.1 
[51.3-124.2]**
51.7 
[35.9-75.1]
53.8 
[38.9-78.0]
56.7 
[39.7-85.3]
Intermediate 
MTX-PG3
40.6 
[24.6-53.7] ***¥
50.2 
[36.3-65.8]
56.4 
[36.4-81.6]
48.8 
[36.4-61.5] ¥
58.1 
[46.7-70.7]#
66.2 
[45.9-77.5]
Long-chain 
MTX-PG4+5
8.7 
[4.4-21.8]*** ¥
18.1 
[6.5-34.0]**
25.3 
[14.1-45.3 ]
23.9 
[13.2-38.3] ¥
26.1 
[14.8-44.5]
31.7 
[16.3-48.6]
Total MTX 118.4 
[79.1-158.7] ¥
153.2 
[110.6-196.0]
169.8 
[127.7-217.4]
132.8 
[98.5-168.1] ¥
147.2 
[113.5-194.6]
159.0 
[119.4-225.0]
Percentage of total MTX-PG [IQR] Percentage of total MTX-PG [IQR]
Short-chain 
MTX-PG1+2
57 
[43-68]*** ¥
53 
[37-63]**
45 
[37-59]**
42 
[31-53 ] ¥
40 
[30-50]
39 
[28-48]
Intermediate 
MTX-PG3
33 
[27-40]*** ¥
36 
[29-41]**
35 
[24-44]
38 
[33-42] ¥
40 
[35-43]
40 
[35-44]
Long-chain 
MTX-PG4+5
8 
[5-16]*** ¥
13 
[6-22]**
16 
[9-23]*
18 
[12-28]
19 
[12-26]
20 
[13-27]
* p<0.05; ** p<0.01; *** p<0.001
Distribution of MTX-PGs
Because it is the long-chain MTX-PGs that are thought to mediate the effect of MTX, we 
were interested in the distribution of the MTX-PG in the cell and the effect of treatment 
dose and treatment duration on the distribution of erythrocyte MTX over time (Table 4). 
Patients in the MTX-R had a larger percentage of short-chain MTX-PG1+2 at t3 (p<0.001), 
t6 (p=0.001) and t9 (p=0.008). However, patients in the MTX-R had a smaller percentage of 
the medium-chain MTX-PG3 at t3 (p<0.001) and t6 (p=0.004). The percentage of long-chain 
MTX-PG4+5 was also significantly lower in the MTX-R at t3 (p<0.001), t6 (p=0.001) and t9 
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(p=0.034). In the MTX-R, the distribution of all MTX-PGs changed significantly from t3 to t6 
(p<0.001) with the percentage of short-chain MTX-PG1+2 decreasing and the percentage 
of medium-chain MTX-PG3 and long-chain MTX-PG4+5 increasing. Between t6 and t9, no 
change in intracellular MTX-PG distribution was observed. 
 In the tREACH, the percentage of short-chain MTX-PG1+2 decreased from t3 to t6 
(p<0.001) and the percentage of medium-chain MTX-PG3 increased from t3 to t6 (p<0.001). 
From t6 to t9 no changes in intracellular MTX-PG distribution were observed. The percentage 
of long-chain MTX-PG4+5 did not change during treatment (Table 4).
Parenteral administration of MTX
Table 5. Erythrocyte MTX-PG concentrations and distribution in patients using parenteral 
methotrexate
MTX-R tREACH
Concentration nmol/L [IQR] Concentration nmol/L [IQR]
t3 t6 t9 t3 t6 t9
N=6 N=7 N=7 N=0 N=14 N=12
Short-chain 
MTX-PG1+2
44.1 
[33.2-130.4]
56.6 
[40.0-119.7]
62.5 
[32.5-131.9]
48.7 
[23.2-63.7]
50.7  
[38.2-61.9]
Intermediate 
MTX-PG3
43.9 
[26.1-56.6]
84.5 
[63.1-99.6]
77.3 
[51.2-96.4]
64.6 
[38.3-81.0]
71.7 
[63.5-82.5]
Long-chain 
MTX-PG4+5
15.3 
[7.8-22.5]
42.0 
[39.0-74.8]
31.9 
[6.0-59.5]
40.5 
[13.8-60.5]
48.1 
[23.6-59.7]
Total MTX 98.7 
[75.8-214.3]
196.6 
[150.9-251.7] 
180.9 
[119.9-299.9]
149.1 
[95.3-205.6]
164.3 
[137.6-203.3]
Percentage of total MTX-PG [IQR] Percentage of total MTX-PG [IQR]
Short-chain 
MTX-PG1+2
49 
[43-72]
29 
[23-48]
44 
[29-58]
31 
[24-36]
25 
[23-42]
Intermediate 
MTX-PG3
36 
[27-44]
43 
[36-46]
41 
[31-48]
41 
[38-49]
43 
[36-47]
Long-chain 
MTX-PG4+5
12 
[4-17]
22 
[17-35]
20 
[5-25]
27 
[19-32]
31 
[18-34]
 A small amount of people in our cohorts received parenteral instead of orally 
administrated MTX. In the MTX-R there were 6 patients at baseline, 7 patients at t3 and 7 
patients at t6 that received parental MTX. In the tREACH, no patients received parenteral 
MTX at baseline, 14 patients at t3 and 12 patients at t6 received parenteral MTX. In the 
MTX-R, the patients that received parenteral MTX did not have different MTX-PG levels at t3 
from patients that received oral MTX. At t6, patients with parenteral administered MTX had 
significantly higher levels of medium-chain MTX-PG3 (p=0.002) and long-chain MTX-PG4 
(p=0.003). At t9, no differences in MTX-PG levels were observed. (table 5). In the tREACH, no 
significant differences in MTX-PG levels were found between patients receiving parenteral 
or oral MTX. 
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 No difference in MTX-PG levels or distribution of MTX-PG species was observed 
between patients receiving parenteral MTX from each cohort. However, within the MTX-R 
the fraction of long-chain MTX-PG4+5 was higher at t6 (p=0.019) in patients that received 
parenteral MTX. 
 In the tREACH, despite no differences in MTX levels between administration routes, 
short-chain MTX-PG1+2 accounted for a lower percentage of the total MTX-PG content in 
patients that received parenteral MTX at t6 (p=0.014) and t9 (p=0.019). At t9, the percentage 
of long-chain MTX-PG4+5 was significantly higher in patients receiving parenteral MTX 
(p=0.034). 
 
DISCUSSION
This report shows the build-up of MTX-PG in erythrocytes over the first 9 months of treatment. 
To our knowledge we are the first to show similar data in two separate prospectively collected 
cohorts treated with MTX. As both cohorts have been treated with different dosages of MTX 
this study enabled us to determine the dosage dependent differences in MTX build-up. 
 We show that the main bulk of MTX-PG accumulation happens during the first 3 
months of treatment with only marginal increases in the months thereafter, regardless of 
the dose of treatment in our cohorts or the extend of polyglutamylation. Despite the fact 
that patients in the MTX-R needed more time to reach steady-state for the long-chain MTX-
PGs, in both cohorts the predominant concentration gain was during the first 3 months 
of treatment and from 6 months of treatment the median MTX-PG levels were essentially 
stable. Other studies have found that while MTX-PG1 and MTX-PG2 reached steady state 
early in treatment (<12 weeks), the other MTX species took significantly longer (>20 weeks). 
This discrepancy might be due to the dosages of MTX that were given in the different studies. 
These studies were done with dosages around 10 mg/week and reported significantly longer 
times to reach steady state.[9, 14] In our study, the cohort treated with a lower dose of MTX 
(MTX-R, mean 15 mg/week) also needed a slightly longer treatment period to reach steady 
state. A large part of the patients in this cohort received an increased MTX dosage during 
treatment, possibly shortening the time needed to reach steady state, leading to the big 
discrepancy in results. 
 We have previously shown that intensive treatment of RA leads to quicker and 
better decline of disease activity without extra risk of adverse events.[17, 23] We also 
showed that erythrocyte MTX-PG levels are correlated with response to treatment and 
that the erythrocyte MTX-PG levels can predict how well patients respond to treatment.
[17, 18] As the higher treatment dose of MTX leads to the faster accumulation of MTX-PGs 
in erythrocytes and to a selective redistribution towards longer chain (and therefore longer 
intracellular retention) MTX-PGs, patients might benefit from receiving more intensive 
treatment in order to reach higher intracellular levels of MTX-PGs earlier in treatment.
Interestingly, the biggest change in disease activity happens during the first three months 
of treatment, coinciding with the largest increase of MTX-PGs. Also, the patient group that 
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received the highest dose of MTX (tREACH) and accumulated the long-chain MTX-PGs fastest 
showed a faster improvement in disease activity than the patient group that received the 
lower dose of MTX (Figure 1).
 Considering that the main bulk of the accumulation of MTX-PGs happens during 
the first three months of treatment, the optimal point of MTX prediction might lie within 
these first three months, when accumulation is more likely to be in a linear phase.
Compliance can be a big problem in chronic diseases and poses a large risk when measuring 
drug levels. We tried to prevent including non/very bad-compliers in our study population 
with by using a cut-off value for compliance of 15 nmol/L total MTX at  each time-point. 
We will probably still have an amount of bad/partial compliers in our study, which could 
be represented by patients with high levels of short-chain MTX-PG1 but little to no levels 
of the longer chain MTX-PGs. We did not have a validated measure for compliance and 
can therefore only speculate on the degree of compliance of the patients in our study. We 
acknowledge that this potential weakness could be influencing our results, and we hope 
that future studies will be able to include a measurement of compliance in order to realize a 
‘true’ picture of drug exposure. Considering that dosage of MTX, and therefore exposure to 
MTX is an important determinant of the erythroctyte MTX-PG levels, compliance could be 
the most important factor in exposure, next to dosage.
 Another important factor of exposure is the route of administration. A small 
percentage of the patients of our cohorts received parenteral administered MTX due to 
adverse events or because response was judged to be too low. In line with previous studies 
on the effect of parenteral administered MTX,[6, 14, 19] we found that parenteral MTX led 
to higher levels of MTX-PGs. Interestingly parenteral MTX users had lower amounts of short 
chain MTX, and there was no difference in MTX-PG levels between the parenteral MTX users 
of both cohorts, despite the difference in administered dose. 
 We found that the distribution of MTX-PGs was also strongly dependent on dose 
and route of administration. There was a selective redistribution towards the (more active) 
long-chain MTX-PGs in patients that were treated with higher dosages of MTX or when 
parenteral administration was used. Even patients that switched to parenteral treatment 
during treatment displayed this difference in distribution of MTX-PGs. These patients also 
reached higher concentrations of MTX-PGs early in treatment, suggesting that treatment 
with higher dosage MTX is more effective at treating RA. This hypothesis is supported by the 
fact that almost half of the MTX-R patients (the cohort that left treatment to the decision of 
the doctor) were started on 20-25 mg/week MTX by 6 months of treatment, whereas they 
started with 15 mg/week (Table 2).
 The accumulation of long-chain MTX-PGs took longer in low-dose treated and 
orally treated patients and short-chain MTX-PGs were higher in these patients. Although the 
total MTX-PG concentrations did not differ between cohorts after six months of treatment, 
the distribution of the MTX species remained different in both cohorts over nine months of 
treatment. This may be caused by changed expression of the MTX metabolism in response 
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to MTX exposure.[24]
 In conclusion, we found that dosage and route of administration significantly alter 
the speed of accumulation and the distribution of MTX species in the cell. From a metabolite 
perspective, this finding favours the use of higher dosages of MTX or parentally administered 
MTX in the treatment of RA.
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Abstract
OBJECTIVE: To investigate if erythrocyte methotrexate-polyglutamate (MTX-PG) 
concentrations in rheumatoid arthritis (RA) patients are associated with disease activity or 
adverse events.
METHODS: We used a longitudinal study-design with two cohorts. The derivation cohort 
included 102 and the validation cohort included 285 RA patients on MTX. We measured 
erythrocyte MTX-PG with 1 to 5 glutamate residues at 3, 6 and 9 months after MTX-start with 
an LC-MS/MS assay. Outcomes were DAS28 and adverse events. Longitudinal associations of 
MTX-PG concentrations after 3, 6, and 9 months with DAS28 were tested with a linear mixed 
model adjusted for age, gender, baseline DAS28, MTX-dose and co-medication.
RESULTS: In the derivation cohort, mean DAS28 decreased from 4.26 (SE=0.14) at baseline to 
2.72 (SE=0.13) after 9 months. Thirty percent of patients in the derivation cohort experienced 
more than 3 adverse events after 3 months, which decreased to 18% after 9 months. In the 
validation cohort, DAS28 and adverse events were comparable with the derivation cohort. 
In the derivation cohort, MTX-PG1 (ß=-0.005), MTX-PG2 (ß=-0.022), MTX-PG3 (β=-0.007) 
and total MTX-PG (ß=-0.004) were associated (p<0.05) with lower DAS28 over 9 months. In 
the validation cohort, MTX-PG2 (ß=-0.015), MTX-PG3 (ß=-0.010), MTX-PG4 (ß=-0.008) and 
total MTX-PG (ß=-0.003) were associated with lower DAS28 over 9 months. None of the 
MTX-PGs was associated with adverse events.
CONCLUSION: In this first longitudinal study, we showed that an increase in erythrocyte 
MTX-PG concentrations were associated with a decreased DAS28 over 9 months in two 
cohorts, and are therefore a potential tool for therapeutic drug monitoring of MTX in RA.
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Introduction
Methotrexate (MTX) is the cornerstone disease-modifying anti-rheumatic drug (DMARD) 
in the treatment of patients with rheumatoid arthritis (RA). However, significant numbers 
of patients fail to achieve adequate suppression of disease activity or experience adverse 
events causing refusal of dose increase or treatment continuation. [1] In those who are 
non-responsive, increasing MTX-dose can be an alternative. Dosage of MTX, required to 
suppress disease activity, varies between patients and is unpredictable. Until now, the 
decision to increase dosage is dependent on assessment of disease activity, accepted upper 
limit of drug dosing, and occurrence of adverse events.  [2] If patients fail to respond to 
MTX, even after dosage increase, or develop severe adverse events within 3 to 6 months, 
additional treatment with biologicals is instituted.  [3] Therapeutic drug monitoring (TDM) of 
intracellular MTX concentrations in erythrocytes may help identifying refractoriness patients 
with non-response and high concentration and patients with a difficulty in accumulating 
MTX or non-compliance who may benefit from a dose increase or treatment of compliance 
issues.
 Plasma MTX is eliminated from plasma within 24 hours  [4] and is unrelated to 
response  [5] and therefore, is not a reliable tool for TDM. [6] MTX is transported intracellularly 
and retained within cells long after it has been eliminated from plasma. [5] Circulating MTX 
contains 1 glutamate moiety (MTX-PG1). Once inside cells, up to 4 additional glutamates 
(PG2-PG5) are added to retain intracellular MTX, which in turn increases its affinity for 
target enzymes in one-carbon metabolism, thus promoting MTX’s anti-inflammatory effects. 
Higher MTX-dose leads to higher intracellular erythrocyteMTX polyglutamate (MTX-PG) 
concentrations. [7, 8]  Summarizing, erythrocyte MTX-PGs could have a promising role as 
biomarkers of patients’ response to MTX and in turn could be potentially used as TDM tool.
 Erythrocyte MTX-PGs have been related to response in several studies in adult 
RA. [4, 9-12] In addition, we showed in an accompanying paper that in juvenile idiopathic 
arthritis (JIA) long-chain erythrocyteMTX-PGs were associated with lower disease activity 
at 3 months and during one year of MTX treatment. [13] However, there have been 
reports with contrasting results in RA and in JIA. [2, 14, 15] Most of these studies used 
cross-sectional analyses [2, 9, 10, 14, 15] in which patients were in different stages of MTX-
treatment varying from 3 months to >10 years. Disadvantages of cross-sectional analysis are 
that you cannot distinguish between those treated for weeks or years and that you cannot 
make causal inference. [16] Additionally, comparison between patients is complicated 
because MTX is stopped in obstinate non-responders and because MTX-PG accumulation is 
a function of time. [5]
 The aim of this prospective, longitudinal study was to investigate if intracellular 
erythrocyteMTX-PG concentrations are related to disease activity or adverse events in RA 
patients on MTX and thus if MTX-PGs could be a tool for TDM.
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Patients and Methods
Study design and patients
The derivation cohort was the ‘Methotrexate in Rotterdam’ cohort (MTX-R). The MTX-R 
is a longitudinal prospective cohort of patients who started MTX between January 2006 
and March 2011 at the Rheumatology Department, Erasmus University Medical Center, 
Rotterdam (Erasmus MC), Netherlands. The validation cohort was the ‘Treatment in 
Rotterdam Early Arthritis Cohort’ (tREACH). The tREACH is a clinical multicentre, stratified 
single-blinded trial (ISRCTN26791028), as described earlier. [17, 18]. The medical ethics 
committee from the Erasmus MC approved both studies and patients gave written informed 
consent before inclusion.
 Derivation cohort patients were included if diagnosed with RA by the physician. 
Validation cohort patients were included in if they fulfilled the 2010 ACR/EULAR criteria for 
RA [19]. Patients on biologicals at baseline were excluded.
 In the derivation cohort, clinicians chose MTX-dosage and co-medication for every 
visit. In the validation cohort, MTX starting dose was set at 25 mg/week (reached after 3 
weeks). If patients had DAS28<2.6 for 2 consecutive visits MTX-dose was decreased with 2.5 
mg/month until stop. Patients were randomized to treatment with or without sulfasalazine, 
hydroxychloroquine and glucocorticoids. Patients in both cohorts received folic acid (10 mg/
week) during MTX treatment. In both cohorts, patients were assessed at baseline, and after 
3, 6 and 9 months.
Biochemical parameters
One additional EDTA blood sample-tube was obtained from patients during every study visit 
besides routine EDTA and serum samples for erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP), Alanine-aminotransferase (ALAT), rheumatoid factor, anti-cyclic citrullinated 
peptide antibody, leukocytes, trombocytes and hemoglobine. The additional EDTA tube was 
immediately put on ice after collection, centrifuged for 10 min at 1700 × g at 4 °C. Plasma 
and cell-pellet aliquots were stored at -80 °C. MTX-PGs were analysed from the cell-pellet 
aliquots with a liquid chromatography-electrospray ionization-tandem mass spectrometry-
based assay using stable-isotope-labelled internal standards, as described recently by us. 
[20] Concentrations of MTX-PGs were  reported in nmol/L packed erythrocytes.
 
Disease activity and adverse events
Disease activity outcome was the disease activity score 28 (DAS28). [21] Adverse event 
outcome was categorized into: one or more (versus none) and three or more (versus 
two or less). Adverse events included gastrointestinal complaints, malaise, psychological 
complaints, hepatotoxicity, bone marrow depression and other complaints. Gastrointestinal 
complaints involved diarrhoea, vomiting, sickness and abdominal pain. Malaise involved 
fatigue, dizziness, headache, sleeplessness and not feeling well. Psychological complaints 
involved depression and personality changes. Other complaints involved dyspnoea, 
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alopecia, infection, mucositis, epistaxis, skin related complaints and other. Gastrointestinal 
complaints, malaise, psychological complaints and other complaints were assessed with a 
questionnaire every visit and scored by a researcher. Hepatotoxicity was defined as ALAT, 3 
times upper level of normal. Bone marrow depression was defined as leucocytes<3.0x109/l 
or thrombocytes<100x109/l.
Statistical analyses
Comparisons of patient characteristics between derivation and validation cohorts were made 
by Student’s t-test, χ2-test, Mann-Whitney U test or Friedman’s two-way analysis of variance 
by ranks as appropriate. Correlations were tested with Spearman’s correlation-test. Multiple 
linear regression analyses was used for cross-sectional analyses of MTX-PG concentrations 
measured at 3, 6 and 9 months with continuous outcomes (DAS28) at corresponding visits. 
Multivariate logistic regression analyses was used for dichotomous outcomes (adverse 
events). Longitudinal analyses of association of MTX-PG concentrations, measured at 3, 6, 
and 9 months, with DAS28 at corresponding study visits were performed with a linear mixed 
model for continuous outcomes. All analyses were corrected for potential confounders: 
age, gender, baseline DAS28, MTX-dose and use of other DMARDs, non-steroidal anti-
inflammatory drugs (NSAID), glucocorticoids and biologicals. Confounders were added as 
covariates to regression analyses. Co-medication and MTX-dose observed 3 months prior to 
the visit analysed were added as covariates.
 Finally, for those MTX-PGs that had significant association with DAS28, cut-off 
concentrations for moderate/good-response versus non-response according to EULAR 
response criteria [22] were determined in the derivation cohort using receiver operating 
characteristic curves. Cut-off concentrations were chosen to have optimal sensitivity and 
specificity. EULAR response criteria allow only patients with baseline DAS28≥3.3. For these 
cut-of concentrations diagnostic parameters: sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) were subsequently determined. Statistics were 
performed with SPSS Statistics Version 20.0.0.1 (SPSS Inc. Chicago, IL, USA).
Results
Patients and MTX-PG concentrations
At baseline, 102 patients were included in the derivation cohort and 285 patients were 
included in the validation cohort (Figure 1). MTX-PGs in the derivation cohort were measured 
in 79 patients after 3 months of treatment, 67 patients after 6 months and 59 patients after 
9 months. In the validation cohort, MTX-PGs were measured in 228 patients after 3 months, 
183 patients after 6 months and 177 patients after 9 months.
 Disease activity at MTX start was lower in the derivation cohort compared with 
the validation cohort (table 1). MTX-dose was higher in the validation cohort (25 mg/week) 
compared with the derivation cohort (15 mg/week). Patients in the derivation cohort used 
more NSAIDs, less steroids and more parenteral MTX than patients in the validation cohort. 
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Figure 1. Flow chart of patient follow up for both cohorts. *Reasons for drop out were: patient refusal, adverse 
events, communication problems, no compliance, lost to follow up, and MTX stopped; **Reasons for time point 
skipped were: there was insufficient material available for determinations of MTX-PG concentrations, and patients 
did not show up. tREACH, treatment in Rotterdam Early Arthritis Cohort; RA, rheumatoid arthritis; ACR, American 
College of Rheumatology; MTX-PG, methotrexate-polyglutamate.
Table 1. Baseline characteristics per cohort.
Laboratory parameters Derivation cohort Validation cohort p-value
n=102 n=285
Rheumatoid factor positive 41% 66% <0.001
Anti-cyclic citrullinated peptide antibody positive 41% 70% <0.001
Erythrocyte sedimentation rate  mm/h, median (IR) 19 (9-33) 23 (13-40) 0.011
Clinical parameters
Gender, male 29% 30% 0.991
Age, mean (SD) 52 (16) 54 (14) 0.299
VAS mm, mean (SD) 54 (26) 53 (22) 0.704
28 tender joint count (SD), median (IR) 4 (1-8) 6 (3-10) <0.001
28 swollen joint count (SD), median (IR) 3 (1-7) 6 (3-10) <0.001
DAS28, mean (SD) 4.26 (1.43) 4.94 (1.15) <0.001
Medication
Methotrexate dose, mean (SD) 15 (2) 25 (1) <0.001
NSAIDs 36% 14% <0.001
Other DMARDs 57% 62% 0.408
Oral corticosteroids 11% 62% <0.001
Parenteral corticosteroids 3% 32% <0.001
Parenteral methotrexate 6% 0% <0.001
IR, interquartile range; SD, standard deviation; VAS, patient global assessment of general health on a visual 
analogue scale; DAS, disease activity score; NSAID, non-steroid anti-inflammatory drug; DMARD, disease 
modifying anti-rheumatic drug.
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 Table 2 shows medians and ranges of erythrocyte MTX-PG concentrations at 3, 6 
and 9 months in both cohorts. Supplementory table 1 shows dosing adjustments. In both 
cohorts constant concentration was achieved for MTX-PG1 and MTX-PG2 after 3 months. 
However in the derivation and validation cohort, MTX-PG3 (p<0.001, p<0.001), MTX-PG4 
(p<0.001, p=0.009), MTX-PG5 (p<0.001, p=0.003) and total MTX-PG (p=0.024, p<0.001) 
had higher concentrations after 6 months compared to 3 months. The concentrations at 6 
months and 9 months were the same for all MTX-PGs in both cohorts.
 Supplementory table 2a/b shows the correlations between all MTX-PGs at 3 
months. After 3 months, MTX-PG3 (40 versus 48 nmol/L; p=0.001), MTX-PG4 (8 versus 19 
nmol/L; p<0.001) and MTX-PG5 (1 versus 5 nmol/L; p<0.001) concentrations were lower 
in the derivation cohort compared with the validation cohort. After 6 months, MTX-PG5 
(3 versus 4 nmol/L; p=0.003) concentrations were lower in the derivation cohort. After 9 
months there were no differences in MTX-PG concentrations between cohorts.
Table 2. Erythrocyte-MTX-PG concentrations, median (minimum-maximum), in nmol/L 
packed erythrocytes over time in both cohorts.
Derivation cohort 3 months 6 months 9 months
MTX-PG1 35 (0-258) 36 (0-248) 38 (0-199)
MTX-PG2 23 (0-69) 26 (0-65) 23 (0-77)
MTX-PG3 40 (0-88) 54 (0-116) 59 (0-125)
MTX-PG4 8 (0-61) 16 (0-79) 18 (0-76)
MTX-PG5 1 (0-26) 3 (0-31) 4 (0-50)
Total MTX-PG 117 (0-396) 153 (0-396) 158 (0-396)
Validation cohort  3 months 6 months 9 months
MTX-PG1 28 (0-337) 30 (0-186) 29 (0-166)
MTX-PG2 21 (0-82) 21 (0-69) 21 (0-105)
MTX-PG3 48 (0-97) 56 (0-136) 56 (0-173)
MTX-PG4 19 (0-88) 20 (0-100) 20 (0-103)
MTX-PG5 5 (0-64) 4 (0-82) 4 (0-48)
Total MTX-PG 130 (0-476) 144 (0-413) 139 (0-559)
MTX-PG, methotrexate-polyglutamate
Disease activity
In the derivation cohort, mean DAS28 decreased from 4.26 (SE=0.14) at baseline to 2.92 
(SE=0.13) after 3 months (p<0.001), to 2.83 (SE=0.15) after 6 months and to 2.72 (SE=0.13) 
after 9 months. In the validation cohort, mean DAS28 decreased from 4.95 (SE=0.07) at 
baseline to 3.12 (SE=0.07) after 3 months (p<0.001), to 2.93 (SE=0.08) after 6 months and to 
2.66 (SE=0.08) after 9 months. Supplementory table 3 shows numbers of patients switching 
between moderate/good-response and non-response.
 Table 3 shows results for both cohorts of cross-sectional analyses for associations 
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between each MTX-PG measured after 3, 6 or 9 months with DAS28 determined at the 
corresponding study visit. In the derivation cohort after 3 months, higher MTX-PG1 (β=-
0.006; SE=0.002), MTX-PG2 (β=-0.021; SE=0.008), MTX-PG3 (β=-0.016; SE=0.006), MTX-PG4 
(β=-0.021; SE=0.010) and total MTX-PG (β=-0.006; SE=0.002) were associated with lower 
DAS28. After 9 months MTX-PG2 (β=-0.019; SE=0.009) and MTX-PG5 (β=0.037; SE=0.016) 
were associated with DAS28. In the validation cohort, after 6 months, MTX-PG2 (β=-
0.015; SE=0.007), MTX-PG3 (β=-0.011; SE=0.003) and after 9 months, MTX-PG2, (β=-0.012; 
SE=0.006), MTX-PG3 (β=-0.007; SE=0.003) and total MTX-PG (β=-0.002; SE=0.001) were 
associated with lower DAS28.
Table 3. Cross-sectional and longitudinal analysis of MTX-PG concentrations in nmol/L 
packed erythrocytes and DAS28.
Cross-sectional analysis, Longitudinal analysis,
β (SE) β (SE)
3 months 6 months 9 months 0-9 months
MTX-PG1 -0.006 (0.002)* -0.004 (0.004) -0.005 (0.003) -0.005 (0.002)*
MTX-PG2 -0.021 (0.008)* -0.020 (0.011) -0.019 (0.009)* -0.022 (0.005)**
MTX-PG3 -0.016 (0.006)* 0.000 (0.007) 0.002 (0.005) -0.007 (0.003)*
MTX-PG4 -0.021 (0.010)* 0.007 (0.009) -0.002 (0.008) -0.006 (0.004)
MTX-PG5 -0.055 (0.029) 0.015 (0.025) 0.037 (0.016)* 0.006 (0.012)
Total MTX-PG -0.006 (0.002)* -0.002 (0.002) -0.002 (0.002) -0.004 (0.001)**
Validation
cohort 3 months 6 months 9 months 0-9 months
MTX-PG1 -0.002 (0.002) 0.000 (0.002) -0.004 (0.002) -0.002 (0.001)
MTX-PG2 -0.014 (0.007) -0.015 (0.007)* -0.012 (0.006)* -0.015 (0.003)**
MTX-PG3 -0.004 (0.004) -0.011 (0.003)* -0.007 (0.003)* -0.010 (0.002)**
MTX-PG4 -0.004 (0.005) -0.007 (0.005) -0.006 (0.004) -0.008 (0.002)*
MTX-PG5 -0.006 (0.009) -0.007 (0.008) -0.007 (0.009) -0.008 (0.005)
Total MTX-PG -0.002 (0.001) -0.002 (0.001) -0.002 (0.001)* -0.003 (0.001)**
*p<0.05. **p<0.001. 
Results are corrected for baseline DAS28, gender, age, MTX-dose, other DMARDs use, NSAID use, glucocorticoid 
use and biological use. In the cross-sectional analysis, each MTX-PG concentration at each timepoint was 
associated with the DAS28 at the same time point using linear regression. For the longitudinal analyses a mixed 
model was used during the first 9 months treatment. MTX-PG, methotrexate-polyglutamate; DAS, disease 
activity score; DMARD, disease modifying anti-rheumatic drug; NSAID, non-steroid anti-inflammatory drug.
 In the derivation cohort, longitudinal analyses showed that MTX-PG1 (β=-0.005, 
SE=0.002), MTX-PG2 (β=-0.022, SE=0.005), MTX-PG3 (β=-0.007; SE=0.003) and total MTX-
PG (β=-0.004, SE=0.001) were associated with lower DAS28 over the first 9 months. In the 
validation cohort, MTX-PG2 (β=-0.015, SE=0.003), MTX-PG3 (β=-0.010, SE=0.002), MTX-PG4 
(β=-0.008; SE=0.002) and total MTX-PG (β=-0.003, SE=0.001) were longitudinally associated 
with lower DAS28. For an increase in 1 nmol/L MTX-PG2 there is a decrease of 0.02 in DAS28. 
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For an increase in 1 nmol/L MTX-PG3 there is a decrease of 0.01 in DAS28. For an increase 
in 1 nmol/L total MTX-PG there is a decrease of 0.003 in DAS28. 
Figure 2. Mean concentration total erythrocyteMTX-PG in both cohorts for patients with < 3 adverse events and 
patients with ≥ 3 adverse events after 3, 6 and 9 months. MTX-PG, methotrexate-polyglutamate. 
Adverse events
In the derivation cohort after 3 months 20% of the patients (n=16) had no adverse events, 
42% (n=33) gastrointestinal complaints, 49% (n=39) malaise, 13% (n=10) psychological 
complaints, 2% (n=2) hepatotoxicity, 2% (n=2) bone marrow depression, 26% (n=21) other 
adverse events and 30% (n=24) 3 or more adverse events. After 9 month 15% (n=9) had 
no adverse events, 31% (n=18) gastrointestinal complaints, 23% (n=14) malaise, 4% (n=2) 
psychological complaints, 4% (n=2) hepatotoxicity, 1% (n=1) bone marrow depression, 28% 
(n=17) other adverse events and 18% (n=11) 3 or more adverse events. In the validation 
cohort, percentages of patients with adverse events were comparable with the derivation 
cohort. After 3 months 31% (n=71) experienced 3 or more adverse events, which decreased 
to 15% (n=27) after 9 months.
 Figure 2 shows the concentrations of total MTX-PGs after 3, 6 and 9 months in both 
cohorts, stratified for patients with 3 or more adverse events and patients with 2 or fewer 
adverse events. Patients with >3 adverse events had higher MTX-PG concentrations than 
patients with ≤2 adverse events after 6 months in the validation cohort (142 versus 178 
nmol/L, p=0.019). In the derivation cohort after 3 months, total MTX-PG was not associated 
with no adverse events (OR=1.00; 95%CI=0.99-1.01), gastrointestinal complaints (OR=1.00; 
95%CI=0.99-1.00), malaise (OR=1.01; 95%CI=1.00-1.01), psychological complaints (OR=1.00; 
95%CI=0.98-1.01), hepatotoxicity (OR=0.92; 95%CI=0.80-1.05), bone marrow depression 
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(OR=0.96; 95%CI=0.86-1.07), other adverse events (OR=1.00; 95%CI=0.99-1.01) and 3 or 
more adverse events (OR=1.00; 95%CI=0.99-1.01). Same results were obtained for cross 
sectional analyses after 6 and 9 months and for all individual MTX-PGs. In the validation 
cohort, all results from the cross sectional analyses were comparable to the derivation 
cohort. Thus, no significant associations were found in this study between any of the MTX-
PGs and adverse events.
Cut-off concentrations
MTX-PG2, MTX-PG3, MTX-PG4 and total MTX-PG were longitudinally associated with lower 
DAS28 during 9 months treatment. Therefore, cut-off concentrations for EULAR moderate/ 
good-response and their diagnostic parameters were determined. Table 4 shows that cut-
off concentrations of ≥22 nmol/L for MTX-PG2 and ≥74 nmol/L for total MTX-PG could 
discriminate well between patients with moderate/good versus non-response.
Table 4. Cut-off values in nmol/L packed erythrocytes, sensitivity and specificity of 
erythrocyte MTX-PGs to predict EULAR moderate/good-response at 3 months.
MTX-PG2 MTX-PG3 MTX-PG4 Total MTX-PG
AUC 72% 68% 64% 71%
95% CI for AUC 56%-88% 48%-87% 42%-85% 53%-89%
p-value for AUC 0.025 0.072 0.163 0.034
Cut-off concentration 22 nmol/L 32 nmol/L 6 nmol/L 74 nmol/L
Sensitivity 65% 67% 74% 87%
Specificity 82% 73% 64% 64%
Positive predictive value 78% 71% 67% 71%
Negative predictive value 70% 69% 71% 83%
Determined in the derivation cohort after 3 months with receiver operating characteristic curves using EULAR 
moderate/good-response as determinant for good response. EULAR response criteria allow only patients with 
baseline DAS28≥3.3 (n=57). MTX-PG, methotrexate-polyglutamate; AUC, area under the curve.
Discussion
We investigated in this first longitudinal study whether erythrocyteMTX-PG concentrations 
at 3, 6 and 9 months after MTX start were associated with disease activity and adverse events 
in two RA cohorts. In both cohorts, an increase in MTX-PG concentrations is associated with 
a decrease in DAS28 during the first 9 months. Associations were strongest for MTX-PG2 
and MTX-PG3. Cut-off concentrations (total MTX-PG: ≥74 nmol/L) could be used to identify 
patients with moderate/good-response to MTX treatment. In this study, we did not find an 
association between MTX-PG concentrations and adverse events. Besides our results from 
the present study in adult RA, we also show in an accompanying paper that MTX-PG3, MTX-
PG4, MTX-PG5 and total MTX-PG concentrations are related to lower disease activity in JIA. 
[13]
 MTX-PG concentrations in erythrocytes have been associated with response to 
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MTX in arthritis patients before. [4, 9-12] A study showed that erythrocyte MTX-PGs in 
responders and partial responders were significantly higher than in non-responders. [9] 
Others  showed that lower MTX-PG levels were associated with higher disease activity 
and lower decrease in DAS28 [10] and that patients with less decrease in DAS28 had lower 
MTX-PG levels. [11] Others showed that erythrocyte MTX levels were significantly higher 
in patients responding to MTX therapy than in patients classified as non-responders. [4] 
MTX-PG2 was found to have positive correlation with improvement in DAS28 over the first 
16 weeks. [12] Contrary to all these studies, MTX-PG4, MTX-PG5, MTX-PG3-5 and total MTX-
PG were found higher in patients with high disease activity. [2] These results were based 
on cross-sectional analyses with independent t-tests, nonparametric Mann-Whitney U-tests 
and chi-square tests for patient divided into non-responders (DAS28>3.2) and responders 
(DAS28≤3.2). Furthermore, Stamp et al. [2] analysed patients who received MTX for a period 
of 3 months to 19 years (median 3 years). In the present study, however, disease activity 
was determined in patients starting MTX treatment using a continuous outcome variable 
(DAS28), which provided more power. Also, this enabled us to perform analyses with linear 
multivariate models so that we could adjust for a variety of possible confounders. Moreover 
in our cross-sectional approach all patients used MTX for the same length of time and the 
cross-sectional approach was repeated at 3 study visits. We also performed longitudinal 
analyses to determine the association of MTX-PGs with disease activity during the entire 
9-month follow-up. Taken together, the cross-sectional analyses in a heterogeneous 
population may have caused discrepant results compared with the present study.
 In line with other studies [2, 9, 13, 23], we did not find any association between 
MTX-PG concentrations and adverse events. However, relationships between MTX-adverse 
events and higher concentrations of MTX-PG4 and MTX-PG5 have been reported. [24] Also, 
in JIA an association between elevated liver function tests and gastrointestinal adverse 
events and high MTX-PG3-5 concentrations has been found. [14] In our cohorts, all patients 
were treated with folic acid. This treatment has been proven to reduce MTX adverse events 
in RA patients. [25] This could have diluted the relationship between MTX-PG concentrations 
and adverse events. 
 As others have shown before [7, 8], also in our cohorts MTX-dose seems to have 
an effect on individual MTX-PGs. The higher MTX-dose in the validation cohort caused 
higher MTX-PG3, MTX-PG4 and MTX-PG5 concentrations after 3 months (p≤0.001). After 9 
months there were no differences in MTX-PG concentrations between cohorts. This may be 
explained because 28% of patients in the derivation cohort used 25 mg MTX/week after 9 
months. Also, the longer MTX use could have caused higher MTX-PG concentrations. [5]
Maximum dose for MTX in RA is 25 mg/week. Performing TDM is most important in patients 
with lower MTX-dose short after MTX start. We therefore determined cut-off values for MTX-
PGs for achieving EULAR moderate/good-response in the derivation cohort at 3 months. 
Patients with total MTX-PG concentration <74 nmol/L after 3 months MTX may need dose 
increase to achieve lower disease activity. In the derivation cohort, 11 (14%) and in the 
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validation cohort 35 (15%) patients achieved total MTX-PG concentrations ≥74 nmol/L after 
3 months and were non-responder. This group of patients probably has no benefit from 
MTX despite an adequate total MTX-PG concentration and may need additional medication.
 There are some inconsistencies between the cohorts in the associations of each PG 
with disease activity (Table 3). This could be a dose effect since higher dose in the validation 
cohort drives the formation of longer MTX-PGs. This is visible in our study because MTX-
PG3, MTX-PG4 and MTX-PG5 have higher concentrations after 3 months in the validation 
cohort. Based on our study, MTX-PG2 and MTX-PG3 would be the best candidates for TDM 
or prediction of clinical response. MTX-PG2 was slightly superior to MTX-PG3 in terms of 
the effect size (Beta’s Table 3) and diagnostic test accuracy (Table 4). On the other hand, 
MTX-PG3 is more abundant and therefore, can be measured with more (analytical) precision 
(SEs Table 3). Additionally, due to the kinetics of MTX-PG accumulation, the variability in the 
accumulation half-life of MTX-PG2 is larger than that of MTX-PG3 [5] making MTX-PG3 a 
more suitable predictor to measure. However, from a clinical point of view, it would be even 
better to predict response and to optimize MTX dose much earlier than 3 months. To this 
aim, MTX-PG2 would be a better candidate because of its much shorter accumulation half-
time than MTX-PG3 [5] (see also Table 2). Future prospective studies should investigate the 
predictive power of MTX-PGs measured much earlier after the start of MTX treatment. In 
the accompanying study, especially long chain MTX-PGs were associated with lower disease 
activity in JIA. [13] 
 The hypothesis in this study was based on MTX working mechanism and therefore 
MTX monotherapy would have been ideal. However, more than half of patients in this study 
received other DMARDs, NSAIDs and corticosteroids besides MTX. These drugs also have 
an impact on disease activity and can cause similar adverse events. Therefore, all analyses 
were corrected for co-medication. Corrected results were not significantly different from 
uncorrected results. This was not a pharmacokinetic study. However, we compared MTX-PG 
concentrations between 3, 6 and 9 months. MTX-PG1 and MTX-PG2 achieved a constant 
concentration after 3 months and MTX-PG3,4,5 and total MTX-PG achieved constant 
concentration after 6 months. Dervieux et al. [7] reported steady-state after 7 weeks for 
MTX-PG1-5. Others [5] showed that median times to reach steady state were 6.2, 10.6, 
41.2, 149.0 and 139.8 weeks, respectively, for MTX-PG1,2,3,4 and 5. For MTX-PG4 and MTX-
PG5 in our study it took less time (6 months) to reach constant concentration. Differences 
after 6 months may be too small to pick up with simple statistics. There were many 
differences in baseline characteristics of both cohorts. But, in the way we collected the data 
methodologically, both cohorts are almost identical. Having longitudinal data of MTX-PGs 
for 3 visits in first 9 months of MTX treatment in two different cohorts is unique. Because 
we find similar relationships between MTX-PGs and DAS28 in both cohorts, despite these 
differences between cohorts, supports the conclusion that erythrocyteMTX-PG levels are 
related to clinical response.
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 In conclusion, higher erythrocyte MTX-PG concentrations were associated with 
lower DAS28 during 9 months MTX treatment in RA patients in two independent cohorts. 
MTX-PGs were not associated with adverse events. Erythrocyte MTX-PG concentrations are 
a potential tool for therapeutic drug monitoring of MTX therapy in RA patients.
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Supplementory table 1. Number of patients with MTX-dose adjustments and mean 
MTX-dose per visit.
Derivation cohort Baseline 3 months 6 months
MTX-dose increase to 25 
mg/week
1 (1%) 18 (18%) 29 (28%)
Mean MTX-dose (SD) 15 (2) 16 (6) 16 (8)
Validation cohort
MTX-dose decrease to 15 
mg/week
1 (0.4%) 14 (5%) 23 (8%)
Mean MTX-dose (SD) 25 (1) 22 (7) 19 (8)
The MTX-dose observed at the visits 3 months prior to the visits were MTX-PG was measured are given, 
because this was the dose were the patients were exposed to in the 3 months prior to the visit were MTX-PG 
concentrations were measured. MTX, methotrexate; SD standard deviation.
Supplementory table 2a. Spearman’s correlations in the derivation cohort at 3 months.
Total MTX-PG MTX-PG1 MTX-PG2 MTX-PG3 MTX-PG4  MTX-PG5 
Total MTX-PG Correlation 
Coefficient
1,000 ,795** ,755** ,825** ,587** ,441**
Sig. (2-tailed) . ,000 ,000 ,000 ,000 ,000
MTX-PG1 Correlation 
Coefficient
,795** 1,000 ,821** ,370** ,059 -,032
Sig. (2-tailed) ,000 . ,000 ,001 ,602 ,780
MTX-PG2 Correlation 
Coefficient
,755** ,821** 1,000 ,448** ,098 -,068
Sig. (2-tailed) ,000 ,000 . ,000 ,382 ,546
MTX-PG3 Correlation 
Coefficient
,825** ,370** ,448** 1,000 ,888** ,726**
Sig. (2-tailed) ,000 ,001 ,000 . ,000 ,000
MTX-PG4 Correlation 
Coefficient
,587** ,059 ,098 ,888** 1,000 ,914**
Sig. (2-tailed) ,000 ,602 ,382 ,000 . ,000
MTX-PG5 Correlation 
Coefficient
,441** -,032 -,068 ,726** ,914** 1,000
Sig. (2-tailed) ,000 ,780 ,546 ,000 ,000 .
** Correlation is significant at the 0.01 level (2-tailed).
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Supplementory table 2b. Spearman’s correlations in the validation cohort at 3 months.
Total MTX-PG MTX-PG1 MTX-PG2 MTX-PG3 MTX-PG4  MTX-PG5 
Total MTX-PG Correlation 
Coefficient
1,000 ,762** ,692** ,875** ,737** ,652**
Sig. (2-tailed) . ,000 ,000 ,000 ,000 ,000
MTX-PG1 Correlation 
Coefficient
,762** 1,000 ,719** ,450** ,249** ,167*
Sig. (2-tailed) ,000 . ,000 ,000 ,000 ,011
MTX-PG2 Correlation 
Coefficient
,692** ,719** 1,000 ,581** ,256** ,146*
Sig. (2-tailed) ,000 ,000 . ,000 ,000 ,028
MTX-PG3 Correlation 
Coefficient
,875** ,450** ,581** 1,000 ,858** ,771**
Sig. (2-tailed) ,000 ,000 ,000 . ,000 ,000
MTX-PG4 Correlation 
Coefficient
,737** ,249** ,256** ,858** 1,000 ,979**
Sig. (2-tailed) ,000 ,000 ,000 ,000 . ,000
MTX-PG5 Correlation 
Coefficient
,652** ,167* ,146* ,771** ,979** 1,000
Sig. (2-tailed) ,000 ,011 ,028 ,000 ,000 .
** Correlation is significant at the 0.01 level (2-tailed); * Correlation is significant at the 0.05 level (2-tailed).
Supplementory table 3. Switching between moderate/good-response and non-response 
according to EULAR response criteria.
Derivation cohort Between 3 and 6 months Between 6 and 9 months
Moderate/good-responder to non-
responder
9 (19%) 0 (0%)
Stayed non-responder 3 (6%) 5 (12%)
Non-responder to moderate/good-
responder
5 (10%) 4 (10%)
Stayed moderate/good-responder 31 (65%) 32 (78%)
Validation cohort
Moderate/good-responder to non-
responder
19 (8%) 13 (6%)
Stayed non-responder 8 (3%) 4 (2%)
Non-responder to moderate/good-
responder
30 (13%) 21 (10%)
Stayed moderate/good-responder 173 (75%) 170 (82%)
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Because of its high efficacy and good safety profile the folate antagonist methotrexate (MTX) 
is the ‘anchor drug’ in the treatment of rheumatoid arthritis and other arthritic diseases. 
However, its use is hampered by high inter-patient variation in response and 20-40% do not 
respond well to treatment. Furthermore, about 30% of patients develop adverse events 
leading some to discontinue treatment. [1] 
 Methotrexate is administered in a fixed (non-individualized) dose and treatment 
regime is adapted according to how the patient reacts, leading to an unpredictable search 
by trial and error for the correct dosage and treatment regime. A tool to predict how and 
if patients will respond to initial methotrexate treatment would greatly enhance clinical 
practice and help tailor treatment to the individual patient. 
 It has been shown that the intracellular metabolites of methotrexate, the 
methotrexate-polyglutamates, are associated with response to treatment. [2-8] These MTX-
PGs might be a valuable target for therapeutic drug monitoring. 
The aims of this thesis were (see Chapter 1);
1) To develop a quantitative method for the measurement of erythrocyte MTX-PG. 
2) To examine which clinical, genetic, socio-demographic, and biochemical factors 
influence the MTX-PG levels in patients treated with low-dose MTX .
3) To examine the prospective accumulation of MTX-PGs in erythrocytes during low-
dose pulse MTX treatment and its association with response
To achieve this we developed a method for the quantative determination of methotrexate 
polyglutamates in erythrocytes. Using this method, we measured the MTX-PG levels in 
erythrocytes from patients of two independent prospective cohorts and we examined the 
factors that influence MTX-PG accumulation as well as studying the speed and distribution 
of MTX-PG accumulation. Finally, we correlated MTX-PG levels to reponse to treatment in 
RA. The results of this thesis validate the use of erythrocyte MTX-PG for TDM and shed new 
light on the factors that influence the MTX-PG levels. The knowledge gained during this 
research will aid in the development of personalized treatment of RA.
Main findings of this thesis:
1. An ultrafast method for the measurement of MTX-PGs has been developed using 
novel MALDI-MS/MS technology. This method will be of great value for large scale 
studies because of the speed of measurement. (chapter 2)
2. A new LC-MS/MS/based method has been developed for the quantitation of 
MTX-PGs. This method is the first to use stable isotope labeled standards and is 
easily applicable in the clinical lab due to non-complicated sample preparation 
and short runtimes. (chapter 3)
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3. A new method for the measurement of MTX in plasma has been developed, 
which will be of great use for potential pharmacokinetic studies and for the 
measurement of MTX in ALL patients, especially in the setting of carboxylase-G2 
rescue. (chapter 4)
4. We found that an immune-assay based method is a promising low-tech and 
easy to use assay for the determination of total MTX-PG content in erythrocytes. 
(chapter 5)
5. We determined that age, MTX dosage, erythrocyte folate content and the 
FPGS rs4451422 SNP are the major factors that influence MTX-PG levels in two 
independent cohorts. (chapter 6)
6. We showed that MTX-PG accumulation and distribution in the erythrocyte is driven 
by dosage and that higher dose not only leads to higher MTX-PG concentration, 
but also that distribution shifts  towards long-chain MTX-PGs.  (chapter 7)
7. The accumulation of MTX-PGs in erythrocytes occurs mainly in the first three 
months of treatment and steady state is generally achieved before 6 months of 
treatment. (chapter 7)
8. We show that the MTX-PGs levels in erythrocytes are related to response and 
that the MTX-PG levels at 3 months of treatment can predict how well patients 
respond during the first 9 month of treatment. (chapter 8)
Aim 1: To develop a quantitative method for the measurement of erythrocyte MTX-PG
Because the measurement of MTX-PGs is difficult and not many methods have been 
published that are clinically applicable, we developed multiple assays for the quantitation of 
MTX-PGs in erythrocytes. 
 In chapter 2, we described the development of a MALDI-QqQ-MS/MS method for 
the quantitation of erythrocyte MTX-PGs. This method uses relatively new and advanced 
technology that combines a high-repetition matrix-assisted laser desorption/ionization 
(MALDI) source with a triple quadruple mass analyzer, thereby negating the time-consuming 
chromatography step utilized in most MS based assays to separate the analytes of interest. 
This new technology has been shown to aproach the performance of LC-MS/MS [9] and has 
been successfully used in multiple studies. [10-16]
 This method was able to measure accurately and sensitively within the clinically 
relevant range of erythrocyte MTX-PGs from patients receiving low-dose MTX therapy 
and uses fast and relatively simple solid-phase extraction for the isolation of the MTX-PGs 
from the erythrocyte. Accuracy and precision were well within the FDA-guidelines [17] 
approved range and the MTX-PG levels that were measured in patient samples were in 
good agreement with previously reported concentrations. Because of the high speed of the 
analysis (10 seconds per analysis) this method is well suited for large studies where many 
samples need to be measured in a batch-type design. 
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 A major advantage of the MALDI-QqQ-MS/MS instrumentation is that it is directly 
available for analysis of other substances without downtime of the instrumentation 
compared with common LC-MS instrumentation due to exchange of separation columns and 
equilibration of the applied instrumentation. The method compares well with other reported 
methods that generally require >20 minutes per sample because of the chromatography 
step required for the adequate separation of MTX-PGs. 
 Although the method described in chapter 2 is fast and precise, because of the novel 
nature of the technology, the routine clinical lab is not likely to possess such a machine and 
an assay on a more accessible machine would be preferred. Because of this we developed 
a simple LC-MS/MS-based method for the separate quantitation of individual MTX-PGs in 
human erythrocytes, which is described in chapter 3. 
 This is the first method described in the literature using stable-isotope-labelled 
internal standards for the measurement of the intracellular MTX-PGs. It is greatly improved 
over previously reported assays by a shorter and simpler sample-preparation, the use of 
mass spectrometry and a relatively short analysis time. Because of the MS based nature of 
this assay and the use of stable isotope internal standards this method is not disadvantaged 
by interference from compounds similar to MTX, such as endogenous folates or MTX 
breakdown products such as DAMPA and 7-OH-MTX. 
 The described method has a linear range that encompasses the known clinical 
range of the different MTX-PGs and the LLOQ for the different MTX-PGs is comparable to or 
lower than previously reported methods. This is especially important for the longer-chain 
MTX-PGs, as these are generally present in lower concentrations than the short-chain MTX-
PGs. The LLOQ could however still be improved by more extensive sample clean-up such 
as SPE, but this would increase the cost and preparation time of the method. Because this 
method is relatively simple and uses equipment found in most clinical laboratories it is easy 
to transfer to routine measurement. 
 We used our method to analyse the erythrocyte MTX-PG content of 50 samples 
obtained from MTX-treated RA patients. The concentrations and distribution of MTX PG1–5 
as measured by our method were in line with those previously reported.
 Theoretically, MTX-PG6 and MTX-PG7 are also present in the erythrocytes. 
However, the presence of these MTX-PGs has not been demonstrated  conclusively. As 
analysis of multiple patients in different studies reported in literature as well as our own 
patient samples did not reveal detectable amounts of MTX-PG6 and MTX-PG7 in low-dose 
MTX treatment. Therefore, and because of the prohibitive cost of the MTX-PG6 and MTX-
PG7 stable-isotope-labelled internal standards, we decided not to focus on MTX-PG6 and 
MTX-PG7 in our studies. Although the transition of MTX-PG6 and MTX-PG7 was always 
included in our analyses, we never found a signal about the background for these analytes. 
Possibly, in long-term high-dose (ALL) patients these MTX-PGs will be present in measureable 
quantities. 
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 As shown in our validation experiments, recovery and matrix-effects differ strongly 
for each MTX-PG and between different erythrocyte pellets. Concomitantly, the use of a 
stable-isotope-labelled internal standard is mandatory for a reliable quantitation in a 
complex matrix such as erythrocytes. 
 In conclusion, we describe a LC-MS/MS-based method to measure MTX in 
erythrocytes with minimal sample pre-treatment, relatively short analysis time, and good 
diagnostic performance that can be applied in routine clinical TDM. The method is validated 
for the clinical lab and is currently the only method that measures MTX-PG1–5 separately 
using stable-isotope-labelled internal standards. 
Plasma levels of MTX are low to non-existent in low-dose MTX treatment such as used 
in RA. However, for pharmacokinetic studies where samples are collected quickly after 
taking the drug and plasma levels are still present, an accurate and specific method for 
the quantitation of MTX in plasma would be of great value. Moreover, a reliable method 
to measure plasma MTX levels in high-dose MTX treatment such as ALL would also be of 
clinical value. Most clinical laboratories use an immunoassay for the detection of MTX in 
plasma. However, immuno-assays generally have less specificity and higher LLOQs than LC-
MS/MS-based assays. As the plasma MTX levels are used to guide clinical decision making 
and considering the quick clearance of MTX and the low levels that are reached a more 
sensitive, interference-free method would be very valuable. 
 In chapter 4 we describe the development and validation of a straightforward and 
robust LC–MS/MS–based method for the measurement of MTX in plasma. This method is 
adapted from our erythrocyte MTX-PG method. The presented method does not require 
expensive and time-consuming sample preparation, such as solid-phase extraction, and 
because of the use of a stable isotope-labelled internal standard, it is a very useful method 
for implementation within the clinical laboratory. The short analysis time of 3 minutes per 
sample makes the method attractive for high-throughput settings and clinical studies. 
 Compared with other methods and the traditional immuno-assays for the detection 
of MTX in plasma, our method has improved LLOQ and a larger dynamic range. As with our 
erythrocyte MTX-PG method, improvements in LLOQ can be made with the addition of more 
extensive sample clean-up, such as solid-phase extraction, but this would also increase the 
cost and preparation time of the method.
 When comparing with the standard immunoassay-based analysis, good agreement 
was found. This was somewhat unexpected due to reports about the poor specificity of the 
immunoassay. [18-20] The developed method will be very valuable for pharmacokinetics 
studies due to the high specificity and low LLOQ. Also, in certain situations, such as in the 
case of carboxylase-G2 (glucarpidase) rescue of toxic plasma levels of MTX, immunoassays 
may be severely hampered by interference of MTX metabolites such as DAMPA. [18-21] 
In such cases, a more selective method for the determination of MTX in plasma is very 
important. We showed that during glucarpidase rescue of toxic MTX levels in ALL patients, 
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the immunoassay experienced strong positive interference from DAMPA while our LC-MS/
MS assay was free from interference and was able to correctly measure the disappearance 
of the plasma MTX induced by glucarpidase. [22] In conclusion, we developed an LC–MS/
MS–based method to measure MTX in plasma with minimal sample pre-treatment, relative 
short analysis time, and good performance that can be applied for routine therapeutic drug 
monitoring.
The methods described in chapter 3 and chapter 4 were both tested thoroughly for the 
presence of matrix effects. For both methods, the recovery and matrix effect experiments 
emphasize the need for a proper internal standard when working with complex and highly 
variable matrices such as biological samples in an LC–MS/MS setting. 
 We were able to compare the plasma method to the routine and  ‘gold standard’ 
method for measuring MTX in plasma. This demonstrated that we measure comparable 
and ensured that the developed assay does not differ from other reported values, enabling 
comparison between methods and studies. For the erythrocyte MTX-PG method there is 
no standard method. Although multiple methods have been reported for the measurement 
of erythrocyte MTX-PG, none of these is used routinely. [23-26] Although validation of our 
method was good, this was done using erythrocyte samples with extra-cellular added MTX-
PG. The extend of extraction is impossible to determine and could differ widely per method, 
leading to very different results which could in turn lead to differences in the perceived 
relation between erythrocyte MTX-PG and response to treatment. Cross-calibration 
between methods would be very important to adequately compare and standardize results. 
In order to do this a proficiency testing scheme would need to be set up similar to the 
testing that is done regularly for assays such as vitamin B6, using well defined samples 
that are measured by each method. Such a comparison would greatly enhance the clinical 
usefulness of erythrocyte MTX-PG measurement. 
 Although there is no golden standard for the measurement of erythrocyte MTX-
PG, the company Exagen offers a commercial measurement of erythrocyte MTX-PG. [23] 
Although they only measure and report MTX-PG3, it enabled us to compare results when 
measuring the same sample set. The comparison of 60 samples showed good agreement 
between methods (LC-MS/MS=-0.89  [95% CI: -1.59 to 0.42] × FPIA – 0.87 nM  [95% CI: 0.84 
to 0.90], Figure 1). Considering the difference in detection method and sample preparation 
this is good and shows that results obtained using our method can be compared to results 
obtained from methods based on the method used by Exagen.
 Due to the increasing evidence of the relation between MTX-PG and response in 
RA and JIA it would be beneficial to have a quick, easy-to-use assay for the measurement of 
the total MTX-PG content in erythrocytes that utilizes an existing, robust platform like the 
FLx immuno-analyser in order to enhance the clinical availability of this measurement. 
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In chapter 5 we describe our attempt to utilize an adapted FLx-based MTX assay for the 
quantitation of total erythrocyte MTX-PG content. This method utilizes the immunoassay’s 
high cross-reactivity between MTX-PG species in order to measure total erythrocyte MTX-
PG. Although the method performed well during validation using spiked erythrocyte 
samples, and Passing and Bablok method comparison between the FLx-based assay with our 
in-house validated LC-MS/MS assay showed no significant bias, a clear difference between 
both methods was visible. FLx measured samples generally yielded higher concentrations of 
total MTX-PG than the same samples measured on LC-MS/MS. Furthermore, the correlation 
between FPIA and LC-MS/MS in patient samples was much poorer than in calibration 
samples (R2 = 0.42 vs 0.999), which generated large differences in total erythrocyte MTX-PG 
levels in individual patients between methods.  
 Although we demonstrate that an adapted FLx-based assay can be used to measure 
erythrocyte total MTX-PG levels, the method in general shows a positive bias, low specificity 
and high imprecision. This might be partially due to pre-analytical variability as the turbidity 
and color were not consistent between different samples which might influence the 
measurement or be a reflection of extraction efficiency. Interference from cross-reacting 
MTX metabolites such as DAMPA and 7-OH-MTX might also yield these differences. [19, 21, 
27] While the FLx-based assay seems promising, sample preparation needs to be further 
optimized before it can be utilised in a clinical setting. As the method cannot be translated 
directly from the original article [28], this study shows the importance of cross-validating 
newly developed or implemented methods with a (reference) method on a different 
platform using real patient material. 
Figure 1. Preliminary results of the comparison of 60 samples between HPLC/UV and our LC/MS-MS method.
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Based on our studies we advise the following concerning the measurement of plasma or 
erythrocyte MTX:
• When using mass spectrometry the use of stable isotopes for each 
 individual MTX-PG species is mandatory for quantification;
• LC-MS/MS should be the preferred method for routine clinical measurement 
 of erythrocyte MTX-PG levels in low-dose MTX therapy;
• MALDI-QqQ-MS/MS could be a useful method in large-scale epidemiological
 studies, especially coupled with stable isotope internal standards;
• LC-MS/MS is the preferred method to monitor plasma MTX in patients on
 glucarpidase therapy;
• Methods that use immunoassays to measure intracellular MTX should not be used
 in patients because of the high imprecision;
• A proficiency testing scheme should be developed for erythrocyte MTX-PG levels
 in order to standardize the different methods;
• More research should indicate whether other tissues such as WBC are also/more
 useful to monitor MTX response in patients;
• More research will need to be done to determine which MTX-PG species 
 correlates best to response in order to simplify measurement.
Aim 2: determinants of erythrocyte MTX-PG in low-dose MTX treatment
In order to be able to individualize treatment with MTX, it is important to understand 
the factors that influence the intracellular levels of MTX-PGs. Therefore, in chapter 6 we 
investigated which biological, genetic and behavioral factors influence the intracellular 
levels of MTX-PGs using two independent prospective cohorts. 
 Our results show that in both cohorts age, MTX dosage, erythrocyte folate content 
and the FPGS rs4451422 SNP were major determinants of intracellular MTX-PG levels at 
three months of treatment. We chose the MTX-PG levels at three months of treatment 
as in our study this was the first clinical decision point for the rheumatologist, after which 
medication would be adapted if necessary. When tailoring treatment to the individual 
patient it is important to know which factors determine the MTX-PG levels at the earliest 
time-point relevant to treatment in order to optimize the use of these factors. 
 There have been multiple studies focusing on the determinants of MTX-PG levels 
during treatment and previous research found dose of MTX, route of administration, age 
and renal function to be strongly associated with MTX-PG levels. [5, 29, 30] In concordance 
with this data, we found MTX dose and age to be strong determinants. However, renal 
function was not significantly associated with MTX-PG levels in our cohorts. 
 The discrepancy between results from previous studies and our study can be 
partially explained by the cross-sectional nature of the cohorts that were used in previous 
studies. In our study, patients were prospectively followed while other studies used patients 
that had been treated with MTX for up to 18 years. The MTX-PG accumulation over such a 
Chapter
9
161
Discussion
long period of time would be very different, as patients will have received multiple dosage 
adjustments. Also, long-term MTX-PG levels might be controlled by different factors.
 Despite strong correlations, the determinants found in this study only explained 
up to 21%  of the variability in the derivation cohort, and even less in the validation cohort 
(up to 10%). This was also seen in the combined cohort where only up to 16% of variability 
was explained by the model which included dose of treatment. This is lower than found 
previously in a cross-sectional study of RA patients [30], where up to 30% of the intracellular 
variability in MTX-PG levels was explained by dose of treatment, route of administration age 
and renal function. This indicates that other, as of yet undiscovered, factors influence the 
MTX-PG status besides the factors found in our study. 
 One such factor could be the alternative splicing of FPGS [31], which has been 
shown to influence response to MTX in leukemia cell lines. Alternative splicing leads to loss of 
function of FPGS, resulting in a different polyglutamylation status and loss of MTX retention 
in the cell. Another possibility could be differences in methylation status [unpublished data] 
[32], which could lead to differences in expression of the folate pathway genes, thereby 
leading to variation in MTX uptake, or metabolism. 
 Finally, compliance is a very important factor as it is directly connected to exposure 
and known to be poor in chronic diseases. [33-35] We did not include any measure for 
the above mentioned factors in our study and these should be explored in future studies. 
Measurement of erythrocyte MTX-PG levels could also be very useful to monitor compliance 
in patients on low-dose MTX.
 In our cohorts, the MTX-PG levels were similar to those previously reported in cross-
sectional studies. [2, 23, 29, 30, 36] This was unexpected because in these cross-sectional 
studies patients were treated with MTX anywhere between 3 months and 18 years. While 
other studies used lower dosages of MTX, the longer time of treatment combined with 
the previously reported time to steady state of the erythrocyte MTX-PGs [37] suggested 
that more time was needed to reach similar levels and as we looked at the prospective 
accumulation at three months of treatment, we expected the MTX-PG levels to be (much) 
lower. This shows that the bulk of the MTX-PG accumulation occurs during the first three 
months.
Aim 3: To examine the prospective accumulation of MTX-PGs in erythrocytes during low-
dose pulse MTX treatment and its association with response
Although the MTX-PGs are potential targets for a TDM based approach to RA treatment, 
not much is known about the speed of accumulation and distribution of intracellular 
MTX-PGs or what effect different treatment dosages have. In chapter 7, we focused on 
the accumulation of MTX-PG in erythrocytes over the first 9 months of treatment in two 
separate prospectively collected cohorts that have been treated with two different dosage 
regimes. We found that for both cohorts, the largest part of the accumulation of the short- 
and medium-chain MTX-PGs occurred during the first 3 months of treatment with only a 
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marginal increase in the months thereafter. Steady state levels for all MTX-PGs were reached 
around 6 months of treatment in both cohorts. However, for the long-chain MTX-PGs the 
low-dose (15 mg/week) treated cohort took significantly longer to achieve similar levels 
than the cohort treated with a higher dose (25 mg/week). After 9 months of treatment 
the low-dose treated patients had achieved similar levels of long-chain MTX-PGs, but these 
constituted a significantly smaller part of the total erythrocyte MTX-PG content.
 During the early phase of treatment, low-dose treated patients had significantly 
higher levels of the short-chain MTX-PGs but lower levels of long-chain MTX-PGs. Patients 
treated with low-dose MTX also had a selective redistribution of MTX-PGs towards short-
chain MX-PGs whereas in high-dose treated patients the distribution favored the long-chain 
MTX-PGs. This difference in MTX-PG distribution persevered throughout the 9 months that 
patients were followed, even though at 9 months of treatment the total MTX-PG levels were 
not different between cohorts. 
 Interestingly, in the few patients that received parenteral MTX, there was no 
difference in distribution or concentration of the MTX-PG levels between cohorts, despite a 
difference in treatment dose. But parenteral MTX did lead to similar effects as the high dose 
treatment, i.e., lower levels of short chain MTX-PGs and higher levels of long chain MTX-
PGs. 
 Long chain MTX-PGs are considered to be the more active MTX-species. As higher 
treatment dose of MTX led to a faster accumulation and higher concentrations of long-chain 
MTX-PGs as well as resulting in a selective distribution towards long-chain MTX-PGs, we 
propose that more intensive dosage regimes may be more efficient in the treatment of RA. 
This is supported by a shift towards higher treatment doses and extended co-medication 
over time in the low-dose treated patients. In fact, half of the patients that started at low-
dose MTX, were increased to 20-25 mg/week MTX after 6 months of treatment, whereas in 
the high-dose treated patients medication stayed more or less stable. 
 Because in our cohorts the main bulk of the accumulation of MTX-PGs happens 
during the first three months of treatment, we propose that the optimal point of MTX 
prediction will be during this time, when accumulation is more likely to be in a linear phase, 
enhancing the differences between patients.
There have been multiple studies that show a relation between MTX-PGs and clinical response. 
However, no large prospective studies with a validation cohort have been performed. In 
chapter 8 we investigate the relation of if the erythrocyte MTX-PG concentrations in RA 
patients are associated with disease activity or adverse events over time in two independent 
prospective RA cohorts. Although we did not find a relation between the erythrocyte MTX-
PGs and adverse events, we found that in both cohorts an increase in erythrocyte MTX-PG 
concentrations at three months of treatment was associated with a decrease in disease 
activity during the first 9 months of treatment as measured by the DAS28. Erythrocyte MTX-
PG levels are therefore a potential tool for therapeutic drug monitoring of MTX in RA.
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 In this study a cut-off value of 74 nmol/L erythrocytes of total MTX-PG was 
determined at three months of treatment, which can be used for the identification of 
moderate/good-responders to MTX. Patients below this cut-off might benefit from a dose 
increase to achieve lower disease activity. Maybe more importantly, this cutoff will be able 
to identify patients that have high MTX-PG concentrations (above the cut-off) but show no 
decrease in disease activity. These patients will have no benefit from increased MTX and will 
need additional medication to achieve remission of disease activity. 
 Based on this study, MTX-PG2 and MTX-PG3 would be the most suited candidates 
for TDM for the prediction of clinical response. MTX-PG2 was slightly superior to MTX-PG3 
in terms of the effect size. On the other hand, MTX-PG3 is more abundant and therefore, can 
be detected more easily and with more (analytical) precision. 
 Although the established cut-off enables discrimination of moderate/good-
responders to MTX at three months of treatment, from a clinical point of view, it would 
be preferable to predict response much earlier than at 3 months of treatment to adapt 
treatment to the individual patient as earlier and reach a decrease in disease activity as 
quickly as possible. Because of this, MTX-PG2 might be better candidate because of its much 
shorter accumulation half-time compared to MTX-PG3. 
 We strongly recommend future studies to investigate the predictive power of 
erythrocyte MTX-PGs in the first three months of treatment, preferably as soon as possible 
after the start of MTX treatment. 
 Having longitudinal data of MTX-PGs for 3 visits in first 9 months of MTX treatment 
in two different cohorts is unique. Even though the cohorts used in this study have different 
treatment regimens and differ in disease activity and baseline characteristics, the relation 
between erythrocyte MTX-PG and response is shown in both cohorts, supporting the 
conclusion that erythrocyte-MTX-PG levels are related to clinical response.
Future perspectives
In this thesis we have developed a method for the quantitation of MTX-PG in erythrocytes. 
Using this method we have investigated the erythrocyte MTX-PG content of multiple MTX 
treated RA patients in two independent prospective cohorts. We have determined some 
of the factors that influence the erythrocyte MTX-PG levels. By comparing two different 
treatment regimens we have shown that dosage drives the speed of accumulation and 
distribution of the MTX-PGs, and we have determined the relation between MTX-PG levels 
and response. However there is still much room for improvement and research.
Validation
We have determined a cut-off concentration which can be used for the identification of 
moderate/good-responders to MTX. Further validation will need to be done in order to 
determine the clinical use of the cut-off value and an erythrocyte MTX-PG based intervention 
study should be performed. Ideally future research will also determine cut-off value for non-
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response and non-compliance. Though these cut-off  values will be of great use, the clinical 
use will be greatly enhanced if the cut-off values are translatable between methods and 
treatment strategies. In order to make the cut-off values useful on multiple methods, it is 
important that different methods are compared through standardization or harmonization 
of the MTX-PG assays. 
Dried blood spots
While our LC-MS/MS based method is easily applicable and well suited for study and routine 
use, it would be more patient-friendly if patients do not need to have blood samples drawn 
at the clinic. Dried blood spots would be a possible solution as patients can spot these 
themselves from the comfort of their home and send them to the laboratory by regular 
post. This would help those patients that have low mobility due to the severity of their 
disease, as well as preventing high amounts of sick-leave and days off from work because 
patients need to attend the clinic to have blood drawn. This may be of special interest for 
application in remote areas and less developed countries where analytical laboratories are 
more difficult to reach.
White blood cells
We have used the erythrocyte MTX-PG levels in this project, but the physiological action of 
methotrexate (MTX) is most likely exerted by the white blood cells (WBCs). Because of this, 
the WBC MTX-PG levels might be a better predictor of response than the erythrocyte MTX-
PG levels. A previous study found a relation between WBC MTX-PGs and response but in the 
same study it was found that the effect of erythrocyte MTX-PG was more pronounced and 
more significant.[8] 
 Currently there is no clinically validated method for the measurement of MTX in 
WBCs in patient samples. The LC-MS/MS based method we developed could be adapted 
for the measurement of WBC MTX-PGs, however, a WBC based method may be analytically 
less robust because of the lower numbers of WBCs and the more complicated pre-analytical 
phase. 
 Because erythrocytes lack an active MTX metabolism, the erythrocyte MTX-PG 
content is likely to be stable throughout sample handling and for at least two days at room 
temperature (unpublished data). WBCs on the other hand contain an active MTX metabolism 
and will continue to process MTX-PGs during transport and sample preparation, possibly 
leading to irreproducible results. This may be averted by strict standardization of sample 
drawing and collection, but this will limit its use in a clinical setting, making the collection of 
a trustworthy sample population difficult.
Compliance
The determinants found in our study only explain a small part of the total variability of the 
erythrocyte MTX-PG levels, more research is needed to find out what other factors influence 
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this variability. An obvious and important target is compliance. Because compliance has been 
shown to be low in chronic patients, it is important to have a measure for compliance to be 
able to correct for levels of compliance. MTX-PG levels themselves might be an indicator of 
compliance as the extend of polyglutamylation is dose-(and therefore exposure-) driven. The 
use of MTX-PG levels as a measure for compliance needs to be verified first by comparison 
to an independent measure of compliance. 
(epi-)genetics
In our study we have investigated the effect for different genetic polymorphisms in the 
folate metabolism. While this is an important part of determining the genetic factors that 
influence MTX levels. a great start, there are many more ways that genetics can influence 
the metabolism. Methylation, for example, might down regulate the expression of certain 
genes. It has been shown that certain disease types, and certain drugs influence methylation, 
and methylation might prove to be a factor in the variation of the inter-patient MTX-PG 
levels and response. Differences in gene splicing might also explain part of the variability 
of MTX-PG levels, and there are more ways that expression can be altered. This suggests 
that we should look not only into genetic polymorphisms, but also at the mRNA levels and 
eventual protein levels to build a complete picture of the genetic influences.
Interaction between DMARDS
Because of the strictly protocolized nature of the validation cohort, and the low number of 
patients in the derivation cohort we have not been able to study the possible interaction 
between the co-medication and MTX. As some DMARDS may interact, this is worth 
researching in order to optimise treatment.
Earlier prediction point
While we can, with reasonable certainty, discriminate non-responders from moderate/
good-responders, the timepoint at which we are currently able to do this is not optimal, as 
it coincides with the earliest clinical decision point of the rheumatologist. Ideally we would 
be able to predict in advance (preferably at the start of treatment) how, and if, a patients 
will respond to treatment. Using the MTX levels as a guide, this is of course not possible. 
But considering the fast build-up of MTX-PGs in the first three months of treatment, it is 
reasonable to assume that a better prediction point can be found in an earlier phase of 
treatment.
Interaction between MTX and folic acid
Patients treated with MTX also receive folic acid ‘rescue’ therapy, one day after taking MTX. 
This is hypothesized to reduce adverse events though it there is no empirical evidence for the 
treatment scheme. The patients in our cohorts had a significant increase in folate levels in 
both erythrocytes and serum over the course of treatment. Because MTX and folate use the 
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same mechanism, increasing the folate levels this drastically could increase the competition 
for enzymes in the folate pathway, possibly reducing the working of MTX. In addition, it 
is not know which dosage of folic acid, or at what frequency folic acid should be given to 
reduce adverse events. As the erythrocyte and serum levels increase during treatment in 
our patient group, we consider the current folic acid dosage too high. More research should 
be done on the effect of folic acid supplementation and what would be the optimal strategy. 
Our study was not designed to determine this and we have not been able to correct for folic 
acid dose, frequency or time of intake in relation to MTX intake.
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Addendum
Summary
Methotrexate (MTX) is the ‘anchor drug’ in the treatment of Rheumatoid Arthritis (RA) due 
to its high efficacy, low cost and good safety profile. However, its use is hampered by a 
highly variable inter-patient response and 20-40% of patients do not respond adequately 
to treatment. Also, about 30% of patients suffer from adverse events leading to lower 
adherence and possible premature switching of medication by the treating rheumatologist.
 The intracellular levels of MTX have been correlated with the response to 
treatment and similarly to the clinical response to MTX, the (time to reach) steady-state 
erythrocyte MTX levels are highly variable between patients. This link between inter-patient 
MTX response variability and the large inter-individual variation in the rate and extent of 
erythrocyte MTX accumulation suggests that erythrocyte MTX measurement may be a 
valuable tool for the clinician to individualize MTX treatment in an early phase in order to 
achieve faster disease remission and less erosive damage. 
 While MTX plasma levels can be measured easily, low-dose MTX is rapidly cleared 
from plasma. The therapeutic effects of MTX are thought to be mediated by its intracellular 
levels, which are more difficult to measure. MTX is transported into the cell primarily by the 
reduced folate carrier. Once in the cell, MTX-PG1 is rapidly converted to MTX polyglutamates 
(MTX-PGs). Polyglutamylation retains MTX in the cell because the MTX-PGs are a poor 
substrate for the MTX efflux proteins.
 The objectives of this thesis were: 1) to develop a new, clinically applicable method 
for the measurement of MTX-PGs in erythrocytes, 2) the application of this method to 
determine the factors that influence the erythrocyte MTX-PG levels, and 3) examining the 
prospective accumulation of erythrocyte MTX-PGs and the association between erythrocyte 
MTX-PGs and response to treatment.
 In Chapter 2 we describe the development of a new bioanalytical assay to measure 
methotrexate polyglutamates in erythrocytes using a novel high-throughput rapid mass-
spectrometric technology. This technology merges a high-repetition matrix-assisted laser 
desorption/ionization (MALDI) source with a triple quadruple mass analyzer platform. The 
great power of this system lies in the speed at which it can measure, it is at least twenty-five 
times faster than using the fasted LC-MS/MS based system currently available. Although at 
the time stable isotopes of the MTX-PGs were not yet available, acceptable precision, LOQ 
and linearity were achieved. This method will be very valuable when large cohort studies are 
being performed, especially with the addition of stable isotope internal standards.
 Although the MALDI-MS/MS method is a promising method for the high-
throughput analysis of MTX-PGs, for the routine clinical lab a more accessible technique is 
preferred that does not need such specialized and expensive equipment. In order to provide 
routine labs with a clinically applicable method of measuring MTX-PGs we developed an 
LC-MS/MS method that uses a standard UPLC-MS/MS system similar to what many clinical 
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labs have available. In Chapter 3 the validation of this method is outlined. This method uses 
stable isotope-labelled internal standards making it more robust and therefore ideal for the 
use of clinical samples. The method was fully validated according to clinical chemistry and 
FDA guidelines and has high specificity and sensitivity. Because no complicated or expensive 
sample preparation is used it is ideally suited for the routine clinical lab.
 In Chapter 4 this method is adapted and validated for the measurement of MTX 
in plasma in order to complement our erythrocyte method. Compared with the in-house 
immuno-assay the LC-MS/MS based method performed at least similarly, while having a 
better resolution and larger linear range.
 As not every lab has an LC-MS/MS system available but might be interested in 
measuring intracellular MTX-PG levels, an easy, accessible method for the determination 
of total MTX-PGs in erythrocytes is described in Chapter 5. Although the validation of 
this method was good, with reasonable accuracy and precision, it was carried out using 
spiked erythrocyte samples. When in the final phase of method validation the method was 
compared to our previously developed LC-MS/MS assay using patient samples, the immuno-
assay based method displayed high proportional and constant bias as well as a very low 
precision (i.e. high spread).
 We established the LC/MS-MS method for the determination of MTX-PG of 
erythrocyte samples from multiple prospective RA cohorts. In Chapter 6 we investigate which 
factors influence the erythrocyte MTX-PG levels during the first three months of treatment. 
We measured various potential socio-demographic, clinical and biochemical determinants 
at the start of treatment and correlated them to MTX-PG levels in erythrocytes. We found 
that higher age, higher erythrocyte folate levels and the FPGS rs4451422 wildtype were 
all associated with higher medium and long-chain MTX-PG levels in both cohorts. Because 
both cohorts had too little variation in dose of treatment at baseline, the cohorts were 
combined to look at the difference of dosage. In the combined cohort, higher MTX dose had 
a strong association with higher levels of erythrocyte MTX-PG levels. These factors together 
explained up to 21% of the total variability of MTX-PGs, suggesting stronger associations are 
still to be found.
 Because there is little information available about the effect of different MTX dosing 
schemes on the concentration, distribution and speed of accumulation of the intracellular 
MTX-PGs we investigated in Chapter 7 how these are influenced by two different dosing 
schemes. We found that the main bulk of accumulation occurred during the first three 
months of treatment, with only marginal increase in the months thereafter. Patients treated 
with a lower dosage of MTX needed a longer time to reach the same levels of MT-XPGs as 
patients treated with a higher dose of MTX. Also, patient that were treated with a lower 
dose had a selective distribution towards the short-chain MTX-PGs, whereas high dosage 
treatment led to a larger percentage of long-chain MTX-PGs. 
  Finally, Chapter 8 describes the relation between MTX-PGs and response 
in two prospective RA cohorts. We found that higher levels of MTX-PGs were associated with 
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a decrease in disease activity during the first 9 months of treatment. A cut-off value of 74 
nmol/L erythrocytes was determined which can be used for the identification of moderate/
good-responders to MTX. We did not find an association between MTX-PGs and adverse 
events and there was no difference in frequency of adverse events between cohorts.
The data we present in this thesis show that therapeutic drug monitoring in rheumatoid 
arthritis is feasible and that erythrocyte MTX-PG levels can be used to this end. Furthermore, 
our results suggest that more intensive treatment (high-dose or parenteral administration) 
is better in reducing disease activity as higher levels of erythrocyte MTX-PGs are reached 
earlier in treatment, while adverse events do not differ from patients treated with low-dose 
MTX.  Because the bulk of the accumulation of MTX-PGs happens during the first three 
months of treatment, we think that monitoring of MTX-PG levels will be the most valuable 
during this time. Additionally, apart from prediction of clinical (non-)response, measurement 
of erythrocyte MTX-PG may also be used to assess drug adherence.
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Nederlandse samenvatting
Ruim 160.000 patiënten in Nederland lijden aan de gewrichtsziekte reumatoïde artritis 
(hierna: reuma). Elk jaar komen er ongeveer 7200 nieuwe patiënten bij. Reuma komt voor 
onder alle leeftijden, maar openbaart zich in de meeste gevallen tussen het 40e en 60e 
levensjaar. Vrouwen worden vaker getroffen door deze ziekte dan mannen. Reuma is een 
chronische ziekte, die (pijnlijke) ontstekingen veroorzaakt in de gewrichten. Indien reuma 
in een vroeg stadium wordt herkend, is de aandoening goed te behandelen. Echter, als de 
ziekte niet (tijdig) wordt behandeld heeft dit grote gevolgen: permanente gewrichtsschade, 
beperkingen in de mobiliteit en een sterke vermindering van de kwaliteit van leven. 
Bovendien kan het niet behandelen van de reuma leiden tot ontstekingen aan hart, longen 
en bloedvaten. 
 Methotrexaat (MTX) is één van de belangrijkste geneesmiddelen om reuma te 
behandelen. MTX wordt standaard als eerste geneesmiddel ingezet omdat het middel 
effectief, veilig en goedkoop is. Patiënten krijgen in eerste instantie een standaarddosering 
voorgeschreven. Als dit onvoldoende effect heeft, wordt de dosering aangepast. Ondanks 
het succes van dit geneesmiddel blijkt 20 tot 40% van de patiënten onvoldoende te reageren 
op MTX. Daarnaast ervaart 30% van de patiënten bijwerkingen, zoals mucositis, misselijkheid 
en algehele malaise, waardoor zij soms voortijdig stoppen met het innemen van MTX.
 Op dit moment is er nog geen methode om de dosering van het medicijn op de 
individuele patiënt af te stemmen. Daarmee kan nog niet goed worden voorspeld hoe 
patiënten reageren op het gebruik van MTX. Als gevolg hiervan wordt iedere patiënt 
blootgesteld aan een onvoorspelbare zoektocht naar de juiste dosering totdat de gewenste 
dosering op basis van ’trial and error’ kan worden vastgesteld. Dit leidt tot onnodige overlast 
voor patiënten en hogere kosten voor het bestrijden van reuma.
 Uit eerder onderzoek blijkt dat de concentraties van MTX in de bloedcellen een 
mogelijk aanknopingspunt vormen om tot een voorspelbare, op de individuele patiënt 
afgestemde dosering van het medicijn te kunnen komen.  De concentraties van MTX in de 
cel blijken namelijk sterk samen te hangen met de wijze waarop de patient reageert op de 
behandeling met MTX. 
 Bij behandeling met MTX is er niet alleen veel variatie in de mate waarin het 
medicijn effectief is, maar ook de tijd die nodig is om te komen tot stabiele MTX concentraties 
in de bloedcellen èn de uiteindelijke hoogte van die concentraties lopen erg uiteen. Dit 
suggereert dat het meten van MTX mogelijk een manier is om te komen tot een op de 
individuele patiënt toegesneden MTX dosering. Hierdoor kan reuma eerder en met minder 
overlast voor de patiënt worden bestreden.
 Het therapeutisch effect van MTX wordt waarschijnlijk gemedieerd door de 
intracellulaire spiegels van MTX. Wanneer MTX wordt opgenomen in de cel door de reduced 
folate carrier, worden er stapsgewijs meerdere glutamaat groepen aan toegevoegd. Hierdoor 
worden de MTX poly-glutamaten (MTX-PG’s) gevormd. Deze MTX-PG’s zorgen ervoor dat de 
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intracellulaire MTX in de cel wordt behouden omdat MTX-PG’s geen goed substraat zijn voor 
de export enzymen.
Dit proefschrift is het verslag van de zoektocht naar: 1) een nieuwe, klinisch toepasbare 
methode voor het meten van de intracellulaire MTX-PG spiegels, 2) het toepassen van 
deze methode voor het bepalen van de factoren die de hoogte van de intracellulaire MTX-
PG spiegels beïnvloeden en 3) het onderzoeken van de opbouwsnelheid van MTX-PG’s 
in de rode bloedcel en de relatie tussen MTX-PG’s in de rode bloedcel en de afname van 
ziekteactiviteit.
 Deze methode moet het voor de reumatoloog mogelijk maken om eerder en 
efficiënter in te grijpen waardoor de overlast voor patiënten wordt beperkt, de kosten voor 
de gezondheidszorg worden beperkt en patiëntentrouw bij het innemen van medicatie 
bevordert.
 In hoofdstuk 2 wordt de ontwikkeling van een nieuwe methode beschreven voor 
het meten van de intracellulaire MTX-PG spiegels in rode bloedcellen door middel van een 
nieuwe, zeer snelle massa-spectrometrische methode. Deze technologie maakt gebruik 
van een MALDI ionisatiebron gekoppeld aan een tandem massaspectrometer (MS/MS). De 
kracht van het systeem ligt in de snelheid waarmee er gemeten kan worden, per monster 
is het minimaal 24 keer sneller dan met de snelste huidige reguliere LC-MS/MS gebaseerde 
methode. Tijdens de ontwikkeling van deze methode waren er jammer genoeg nog geen 
stabiele isotopen beschikbaar. Desondanks werden acceptabele precisie, detectie limiet en 
lineariteit bereikt. Deze methode zal bijzonder waardevol blijken bij grote cohort studies 
en de toevoeging van een stabiele isotoop als interne standaard zal de metingen een stuk 
betrouwbaarder maken.
 De MALDI-MS/MS methode is een veelbelovende methode voor de analyse van 
grote aantallen monsters. Echter, voor de meer routinematig ingestelde klinische laboratoria 
zou een meer toegankelijke techniek beter toepasbaar zijn. Om aan die behoefte te voldoen 
hebben wij een vloeistof chromatografische (LC) gebaseerde analyse methode ontwikkeld 
die gebruikt maakt van een standaard LC-MS/MS systeem waarover vele klinische laboratoria 
al beschikken. 
 In hoofdstuk 3 wordt de validatie van deze methode beschreven. Tijdens het 
ontwikkelen van deze methode waren wel stabiele isotoop gelabelde standaarden 
beschikbaar, hierdoor is de methode extra robuust en daardoor ideaal voor het gebruik 
met klinische monsters. De methode is volledig gevalideerd op basis van klinisch-chemische 
en FDA richtlijnen en heeft hoge specificiteit en gevoeligheid. Omdat er geen ingewikkelde 
of kostbare monster-voorbehandeling word gebruikt is de methode ideaal voor het gebruik 
in het klinische laboratorium.
 In hoofdstuk 4 wordt deze methode aangepast en gevalideerd voor het meten van 
MTX in plasma.  Vergeleken met de huidige ‘gouden standaard’ methode voor het meten 
van MTX in plasma heeft de in dit hoofdstuk ontwikkelde massaspectrometrische methode 
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een betere specificiteit en gevoeligheid voor MTX .
 Aangezien niet elk laboratorium de beschikking heeft over een LC-MS/MS, maar 
wellicht wel de intracellulaire MTX-PG spiegels wilt meten, zou een snelle, makkelijke en 
toegankelijke methode uitkomst bieden. In hoofdstuk 5 beschrijven wij zo een methode. 
Ondanks redelijke resultaten tijdens de validatiestap, was de uiteindelijke vergelijking van 
patiëntenmonsters tussen deze methode en de eerder ontwikkelde LC-MS/MS methode 
niet goed. Tussen methoden was er een hoge mate van spreiding en de beschreven methode 
had een lage precisie. Hierdoor is deze methode niet geschikt voor het betrouwbaar meten 
van patiëntenmonsters.
 De methode ontwikkeld in hoofdstuk 4 is toegepast op monsters van 
reumapatiënten uit meerdere prospectieve cohorten. In hoofdstuk 6 onderzoeken we 
welke factoren de MTX-PG spiegels in de rode bloedcel beïnvloeden gedurende de eerste 
drie maanden van therapie. Hiervoor hebben we meerdere potentiele socio-demografische, 
klinische en biochemische determinanten gemeten bij aanvang van de behandeling. Deze 
hebben we vervolgens gecorreleerd aan de MTX-PG spiegels in de rode bloedcellen. Hieruit 
bleek dat in beide cohorten een hogere leeftijd, hogere folaat spiegels in de bloedcel en de 
wildtype variant van een polymorfisme in het gen dat MTX metaboliseerd (FPGS rs4451422) 
geassocieerd waren met hogere rode bloedcel MTX-PG spiegels. Omdat er in beide cohorten 
te weinig variatie in behandeldosis was om deze apart te toetsen, werden de cohorten 
gecombineerd om te kijken naar de invloed van het verschil in behandeldosis op de rode 
bloedcel MTX-PG spiegels. In het gecombineerde cohort bleek een hogere behandeldosis 
sterk geassocieerd was met de rode bloedcel MTX-PG spiegels. Samengenomen voorspellen 
de gevonden factoren tot 21% van de gevonden  MTX-PG variatie. Dit suggereert dat er 
andere, nog sterkere associaties zijn die niet gevonden werden in dit onderzoek.
 Omdat er weinig bekend is over het effect van verschillende doseringen op 
de concentratie, distributie en accumulatie snelheid  van de intracellulaire MTX-PG’s 
hebben wij in hoofdstuk 7 gekeken hoe deze beïnvloed worden door twee verschillende 
doseringsschema’s. Hier vonden wij dat het grootste deel van de opbouw van MTX-PG’s in 
rode bloedcellen plaatsvindt tijdens de eerste drie maanden van behandeling, met slechts 
een kleine stijging in de maanden erna. Patiënten die behandeld werden met een lagere 
dosis MTX hadden meer tijd nodig om vergelijkbare spiegels te bereiken als patiënten die 
en hogere dosis MTX kregen. Tevens werden er bij lage MTX dosering minder additionele 
glutamaatgroepen toegevoegd aan de MTX-PG’s  terwijl er bij een hoge MTX dosering juist 
meer glutamaatgroepen toegevoegd. 
 Tenslotte beschrijven we in hoofdstuk 8 de relatie tussen MTX-PG’s en de reactie 
op behandeling in twee prospectieve studies. Hieruit bleek dat hogere rode bloedcel MTX 
spiegels geassocieerd waren met een sterkere afname in ziekteactiviteit tijdens de eerste 
negen maanden van therapie. We hebben een afkappunt kunnen bepalen waarmee er een 
onderscheid kan worden gemaakt tussen ‘moderate/good responders’ en ‘non-responders.’ 
Er werd geen associatie gevonden tussen MTX-PG’s en bijwerkingen.
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De data die in dit proefschrift zijn gepubliceerd laten zien dat therapeutic drug monitoring 
in reuma haalbaar is en dat de rode bloedcel MTX-PG spiegels hiervoor kunnen worden 
gebruikt. Verder suggereren de resultaten van dit onderzoek dat een hogere behandeldosis 
van MTX een effectievere methode is om reuma te bestrijden omdat er dan sneller hogere 
MTX spiegels worden bereikt waarvan wij hebben aangetoond dat deze gerelateerd zijn aan 
de afname van ziekteactiviteit, terwijl bijwerkingen niet afwijken van patiënten die met een 
lagere dosis worden behandeld. Omdat het grootste deel van de opbouw van de MTX-PG 
spiegels plaatsvind tijdens de eerste drie maanden van de behandeling verwachten we dat 
het monitoren van de MTX-PG spiegels het meest waardevol zal blijken in deze periode. 
De MTX-PG meting zou mogelijk ook kunnen worden ingezet voor het controleren van de 
therapietrouw van patienten.
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List of abbreviations
7-OH-MTX  7-hydroxy methotrexate
ABC   ATP-binding cassette
ACR   American College of Rheumatology
ALAT    Alanine-aminotransferas
ALL    Acute lymphoblastic leukemia 
Anti-CCP  Anti-cyclic citrullinated peptide antibody
CRP   C-reactive protein 
CV   Coefficient of variation
DAMPA   4-amino-4-deoxy-N-methylpteroic acid
DAS    Disease Activity Score
DMARD   Disease modifying anti-rheumatic drug
eGFR-MDRD   estimated Glomerular filtration rate using Modification of Diet  
   in Renal Disease formula
EMIT    Enzyme multiplied immunoassay technique 
ESI   electrospray ionization
ESR   Erythrocyte sedimentation rate 
EULAR   European League Against Rheumatism 
FDA   United States Food and Drug Administration
FPGS   folylpolyglutamate synthase
FPIA   fluorescence polarization immunoassay
GGH   γ-glutamyl hydrolase
IQR    Interquartile range
IS   Internal Standard
JIA   Juvenile Idiopathic Arthritis
LC-MS/MS   Liquid chromatography tandem mass spectrometry 
LLOQ   Lower Limit of Quantitation
LOD   Lower Limit of Detection
MALDI   Matrix-Assisted Laser Desorption/Ionization
MTX   Methotrexate
MTXd3    Methotrexate deuterium labeled internal standard
MTX-PG   Methotrexate polyglutamate
MTX-PG(M+6)    Methotrexate polyglutamate (13C5, 15N)- stable isotope   
   labeled  internal standard
MTX-R   Methotrexate in Rotterdam, Netherlands cohort 
NSAID   Non-steroidal anti-inflammatory drugs (NSAID)
RA   Rheumatoid Arthritis
TDM    Therapeutic drug monitoring
tREACH   treatment in Rotterdam Early Arthritis CoHort 
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SD   standard deviation 
SNP   Single nucleotide polymorphisms
S/N   signal-to-noise ratio
SPE    Solid phase extraction
ULOQ   Upper limit of quantitation
Var   Variant genotype
Wt    Wildtype
WBC   White Blood Cell 
QC    Quality control
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Development and Validation of quantitative LC-MS/MS assays for use in 
clinical diagnosis, American Association for Clinical Chemistry
2012
Workshop inDesign CS5 for PhD students and other researchers, MolMed 2012
Photoshop and Illustrator CS5, MolMed 2012
Presenting skills for scientists, MolMed 2012
Integrity in research, Erasmus Medical Centre 2014
(inter)national scientific meetings
6th International Conference of the Metabolomics Society, Amsterdam 
(poster)
2010
Molecular Medicine Day (MOLMED) 14th annual meeting, Rotterdam 
(poster)
2010
NVKC annual scientific meeting, amersfoort (poster) 2011
Molecular Medicine Day (MOLMED) 15th annual meeting, Rotterdam 
(poster)
2011
Mass spectrometry: applications to the clinical laboratory 4th annual 
conference, San Diego, USA (oral presentation + poster)
2012
NVKC annual scientific meeting, amersfoort (oral presentation +poster) 2012
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Molecular Medicine Day (MOLMED) 16th annual meeting, Rotterdam 
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Annual European congress of rheumatology (EULAR) 2013, Madrid, Spain 
(poster)
2013
Annual European congress of rheumatology (EULAR) 2013, Paris, France 
(poster)
2014
Teaching
Supervising research internship of HLO student  7 months 2011-2012
Supervising research internship of HLO student 5 months 2012
Supervising research internship of University Minor student 5 months 2013
Other activities
PhD-student committee member of the MolMed Postgraduate School, 
ErasmusMC
2010-2014
Organisating committee of the ´Get out of your lab days´, a scientific and 
cultural retreat for PhD-student of the MolMed Postgraduate School, 
ErasmusMC
2012
Organisating committee of the yearly scientific gathering of the MolMed 
Postgraduate School, ErasmusMC
2012
Abstract committee MolMed day 2013
Organising and maintaining the blood sample logistics of several clinical 
studies conducted at the department of Clinical Chemistry of the EMC
2010-2013
Grants and awards
Reumafonds conference grant for The European League Against Rheumatism 
(EULAR 2013)
2013
Mass Spectrometry Applied to the Clinical Lab (MSACL2012) young 
investigator travel award
2012
Erasmus MC pilot grant (overall coordinator) for the project: Using intracellular 
methotrexate levels to monitor patient adherence in rheumatoid arthritis 
(50.000 euro)
2012
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Dankwoord
Het is af, klaar, over; mijn proefschrift is gearriveerd. Hoewel ik er ruim vier en een half jaar 
over gedaan heb, lijkt het allemaal te snel te zijn gegaan en met veel te weinig resultaat; ik 
heb zeker nog voor drie jaar werk liggen aan ideeën en data. 
Uiteraard zijn er vele mensen die op de een of andere manier, op meer of mindere wijze 
hebben bijgedragen aan dit boekje. Bij deze wil ik allen bedanken voor de hulp en steun die 
jullie mij gegeven hebben. 
Hoewel ik niet zo’n fan ben van uitgebreide dankwoorden wil ik toch een paar mensen 
specifiek bedanken. 
Mijn promotor, Jan Lindemans. Beste Jan, ik ben je zeer dankbaar voor het mogelijk maken 
van mijn promotie door het aannemen van iemand die al bijna vier jaar afgestudeerd was en 
eigenlijk niet ideaal aansloot bij de functie, ik dus. Vijf jaar geleden had ik eigenlijk de hoop 
op een AIO-plaats al opgegeven dus toen ik in juni 2009 jouw bericht kreeg aangenomen 
te zijn als UD op de afdeling Klinische Chemie was ik zeker zeer verrast. Ook toen bleek 
dat uiteindelijk ging om die AIO-plaats waar ik op had gesolliciteerd was ik nog steeds blij 
verrast, ik heb dan ook geen moment getwijfeld en het aanbod aangenomen. Hoewel je 
tijdens het project wat op de achtergrond bent gebleven, stond je altijd klaar om vragen te 
beantwoorden of te helpen. 
Mijn co-promotor, Robert de Jonge. Beste Robert, jouw losse stijl van leiding geven sloot 
perfect aan bij wat ik prettig werken vond. Ik heb in ieder geval het gevoel gekregen dat 
ik alles zelf deed en bedacht, met slechts wat sturing van jouw kant. Hoe dit verhoudt tot 
de werkelijkheid is maar de vraag. Vooral ook bedankt voor het geduld om eindeloos de 
slordigheden in mijn stukken aan te stippen en verbeteren, ik vrees dat ik daar nog wel 
even aan moet werken. Ook je hulp met het zoeken naar geldbronnen om het project iets te 
verlengen of te vervolgen ben ik je zeer dankbaar voor. Ik hoop ten zeerste dat de aanvraag 
bij ZONMW doorgaat zodat we onze samenwerking kunnen voortzetten. 
Bertrand, bedankt voor alle praktische en theoretische hulp bij het opzetten van de MS 
methoden en het regelmatige trouble-shooten, ook op afstand en buiten werktijd. Zonder 
jou was de MS methode waarschijnlijk niet zo snel opgezet of zo degelijk gevalideerd. Ook 
de (vaak bijzondere) gesprekken heb ik altijd zeer gewaardeerd, het is zelden dat ik een 
gelijke vind in directheid, interesses en hoeveelheid genuanceerde opmerkingen. Ik ben dan 
ook heel blij dat je mijn paranimf wilt zijn.
Mijn vader, die soms meer gemotiveerd leek dan ik en die ondanks het niet altijd begrijpen 
van mijn onderzoek nooit afliet het in ieder geval te proberen. Bedankt voor je steun, 
de gesprekken, het op korte termijn nakijken van lekensamenvattingen en het (ad hoc) 
opvangen van de kinders. Ik vind het fijn dat je mij ook bij deze belangrijke gebeurtenis wilt 
steunen door als paranimf aan mijn zijde te staan.
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Professor Hazes, Mieke, bedankt voor de nuchtere klinische blik op de artikelen waar jij 
co-auteur was, en ook voor de fijne samenwerking in het schrijven van nieuwe (jammer 
genoeg nog niet succesvolle) projectaanvragen. Ik hoop dat we in de toekomst nog eens 
samen kunnen werken.
Sandra Heil, bedankt voor de begeleiding en goede raad omtrent het AIO-traject en ook 
voor de leuke gesprekken van de afgelopen jaren. 
Saskia Pluijm, heel erg bedankt voor de hulp met de statistiek waar ik altijd zo’n hekel aan 
had en nu (mede dankzij jou) graag meer in zou willen doen. Ook was het geweldig iemand 
tegen te komen met een gelijke liefde voor koffie.
Maurits de Rotte, het was zeer prettig met jou samenwerken, vooral het sparren over 
resultaten en onderzoekslijnen was bijzonder waardevol. Ik wens je veel geluk met je nu nog 
prille huwelijk, en ook met je aankomende promotie waarna de stand tussen je Florentien 
en jij weer gelijk is (wil je een nieuw naambordje?).
Monique de Waart, bedankt voor het eindeloze (on)geduld waarmee je altijd weer klaarstond 
om antwoord te geven op (soms de meest idiote) vragen, te helpen met de logistiek van de 
bloedmonsters en dat je ondanks de problemen met sommige monsters altijd bereid was 
om te blijven helpen.
Verder natuurlijk het lab,  Samira voor de gezelligheid en het soms meeslepen naar koffie 
of lunch, Pamela for the movie (nerd) talk and sambal (did you ever get that recipe?), Pieter 
voor de hulp bij alles DNA en het helpen begeleiden van mijn studenten. Evert voor het MS 
overleg en de soms bijzondere gesprekken, Martin voor de droge opmerkingen en Marjan 
voor Marjan.
And my fellow PhD-students, Cherina, the undisputed ‘queen-of-body-fluids’, your 
enthusiasm and interest was at times enough to make my day, especially when the homefront 
was in turmoil, your never ending appetite for my wife’s food will not be forgotten soon. 
Maja, it was fun being your roommate, the help with all things pharmacological is still very 
much appreciated. I wish you much luck and love with your upcoming marriage.
Pooja, thank you for the help with R, I could not have made my splines without you. Also, 
thank you so much for the Indian food, just don’t forget to bring more thingies.
And all of you for the nice conversations and discussions, despite not being overly present 
at lunch or dinners I really appreciated your company. I wish you all much luck with your 
projects.
De mensen van de stofwisseling en dan speciaal Wilma, Wim en Peggy, jullie hadden een 
bijna eindeloos geduld ondanks dat ik constant de planning overhoop gooide door mijn 
tijden verkeerd in te schatten,  monsters tussendoor wilde draaien, weer eens niets kon 
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vinden of gewoon in de weg liep.
Rob en Marga, voor het helpen met de Sysmex helemaal aan het begin van mijn project, en 
het altijd helpen als ik bloedmonsters nodig had of hulp met de analyes/microscopie.
Ook mijn studenten, Sander, Trung en Anniek, voor de hulp en de chaos die zij verzorgden, 
het was leuk (en leerzaam) jullie te begeleiden. 
Mijn vrienden, en dan specifiek Michael, Bob (Dennis) en Dennis voor jullie begrip voor 
afgezegde afspraken, verjaardagen, trainingen, game-nights etc. Michael, nog reuze bedankt 
voor het maken van de mooie splines plaatjes, jammer dat ze hier niet meer in zijn gekomen, 
maar ze zullen zeker gebruikt worden.
Mijn schoon moeder, Doris, die altijd klaar stond op de kinderen te passen zodat ik mij kon 
richten op mijn project of naar een congres kon. 
Mijn twee zoons, Devin en Aedyn,  voor het vermaak en de ontspanning, voor het nooit 
ech begrijpen wat ik nou deed en waarom ik het nou leuk vond (Devin) en het vertellen op 
school dat ik heel de dag met bloed speel (Aedyn).
En als laatste en belangrijkste, mijn vrouw (mijn allesie ^_^ ), Melanie, bedankt voor het 
mogelijk maken van de afgelopen jaren, zonder jou was dit proefschrift er überhaupt niet 
gekomen. Zelfs in de tijden dat het minder ging en je moeder in het ziekenhuis lag bleef je 
me helpen en steunen, zij het soms met wat gemor. 
En ondanks het feit dat ik zelden op de afgesproken tijd thuis was, soms op onmogelijke 
tijden nog wilde werken, altijd te laat was voor het eten, je nooit precies snapte wat ik nou 
uitvoerde op het Erasmus en dat je van tijd tot tijd ‘part-time single mom’ was, heb je me 
altijd geprobeerd te motiveren en ook aan het werk geschopt waar nodig. 
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